Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,Link,Affiliations,Abstract,Author Keywords,Index Keywords,Molecular Sequence Numbers,Chemicals/CAS,Tradenames,Manufacturers,References,Correspondence Address,Editors,Sponsors,Publisher,Conference name,Conference date,Conference location,Conference code,ISSN,ISBN,CODEN,DOI,Language of Original Document,Abbreviated Source Title,Document Type,Source
"Gao M., Wang M., Zheng Q.-H.","Synthesis of carbon-11 labeled 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolinium derivatives as new potential PET SKCa channel imaging agents",2008,"Applied Radiation and Isotopes",66,2,,194,202,,,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-37149043294&partnerID=40&rel=R8.0.0","Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L-3 Room 202, Indianapolis, IN 46202, United States","Small conductance Ca2+-activated K+ (SKCa) channels play an important role in many functions such as neuronal communication and behavioral plasticity, secretion, and cell proliferation. SKCa channel modulation is associated with various brain, heart, and cancer diseases. N-methyl-laudanosine and its structurally related derivatives, substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums, are reversible and selective SKCa channel blockers. Carbon-11 labeled N-methyl-laudanosine and its tetrahydroisoquinolinium derivatives may serve as new probes for positron emission tomography (PET) to image SKCa channels in the brain, heart, and cancer. The key intermediates, substituted isoquinolines (3a-c), were synthesized using a modification of the Pomeranz-Fritsch procedure. The precursors, substituted 1-(3,4-dimethoxybenzyl)-2-methyl-1,2,3,4-tetrahydroisoquinolines (8a-c), and their corresponding reference standards, substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums (9a-c), were synthesized from compounds 3a-c with 3,4-dimethoxybenzyl chloride (2) in multiple steps with moderate to excellent chemical yields. The precursor 6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline (10) was commercially available, and the methylation of compound 10 with methyl iodide provided N-methyl-laudanosine (11). The target quaternary ammonium tracers, carbon-11 labeled 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums ([11C]9a-c and [11C]11), were prepared by N-[11C]methylation of the tertiary amine precursors (8a-c and 10) with [11C]methyl triflate and isolated by a simplified solid-phase extraction (SPE) purification using a SiO2 or cation-exchange CM Sep-Pak cartridge in 40-65% radiochemical yields. Â© 2007 Elsevier Ltd. All rights reserved.","1-(3,4-Dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums; Carbon-11; Imaging; N-methyl-laudanosine; Positron emission tomography (PET); Small conductance Ca2+-activated K+ (SKCa) channels",,,,,,"Doorty, K.B., Bevan, S., Wadsworth, J.D.F., Strong, P.N., A novel small conductance Ca2+-activated K+ channel blocker from oxyuranus scutellatus taipan venom (1997) J. Biol. Chem., 272, pp. 19925-19930; Gao, M., Miller, M.A., DeGrado, T.M., Mock, B.H., Lopshire, J.C., Rosenberger, J.G., Dusa, C., Zheng, Q.-H., Evaluation of [11C]hemicholinium-15 and [18F]hemicholinium-15 as new potential PET tracers for the high-affinity choline uptake system in the heart (2007) Bioorg. Med. Chem., 15, pp. 1289-1297; Graulich, A., Scuvee-Moreau, J., Alleva, L., Lamy, C., Waroux, O., Seutin, V., Liegeois, J.-F., Synthesis and radioligand binding studies of methoxylated 1,2,3,4-tetrahydroisoquinolinium derivatives as ligands of the apamin-sensitive Ca2+-activated K+ channels (2006) J. Med. Chem., 49, pp. 7208-7214; Graulich, A., Scuvee-Moreau, J., Seutin, V., Liegeois, J.-F., Synthesis and radioligand binding studies of C-5- and C-8-substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK channel blockers related to N-methyl-laudanosine and N-methyl-noscapine (2005) J. Med. Chem., 48, pp. 4972-4982; Hendrickson, J.B., Rodriguez, C., An efficient synthesis of substituted isoquinolines (1983) J. Org. Chem., 48, pp. 3344-3346; Jewett, D.M., A simple synthesis of [11C]methyl triflate (1992) Appl. Radiat. Isot., 43, pp. 1383-1385; Mock, B.H., Mulholland, G.K., Vavrek, M.T., Convenient gas phase bromination of [11C]methane and production of [11C]methyl triflate (1999) Nucl. Med. Biol., 26, pp. 467-471; Popp, F.D., Developments in the chemistry of Reissert compounds (1968-1978) (1979) Adv. Heterocycl. Chem., 24, pp. 187-214; Snabaitis, A.K., D'Mello, R., Dashnyam, S., Avkiran, M., A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1 (2006) J. Biol. Chem., 281, pp. 20252-20262; Tuteja, D., Xu, D., Timofeyev, V., Lu, L., Sharma, D., Zhang, Z., Xu, Y., Chiamvimonvat, N., Differential expression of small-conductance Ca2+-activated K+ channels SK1, SK2, and SK3 in mouse and ventricular myocytes (2005) Am. J. Physiol. Heart Circ. Physiol., 289, pp. H2714-H2723; Wang, J.-Q., Miller, M.A., Fei, X., Stone, K.L., Lopshire, J.C., Groh, W.J., Zipes, D.P., Zheng, Q.-H., Facile synthesis and initial PET imaging of novel potential heart acetylcholinesterase imaging agents [11C]pyridostigmine and its analogs (2004) Nucl. Med. Biol., 31, pp. 957-964; Wang, M., Lacy, G., Gao, M., Miller, K.D., Sledge, G.W., Zheng, Q.-H., Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer (2007) Bioorg. Med. Chem. Lett., 17, pp. 332-336; Weaver, A.K., Bomben, V.C., Sontheimer, H., Expression and function of calcium-activated potassium channels in human glioma cells (2006) Glia, 54, pp. 223-233; Zheng, Q.-H., Mock, B.H., Purification of carbon-11 PET radiotracers from unlabeled precursors by preparative HPLC and SPE (2005) Biomed. Chromatogr., 19, pp. 671-676","Zheng, Q.-H.; Department of Radiology; Indiana University School of Medicine; 1345 West 16th Street, L-3 Room 202 Indianapolis, IN 46202, United States; email: qzheng@iupui.edu",,,,,,,,09698043,,ARISE,10.1016/j.apradiso.2007.08.011,"English","Applied Radiation and Isotopes",Article,Scopus
"Forquer J.A., Harkenrider M., Fakiris A.J., Timmerman R.D., Cavaliere R., Henderson M.A., Lo S.S.","Brain metastasis from non-seminomatous germ cell tumor of the testis",2007,"Expert Review of Anticancer Therapy",7,11,,1567,1580,,,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-37449009309&partnerID=40&rel=R8.0.0","Indiana University Medical Center, Department of Radiation Oncology, 535 Barnhill Drive, Indianapolis, IN 46202, United States; Indiana University Medical Center, Department of Radiation Oncology, 35 Barnhill Drive, Indianapolis, IN 46202, United States; University of Texas Southwestern, Department of Radiation Oncology, 5801 Forest Park Road, Dallas, TX 75390-9183, United States; Ohio State University, Department of Neurology, Division of Neuro-Oncology, 1654 Upham Drive, Columbus, OH 43210, United States; Department of Radiation Medicine, Ohio State University Medical Medicine, Arthur G James Cancer Hospital, 300 West 10th Avenue, Columbus, OH 43210, United States","Brain metastasis occurs rarely in patients with testicular cancer in the modern era where cisplatin-based chemotherapy regimens are used. The occurrence of brain metastasis can be synchronous or metachronous (with or without concurrent systemic disease). Long-term survival can be achieved in some patients. The vast majority of testicular cancer cases with brain metastasis reported in the literature involve nonseminomatous germ cell tumor and this subtype will be the focus of this review. This article reviews the literature of the diagnosis and management of brain metastasis from nonseminomatous germ cell tumor of the testis. Â© 2007 Future Drugs Ltd.","Brain metastasis; Germ cell tumor; Nonseminomatous; Testis",,,,,,"Huyghe, E., Matsuda, T., Thonneau, P., Increasing incidence of testicular cancer worldwide: A review (2003) J. Urol, 170, pp. 5-11; (2005) Cancer: Priciples and Practice of Oncology, , 7th Edition, DeVita JV, Hellman S, Rosenberg SA Ed, Lippincott, Williams & Wilkins, PA, USA; Horwich, A., Shipley, J., Huddart, R., Testicular germ-cell cancer (2006) Lancet, 367, pp. 754-765; International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers (1997) J Clin. Oncol, 15, pp. 594-603. , International Germ Cell Cancer Collaborative Group; Einhorn, L.H., Donohue, J., Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer (1977) Ann. Intern. Med, 87, pp. 293-298; Einhorn, L.H., Williams, S.D., Chemotherapy of disseminated testicular cancer. A random prospective study (1980) Cancer, 46, pp. 1339-1344; Williams, S.D., Birch, R., Einhorn, L.H., Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide (1987) N. Engl. J. Med, 316, pp. 1435-1440; Peckham, M.J., Barrett, A., Liew, K.H., The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP) (1983) Br. J. Cancer, 47, pp. 613-619; Saxman, S.B., Finch, D., Gonin, R., Einhorn, L.H., Long-term follow-up of a Phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience (1998) J. Clin. Oncol, 16, pp. 702-706; Bosl, G.J., Geller, N.L., Bajorin, D., A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors (1988) J. Clin. Oncol, 6, pp. 1231-1238; de Wit, R., Stoter, G., Kaye, S.B., Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group (1997) J. Clin. Oncol, 15, pp. 1837-1843; Culine, S., Kerbrat, P., Kramar, A., Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: A randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) (2007) Ann. Oncol, 18 (5), pp. 917-924; Sonneveld, D.J., Hoekstra, H.J., van der Graaf, W.T., Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era (2001) Cancer, 91, pp. 1304-1315; Spears, W.T., Morphis II, J.G., Lester, S.G., Brain metastases and testicular tumors: Long-term survival (1992) Int. J. Radiat. Oncol. Biol. Phys, 22, pp. 17-22; Logothetis, C.J., Samuels, M.L., Trindade, A., The management of brain metastases in germ cell tumors: Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany (1982) Cancer, 49, pp. 12-18; Vugrin, D., Cvitkovic, E., Posner, J., Hajdu, S., Golbey, R.B., Neurological complications of malignant germ cell tumors of testis: Biology of brain metastases (I) (1979) Cancer, 44, pp. 2349-2353; Williams, S.D., Einhorn, L.H., Brain metastases in disseminated germinal neoplasms: Incidence and clinical course (1979) Cancer, 44, pp. 1514-1516; Lester, S.G., Morphis II, J.G., Hornback, N.B., Williams, S.D., Einhorn, L.H., Brain metastases and testicular tumors: Need for aggressive therapy (1984) J. Clin. Oncol, 2, pp. 1397-1403; Geri, A., Clemm, C., Kohl, P., Schalhorn, A., Wilmanns, W., Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer (1994) Clin. Exp. Metastasis, 12, pp. 226-230; Flechon, A., Culine, S., Theodore, C., Droz, J.P., Pattern of relapse after first line treatment of advanced stage germ-cell tumors (2005) Eur. Urol, 48, pp. 957-963; Aoyama, H., Shirato, H., Tago, M., Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial (2006) JAMA, 295, pp. 2483-2491; Patchell, R.A., Tibbs, P.A., Regine, W.F., Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial (1998) JAMA, 280, pp. 1485-1489; Patchell, R.A., Tibbs, P.A., Walsh, J.W., A randomized trial of surgery in the treatment of single metastases to the brain (1990) N Engl. J. Med, 322, pp. 494-500; Fossa, S.D., Bokemeyer, C., Geri, A., Treatment outcome of patients with brain metastases from malignant germ cell tumors (1999) Cancer, 85, pp. 988-997; Lutterbach, J., Spetzger, U., Bartelt, S., Pagenstecher, A., Malignant germ cell tumors metastatic to the brain: A model for a curable neoplasm? The Freiburg experience and a review of the literature (2002) J. Neurooncol, 58, pp. 147-156; Mathews, V.P., Broome, D.R., Smith, R.R., Bognanno, J.R., Einhorn, L.H., Edwards, M.K., Neuroimaging of disseminated germ cell neoplasms (1990) AJNR Am. J. Neuroradiol, 11, pp. 319-324; Klos, K.J., O'Neill, B.P., Brain metastases (2004) Neurologist, 10, pp. 31-46; Kaye, S.B., Bagshawe, K.D., McElwain, T.J., Peckham, M.J., Brain metastases in malignant teratoma: A review of four years' experience and an assessment of the role of tumour markers (1979) Br. J. Cancer, 39, pp. 217-223; Mahalati, K., Bilen, C.Y., Ozen, H., Aki, F.T., Kendi, S., The management of brain metastasis in nonseminomatous germ cell tumours (1999) Br. J. Urol. Int, 83, pp. 457-461; Higi, M., Scheulen, M.E., Schmidt, C.G., Seeber, S., Brain metastases in malignant testicular teratomas (1981) Onkologie, 4, pp. 84-86; Bokemeyer, C., Nowak, P., Haupt, A., Treatment of brain metastases in patients with testicular cancer (1997) J. Clin. Oncol, 15, pp. 1449-1454; Kaal, E.C., Taphoorn, M.J., Vecht, C.J., Symptomatic management and imaging of brain metastases (2005) J Neurooncol, 75, pp. 15-20; Kaal, E.C., Vecht, C.J., The management of brain edema in brain tumors (2004) Curr. Opin. Oncol, 16, pp. 593-600; Soffietti, R., Ruda, R., Mutani, R., Management of brain metastases (2002) J. Neurol, 249, pp. 1357-1369; Vecht, C.J., Hovestadt, A., Verbiest, H.B., van Vliet, J.J., van Putten, W.L., Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16 mg per day (1994) Neurology, 44, pp. 675-680; Pruitt, A.A., Treatment of medical complications in patients with brain tumors (2005) Curr. Treat. Options Neurol, 7, pp. 323-336; Glantz, M.J., Cole, B.F., Friedberg, M.H., A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors (1996) Neurology, 46, pp. 985-991; Glantz, M.J., Cole, B.F., Forsyth, P.A., Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology (2000) Neurology, 54, pp. 1886-1893; Delattre, J.Y., Safai, B., Posner, J.B., Erythema multiforme and Stevens-Johnson syndrome. in patients receiving cranial irradiation and phenytoin (1988) Neurology, 38, pp. 194-198; Raghavan, D., Mackintosh, J.F., Fox, R.M., Rogers, J., Duval, P., Besser, M., Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment (1987) Br. J. Urol, 60, pp. 364-367; Rustin, G.J., Newlands, E.S., Bagshawe, K.D., Begent, R.H., Crawford, S.M., Successful management of metastatic and primary germ cell tumors in the brain (1986) Cancer, 57, pp. 2108-2113; Kollmannsberger, C., Nichols, C., Bamberg, M., First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases (2000) Ann. Oncol, 11 (5), pp. 553-559; Balmaceda, C., Heller, G., Rosenblum, M., Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: Results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study (1996) J. Clin. Oncol, 14, pp. 2908-2915; Ruben, J.D., Dally, M., Bailey, M., Smith, R., McLean, C.A., Fedele, P., Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy (2006) Int. J. Radiat. Oncol. Biol. Phys, 65, pp. 499-508; (2000) Radiobiology for tbe Radiologist, , 5th Edition, Hall EJ Ed, Lippincott, Williams & Wilkins, PA, USA; Mehta, M.P., Tsao, M.N., Whelan, T.J., The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases (2005) Int. J. Radiat. Oncol. Biol. Phys, 63, pp. 37-46; Nicolato, A., Ria, A., Foroni, R., Gamma knife radiosurgery in brain metastases from testicular tumors (2005) Med Oncol, 22, pp. 45-56; Kulkarni, R.P., Reynolds, K.W., Newlands, E.S., Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis (1991) Br. J. Surg, 78, pp. 226-229; Crabb, S.J., McKendrick, J.J., Mead, G.M., Brain as sanctuary site of relapse in germ cell cancer patients previously treated with chemotherapy (2002) Clin. Oncol. (R. Coll. Radiol.), 14, pp. 287-293; Cohn, D.A., Stuart-Harris, R., Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature (2001) Oncology, 6 l, pp. 184-188; Perry, J.J., Jelinek, J.S., Isolated central nervous system relapse of testicular cancer (1992) Med. Pediatr. Oncol, 20, pp. 68-70; James, P.P., Mead, G.M., Sanctuary site relapse in chemotherapy-treated testicular cancer (1992) Ann. Oncol, 3, pp. 41-43; Stolinsky, D.C., Prolonged survival after cerebral metastasis of testicular carcinoma (1981) Cancer, 47, pp. 978-981; Andrews, D.W., Scott, C.B., Sperduto, P.W., Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randornised trial (2004) Lancet, 363, pp. 1665-1672; Budach, V., Schutz, U., Higi, M., Niederle, N., Radiotherapy in case of intracerebral formation of metastases of non-seminomatous testicle tumors (author's transl.) (1981) Strahlentherapie, 157, pp. 450-454; Logothetis, C.J., Samuels, M.L., Trindade, A., The management of brain metastases in germ cell tumors (1982) Cancer, 49, pp. 12-18; Schmoll, H.J., Souchon, R., Krege, S., European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG) (2004) Ann. Oncol, 15 (9), pp. 1377-1399; Azar, J.M., Schneider, B.P., Einhorn, L.H., Is the blood-brain barrier relevant in metastatic germ cell tumor? (2007) Int. J. Radiat. Oncol. Biol. Phys, 69 (1), pp. 163-166","Lo, S.S.; Ohio State University Medical Center; Arthur G. James Center Hospital; 300 West 10th Avenue Columbus, OH 43210, United States; email: simon.lo@osumc.edu",,,,,,,,14737140,,ERATB,10.1586/14737140.7.11.1567,"English","Expert Review of Anticancer Therapy",Review,Scopus
"Kwee S.A., DeGrado T.R., Talbot J.N., Gutman F., Coel M.N.","Cancer Imaging With Fluorine-18-Labeled Choline Derivatives",2007,"Seminars in Nuclear Medicine",37,6,,420,428,,,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-34848926866&partnerID=40&rel=R8.0.0","University of Hawaii John A. Burns School of Medicine, Honolulu, HI, United States; Hamamatsu/Queen's PET Imaging Center, The Queen's Medical Center, Honolulu, HI, United States; Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Nuclear Medicine, HoÌ‚pital Tenon, AP-HP, Paris, France","The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers. Â© 2007 Elsevier Inc. All rights reserved.",,,,,,,"Katz-Brull, R., Degani, H., Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method (1996) Anticancer Res, 16, pp. 1375-1380; Nakagami, K., Uchida, T., Ohwada, S., Increased choline kinase activity and elevated phosphocholine levels in human colon cancer (1999) Jpn J Cancer Res, 90, pp. 419-424; Ramirez de Molina, A., Rodriguez-Gonzalez, A., Gutierrez, R., Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers (2002) Biochem Biophys Res Commun, 296, pp. 580-583; Hara, T., Kosaka, N., Kishi, H., PET imaging of prostate cancer using carbon-11-choline (1998) J Nucl Med, 39, pp. 990-995; Hara, T., Kosaka, N., Shinoura, N., PET imaging of brain tumor with [methyl-11C]choline (1997) J Nucl Med, 38, pp. 842-847; Yoshida, S., Nakagomi, K., Goto, S., C-choline positron emission tomography in bladder cancer: report of four cases (2006) Int J Urol, 13, pp. 829-831; Picchio, M., Treiber, U., Beer, A.J., Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: Correlation with histopathologic findings (2006) J Nucl Med, 47, pp. 938-944; Gofrit, O.N., Mishani, E., Orevi, M., Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma (2006) J Urol, 176, pp. 940-944. , discussion 944; Farsad, M., Schiavina, R., Castellucci, P., Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis (2005) J Nucl Med, 46, pp. 1642-1649; de Jong, I.J., Pruim, J., Elsinga, P.H., Visualization of prostate cancer with 11C-choline positron emission tomography (2002) Eur Urol, 42, pp. 18-23; de Jong, I.J., Pruim, J., Elsinga, P.H., Visualisation of bladder cancer using (11)C-choline PET: First clinical experience (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1283-1288; Hara, T., Kosaka, N., Kishi, H., Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging (2002) J Nucl Med, 43, pp. 187-199; DeGrado, T.R., Coleman, R.E., Wang, S., Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer (2001) Cancer Res, 61, pp. 110-117; Bansal, A., Wang, S., Harris, R., Biodisposition and Metabolism of [18F]fluorocholine in cultured 9L glioma cells and subcutaneous 9L tumor model (2006) Mol Imaging Biol, 8, p. 78. , [Abstract]; Gilissen, C., de Groot, T.J., Bronfman, F., Evaluation of 18F-FA-4 and 11C-pipzA-4 as radioligands for the in vivo evaluation of the high-affinity choline uptake system (2003) J Nucl Med, 44, pp. 269-275; Hara, T., Bansal, A., Degrado, T.R., Choline transporter as a novel target for molecular imaging of cancer (2006) Mol Imaging, 5, pp. 498-509; Spaeth, N., Wyss, M.T., Weber, B., Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumor recurrence (2004) J Nucl Med, 45, pp. 1931-1938; DeGrado, T.R., Baldwin, S.W., Wang, S., Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers (2001) J Nucl Med, 42, pp. 1805-1814; Iwata, R., Pascali, C., Bogni, A., [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: Preparation and application to the on-column preparation of [18F]fluorocholine (2002) Appl Radiat Isot, 57, pp. 347-352; Lim, J., Dorman, E., Cabral, C., Automated production of[18F]FECh and [18F]FCH: Preparation and use of [18F]fluoroalkane sulfonates and fluoroalkylation agents (2003) J. Label Compd Radiopharm, 46, pp. S403; Hara, T., 18F-fluorocholine: A new oncologic PET tracer (2001) J Nucl Med, 42, pp. 1815-1817; Cuadrado, A., Carnero, A., Dolfi, F., Phosphorylcholine: A novel second messenger essential for mitogenic activity of growth factors (1993) Oncogene, 8, pp. 2959-2968; Breeuwsma, A.J., Pruim, J., Jongen, M.M., In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer (2005) Eur J Nucl Med Mol Imaging, 32, pp. 668-673; Glunde, K., Jacobs, M.A., Bhujwalla, Z.M., Choline metabolism in cancer: Implications for diagnosis and therapy (2006) Expert Rev Mol Diagn, 6, pp. 821-829; Yamaguchi, T., Lee, J., Uemura, H., Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy (2005) Eur J Nucl Med Mol Imaging, 32, pp. 742-748; Kwee, S.A., Coel, M.N., Lim, J., Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation (2004) J Neuroimaging, 14, pp. 285-289; Padma, M.V., Adineh, M., Pugar, K., Functional imaging of a large demyelinating lesion (2005) J Clin Neurosci, 12, pp. 176-178; Schoder, H., Larson, S.M., Positron emission tomography for prostate, bladder, and renal cancer (2004) Semin Nucl Med, 34, pp. 274-292; Shreve, P.D., Grossman, H.B., Gross, M.D., Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose (1996) Radiology, 199, pp. 751-756; Price, D.T., Coleman, R.E., Liao, R.P., Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer (2002) J Urol, 168, pp. 273-280; Basillote, J.B., Armenakas, N.A., Hochberg, D.A., Influence of prostate volume in the detection of prostate cancer (2003) Urology, 61, pp. 167-171; Naughton, C.K., Miller, D.C., Mager, D.E., A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection (2000) J Urol, 164, pp. 388-392; Kwee, S.A., Coel, M.N., Lim, J., Prostate cancer localization with 18fluorine fluorocholine positron emission tomography (2005) J Urol, 173, pp. 252-255; Kwee, S.A., Wei, H., Sesterhenn, I., Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET (2006) J Nucl Med, 47, pp. 262-269; Schmid, D.T., John, H., Zweifel, R., Fluorocholine PET/CT in patients with prostate cancer: Initial experience (2005) Radiology, 235, pp. 623-628; Talbot, J.N., Gutman, F., Fartoux, L., PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT (2006) Eur J Nucl Med Mol Imaging, 33, pp. 1285-1289; Heinisch, M., Dirisamer, A., Loidl, W., Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml? (2006) Mol Imaging Biol, 8, pp. 43-48; Cimitan, M., Bortolus, R., Morassut, S., [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients (2006) Eur J Nucl Med Mol Imaging, 33, pp. 1387-1398; Langsteger, W., Heinisch, M., Fogelman, I., The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast (2006) Semin Nucl Med, 36, pp. 73-92; Martorana, G., Schiavina, R., Corti, B., 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy (2006) J Urol, 176, pp. 954-960. , discussion 960; Kwee, S.A., Ko, J.P., Jiang, C.S., Solitary brain lesions enhancing at MR imaging: Evaluation with fluorine 18 fluorocholine PET (2007) Radiology, 244, pp. 557-565; Ohtani, T., Kurihara, H., Ishiuchi, S., Brain tumour imaging with carbon-11 choline: Comparison with FDG PET and gadolinium-enhanced MR imaging (2001) Eur J Nucl Med, 28, pp. 1664-1670; Goebell, E., Paustenbach, S., Vaeterlein, O., Low-grade and anaplastic gliomas: Differences in architecture evaluated with diffusion-tensor MR imaging (2006) Radiology, 239, pp. 217-222; Provenzale, J.M., McGraw, P., Mhatre, P., Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging (2004) Radiology, 232, pp. 451-460; Burtscher, I.M., Skagerberg, G., Geijer, B., Proton MR spectroscopy and preoperative diagnostic accuracy: An evaluation of intracranial mass lesions characterized by stereotactic biopsy findings (2000) AJNR Am J Neuroradiol, 21, pp. 84-93; Vesselle, H.J., Miraldi, F.D., FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls (1998) Radiographics, 18, pp. 805-823. , discussion 823-804; Wang, T., Sun, Y.E., Yao, S.L., [Value of carbon-11 choline positron emission tomography in patients with pulmonary abnormalities] (2006) Zhonghua Wai Ke Za Zhi, 44, pp. 405-408; Roivainen, A., Parkkola, R., Yli-Kerttula, T., Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium (2003) Arthritis Rheum, 48, pp. 3077-3084; Sasaki, T., [11C]choline uptake in regenerating liver after partial hepatectomy or CCl4-administration (2004) Nucl Med Biol, 31, pp. 269-275; Kubota, K., Furumoto, S., Iwata, R., Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation (2006) Ann Nucl Med, 20, pp. 527-533; Wyss, M.T., Weber, B., Honer, M., 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET (2004) Eur J Nucl Med Mol Imaging, 31, pp. 312-316","Kwee, S.A.; University of Hawaii John A. Burns School of Medicine Honolulu, HI, United States; email: skwee@queens.org",,,,,,,,00012998,,SMNMA,10.1053/j.semnuclmed.2007.07.003,"English","Seminars in Nuclear Medicine",Review,Scopus
"Zhong J., Yao W., Lee W.","Cesium chloride protects cerebellar granule neurons from apoptosis induced by low potassium",2007,"International Journal of Developmental Neuroscience",25,6,,359,365,,,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-35748966721&partnerID=40&rel=R8.0.0","Departments of Pediatrics, Anatomy and Cell Biology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, United States","Neuronal apoptosis plays a critical role in the pathogenesis of neurodegenerative disorders, and neuroprotective agents targeting apoptotic signaling could have therapeutic use. Here we report that cesium chloride, an alternative medicine in treating radiological poison and cancer, has neuroprotective actions. Serum and potassium deprivation induced cerebellar granule neurons to undergo apoptosis, which correlated with the activation of caspase-3. Cesium prevented both the activation of caspase-3 and neuronal apoptosis in a dose-dependent manner. Cesium at 8 mM increased the survival of neurons from 45 Â± 3% to 91 Â± 5% of control. Cesium's neuroprotection was not mediated by PI3/Akt or MAPK signaling pathways, since it was unable to activate either Akt or MAPK by phosphorylation. In addition, specific inhibitors of PI3 kinase and MAP kinase did not block cesium's neuroprotective effects. On the other hand, cesium inactivated GSK3Î² by phosphorylation of serine-9 and GSK3Î²-specific inhibitor SB415286 prevented neuronal apoptosis. These data indicate that cesium's neuroprotection is likely via inactivating GSK3Î². Furthermore, cesium also prevented H2O2-induced neuronal death (increased the survival of neurons from 72 Â± 4% to 89 Â± 3% of control). Given its relative safety and good penetration of the brain blood barrier, our findings support the potential therapeutic use of cesium in neurodegenerative diseases. Â© 2007 ISDN.","Apoptosis; Cesium; GSK3Î²; Lithium; Neuron",,,,,,"Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Nicotera, P., Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function (1995) Neuron, 15, pp. 961-973; Barnham, K.J., Masters, C.L., Bush, A.I., Neurodegenerative diseases and oxidative stress (2004) Nat. Rev. Drug Discov., 3, pp. 205-214; Bhat, R.V., Budd haeberlein, S.L., Avila, J., Glycogen synthase kinase 3: a drug target for CNS therapies (2004) J. Neurochem., 89, pp. 1313-1317; Borson, S., Leverenz, J.B., Basic mechanisms in neurodegenerative disease: implications for behavioral pathogenesis and treatment (1996) Semin. Clin. Neuropsychiatry, 1, pp. 248-260; Centeno, J.A., Pestaner, J.P., Omalu, B.I., Torres, N.L., Field, F., Wagner, G., Mullick, F.G., Blood and tissue concentration of cesium after exposure to cesium chloride: a report of two cases (2003) Biol. Trace Elem. Res., 94, pp. 97-104; Chin, P.C., Majdzadeh, N., D'mello, S.R., Inhibition of GSK3beta is a common event in neuroprotection by different survival factors (2005) Brain Res. Mol. Brain Res., 137, pp. 193-201; Chong, Z.Z., Maiese, K., Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system (2004) Histol. Histopathol., 19, pp. 495-504; Chuang, D.M., Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? (2004) Crit. Rev. Neurobiol., 16, pp. 83-90; Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., Hemmings, B.A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B (1995) Nature, 378, pp. 785-789; Cross, D.A., Culbert, A.A., Chalmers, K.A., Facci, L., Skaper, S.D., Reith, A.D., Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death (2001) J. Neurochem., 77, pp. 94-102; Czyz, A., Baranauskas, G., Kiedrowski, L., Instrumental role of Na+ in NMDA excitotoxicity in glucose-deprived and depolarized cerebellar granule cells (2002) J. Neurochem., 81, pp. 379-389; D'Mello, S.R., Borodezt, K., Soltoff, S.P., Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling (1997) J. Neurosci., 17, pp. 1548-1560; D'Mello, S.R., Galli, C., Ciotti, T., Calissano, P., Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and camp (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 10989-10993; Datta, S.R., Brunet, A., Greenberg, M.E., Cellular survival: a play in three Akts (1999) Genes Dev., 13, pp. 2905-2927; Doble, B.W., Woodgett, J.R., GSK-3: tricks of the trade for a multi-tasking kinase (2003) J. Cell Sci., 116, pp. 1175-1186; Eldar-Finkelman, H., Glycogen synthase kinase 3: an emerging therapeutic target (2002) Trends Mol. Med., 8, pp. 126-132; Jope, R.S., Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes (2003) Trends Pharmacol. Sci., 24, pp. 441-443; Journot, L., Villalba, M., Bockaert, J., PACAP-38 protects cerebellar granule cells from apoptosis (1998) Ann. N Y Acad. Sci., 865, pp. 100-110; Kitayama, M., Miyata, H., Yano, M., Saito, N., Matsuda, Y., Yamauchi, T., Kogure, S., Ih blockers have a potential of antiepileptic effects (2003) Epilepsia, 44, pp. 20-24; Klein, P.S., Melton, D.A., A molecular mechanism for the effect of lithium on development (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 8455-8459; Krantic, S., Mechawar, N., Reix, S., Quirion, R., Molecular basis of programmed cell death involved in neurodegeneration (2005) Trends Neurosci., 28, pp. 670-676; Martin, L.J., Neuronal cell death in nervous system development, disease, and injury (review) (2001) Int. J. Mol. Med., 7, pp. 455-478; Mattson, M.P., Apoptosis in neurodegenerative disorders (2000) Nat. Rev. Mol. Cell. Biol., 1, pp. 120-129; Mora, A., Sabio, G., Gonzalez-polo, R.A., Cuenda, A., Alessi, D.R., Alonso, J.C., Fuentes, J.M., Centeno, F., Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells (2001) J. Neurochem., 78, pp. 199-206; Neulieb, R., Effect of oral intake of cesium chloride: a single case report (1984) Pharmacol. Biochem. Behav., 21 (SUPPL. 1), pp. 15-16; Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Duff, K., Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 6990-6995; Oppenheim, R.W., Cell death during development of the nervous system (1991) Annu. Rev. Neurosci., 14, pp. 453-501; Ren, M., Senatorov, V.V., Chen, R.W., Chuang, D.M., Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 6210-6215; Ryves, W.J., Harwood, A.J., Lithium inhibits glycogen synthase kinase-3 by competition for magnesium (2001) Biochem. Biophys. Res. Commun., 280, pp. 720-725; Sartori, H.E., Nutrients and cancer: an introduction to cesium therapy (1984) Pharmacol. Biochem. Behav., 21 (SUPPL. 1), pp. 7-10; Srivastava, A.K., Pandey, S.K., Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin (1998) Mol. Cell. Biochem., 182, pp. 135-141; Staal, S.P., Hartley, J.W., Rowe, W.P., Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma (1977) Proc. Natl. Acad. Sci. USA, 74, pp. 3065-3067; Thangnipon, W., Kingsbury, A., Webb, M., Balazs, R., Observations on rat cerebellar cells in vitro: influence of substratum, potassium concentration and relationship between neurones and astrocytes (1983) Brain Res., 313, pp. 177-189; Tsubokawa, H., Miura, M., Kano, M., Elevation of intracellular Na+ induced by hyperpolarization at the dendrites of pyramidal neurones of mouse hippocampus (1999) J. Physiol., 517 (PART 1), pp. 135-142; Wei, H., Qin, Z.H., Senatorov, V.V., Wei, W., Wang, Y., Qian, Y., Chuang, D.M., Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease (2001) Neuroscience, 106, pp. 603-612; Zhong, J., Deng, J., Huang, S., Yang, X., Lee, W.H., High K+ and IGF-1 protect cerebellar granule neurons via distinct signaling pathways (2004) J. Neurosci. Res., 75, pp. 794-806; Zhong, J., Yang, X., Yao, W., Lee, W., Lithium protects ethanol-induced neuronal apoptosis (2006) Biochem. Biophys. Res. Commun., 350, pp. 905-910","Zhong, J.; Departments of Pediatrics, Anatomy and Cell Biology; Indiana University School of Medicine; Riley Hospital for Children Indianapolis, IN, United States; email: jizhong@iupui.edu",,,,,,,,07365748,,IJDND,10.1016/j.ijdevneu.2007.07.003,"English","International Journal of Developmental Neuroscience",Article,Scopus
"Azar J.M., Schneider B.P., Einhorn L.H.","Is the Blood-Brain Barrier Relevant in Metastatic Germ Cell Tumor?",2007,"International Journal of Radiation Oncology Biology Physics",69,1,,163,166,,1,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-34547838168&partnerID=40&rel=R8.0.0","Department of Medicine, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, United States; Walther Cancer Institute, Indianapolis, IN, United States","Purpose: Germ cell tumors are uniquely chemosensitive and curable, even with advanced metastatic disease. Central nervous system recurrence can terminate a complete remission in other chemosensitive tumors, such as small cell lung cancer, because of the blood-brain barrier (BBB). We propose to document that the BBB is also relevant in germ cell tumors despite their dramatic chemosensitivity. Methods and Materials: We present five cases illustrating the concept of the BBB in patients with metastatic testicular cancer treated with chemotherapy. Results: In our large series of patients with metastatic testicular cancer treated with chemotherapy, we identified 5 unique patients. These patients were rendered free of disease only to experience relapse in the brain alone. This included 1 patient who initially had good-risk metastatic disease by means of the International Germ Cell Collaborative Group staging system at the onset of chemotherapy. Conclusions: The BBB is relevant in patients with metastatic testicular cancer. Â© 2007 Elsevier Inc. All rights reserved.","Blood-brain barrier; Brain metastasis; Germ cell tumor; Testicular cancer",,,,,,"Einhorn, L.H., Curing metastatic testicular cancer (2002) Proc Natl Acad Sci U S A, 99, pp. 4592-4595; Spears, W., Morphis II, J., Lester, S., Brain metastases and testicular tumors: Long-term survival (1991) Int J Radiat Oncol Biol Phys, 22, pp. 17-22; Bokemeyer, C., Nowak, P., Haupt, A., Treatment of brain metastases in patients with testicular cancer (1997) J Clin Oncol, 15, pp. 1449-1454; Kollmannsberger, C., Nichols, C., Bamberg, M., First-line high dose chemotherapy Â± radiation therapy in patients with metastatic germ-cell cancer and brain metastases (2000) Ann Oncol, 11, pp. 553-559; Nicolato, A., Ria, A., Foroni, R., Gamma knife radiosurgery in brain metastases from testicular tumors (2005) Med Oncol, 22, pp. 45-56; Bhatia, S., Abonour, R., Porcu, P., High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer (2000) J Clin Oncol, 18, pp. 3346-3351; Cooper, M., Einhorn, L.H., Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors (1995) J Clin Oncol, 13, pp. 1167-1169; Hinton, S., Catalano, P., Einhorn, L.H., Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group (2002) J Clin Oncol, 1, pp. 1859-1863; Cohn, D., Stuart-Harris, R., Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis (2001) Oncology, 61, pp. 184-188; Mahalati, K., Bilen, C., Ozen, H., The management of brain metastasis in non-seminomatous germ cell tumours (1999) Brit J Urol Int, 83, pp. 457-461; Salvati, M., Cervoni, L., Vitale, A., Solitary cerebral metastasis from tumor of the testis: Some observations about treatment in two cases (1997) Ital J Neurol Sci, 18, pp. 173-175; Raina, V., Singh, S., Kamble, N., Brain metastasis as the site of relapse in germ cell tumor of testis (1993) Cancer, 72, pp. 2182-2185; James, P., Mead, G., Sanctuary site relapse in chemotherapy-treated testicular cancer (1992) Ann Oncol, 3, pp. 41-43; Perry, J., Jelinek, J., Isolated central nervous system relapse of testicular cancer (1992) Med Pediatr Oncol, 20, pp. 68-70; Lester, S., Morphis, J., Hornback, N., Brain metastases and testicular tumors: Need for aggressive therapy (1984) J Clin Oncol, 2, pp. 1397-1403; Logothetis, C., Samuels, M., Trindade, A., The management of brain metastases in germ cell tumors (1982) Cancer, 49, pp. 12-18; Bart, J., Groen, H., Hendrikse, N., The blood-brain barrier and oncology: New insights into function and modulation (2000) Cancer Treat Rev, 26, pp. 449-462; Warren, K., Gervais, A., Aikin, A., Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors (2004) Cancer Chemother Pharmacol, 54, pp. 206-212; Redina, A., Demeule, M., Laplante, A., Multidrug resistance in brain tumors: Roles of the blood-brain barrier (2001) Cancer Metastasis Rev, 20, pp. 13-25; Mathews, V., Broome, D., Smith, R., Neuroimaging of disseminated germ cell neoplasms (1990) AJNR Am J Neuroradiol, 11, pp. 319-324","Azar, J.M.; Department of Medicine; Division of Hematology and Oncology; Indiana University Indianapolis, IN, United States; email: jazar@iupui.edu",,,,,,,,03603016,,IOBPD,10.1016/j.ijrobp.2007.02.042,"English","International Journal of Radiation Oncology Biology Physics",Article,Scopus
"Berk L., Berkey B., Rich T., Hrushesky W., Blask D., Gallagher M., Kudrimoti M., McGarry R.C., Suh J., Mehta M.","Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119)",2007,"International Journal of Radiation Oncology Biology Physics",68,3,,852,857,,1,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-34249326606&partnerID=40&rel=R8.0.0","Department of Radiation Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, United States; Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA, United States; Department of Radiation Oncology, University of Virginia, Charlottesville, VA, United States; Laboratory of Experimental Neuroendocrinology/Oncology, W. J. B. Dorn Veterans Administration Medical Center, University of South Carolina Arnold School of Public Health, Columbia, SC, United States; Medical Chronobiology Laboratory, S. C. Bassett Research Institute, Cooperstown, NY, United States; Scranton Radiation Medicine Association, Scranton, PA, United States; Department of Radiation Oncology, University of Kentucky, Lexington, KY, United States; Department of Radiation Oncology, Indiana University, Indianapolis, IN, United States; Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, United States; Department of Radiation Oncology, University of Wisconsin, Madison, WI, United States","Purpose: To determine if high-dose melatonin for Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) Class 2 patients with brain metastases improved survival over historical controls, and to determine if the time of day melatonin was given affected its toxicity or efficacy. RTOG 0119 was a phase II randomized trial for this group of patients. Methods and Materials: RTOG RPA Class 2 patients with brain metastases were randomized to 20 mg of melatonin, given either in the morning (8-9 am) or in the evening (8-9 pm). All patients received radiation therapy (30 Gy in 10 fractions) in the afternoon. Melatonin was continued until neurologic deterioration or death. The primary endpoint was overall survival time. Neurologic deterioration, as reflected by the Mini-Mental Status Examination, was also measured. Results: Neither of the randomized groups had survival distributions that differed significantly from the historic controls of patients treated with whole-brain radiotherapy. The median survivals of the morning and evening melatonin treatments were 3.4 and 2.8 months, while the RTOG historical control survival was 4.1 months. Conclusions: High-dose melatonin did not show any beneficial effect in this group of patients. Â© 2007 Elsevier Inc. All rights reserved.","Brain metastases; Chronobiology; Melatonin; Randomized trial; Survival","Brain; Neurology; Oncology; Toxicity; Brain metastases; Chronobiology; Melatonin; Randomized trials; Radiotherapy; melatonin; adult; aged; allergy; analytic method; article; blood toxicity; bone marrow toxicity; brain metastasis; cancer chemotherapy; cancer radiotherapy; cancer survival; chronobiology; clinical article; clinical trial; controlled clinical trial; controlled study; drug megadose; drug response; eye toxicity; fatigue; febrile neutropenia; female; gastrointestinal symptom; headache; hearing disorder; human; infection; male; mini mental state examination; musculoskeletal disease; nausea; neurotoxicity; outcome assessment; pain; phase 2 clinical trial; priority journal; randomized controlled trial; recursive partitioning analysis; skin toxicity; survival rate; survival time; visual disorder; vomiting; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Female; Humans; Melatonin; Middle Aged; Prevalence; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States",,"melatonin, 73-31-4; Antineoplastic Agents; Melatonin, 73-31-4",,"Cardiovascular Research, United States","Reiter, R.J., Pineal melatonin: Cell biology of its synthesis and of its physiological interactions (1991) Endocr Rev, 12, pp. 151-180; Reiter, R.J., Melatonin: Multi-faceted messenger to the masses (1994) Lab Med, 24, pp. 436-441; Blask, D.E., Sauer, L.A., Dauchy, R.T., Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy (2002) Curr Top Med Chem, 2, pp. 113-132; Tan, D.X., Manchester, L.C., Hardeland, R., Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin (2003) J Pineal Res, 34, pp. 75-78; Di, W.L., Kadva, A., Johnston, A., Silman, R., Variable bioavailability of oral melatonin (1997) N Engl J Med, 336, pp. 1028-1029; Dollins, A.B., Zhdanova, I.V., Wurtman, R.J., Lynch, H.J., Deng, M.H., Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance (1994) Proc Natl Acad Sci USA, 91, pp. 1824-1828; DeMuro, R.L., Nafziger, A.N., Blask, D.E., Menhinick, A.M., Bertino Jr., J.S., The absolute bioavailability of oral melatonin (0091-2700) (2000) J Clin Pharmacol, 42, pp. 781-784; Akagi, T., Ushinohama, K., Ikesue, S., Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect (2004) J Pharmacol Exp Ther, 308, pp. 378-384; Bartsch, H., Bartsch, C., Effect of melatonin on experimental tumors under different photoperiods and times of administration (1981) J Neural Transm, 52, pp. 269-279; Blask, D.E., Barthold, H.J., Dauchy, R.T., Melatonin radiosensitizes tumors and radioprotects normal tissues: Time-of-day dependency (2000) Am Assoc Cancer Res, , Abstract 338; Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Conti, A., Maestroni, G., A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms (1994) Cancer, 73, pp. 699-701; Lissoni, P., Meregalli, S., Nosetto, L., Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone (1996) Oncology, 53, pp. 43-46; Haus, E., Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology (2002) Chronobiol Int, 19, pp. 77-100; Rich, T.A., Shelton III, C.H., Kirichenko, A., Straume, M., Chronomodulated chemotherapy and irradiation: An idea whose time has come? (2002) Chronobiol Int, 19, pp. 191-205; Dixon, D.O., Simon, R., Sample size considerations for studies comparing survival curves using historical controls (1988) J Clin Epidemiol, 41, pp. 1209-1213; Crum, R.M., Anthony, J.C., Bassett, S.S., Folstein, M.F., Population-based norms for the Mini-Mental State Examination by age and educational level (1993) J Am Med Assoc, 269, pp. 2386-2391; Tangalos, E.G., Smith, G.E., Ivnik, R.J., The Mini-Mental State Examination in general medical practice: Clinical utility and acceptance (1996) Mayo Clin Proc, 71, pp. 829-837; Barni, S., Lissoni, P., Cazzaniga, M., A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates (1995) Oncology, 52, pp. 243-245; Brackowski, R., Zubelewicz, B., Romanowski, W., Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin (1994) J Biol Regul Homeost Agents, 8, pp. 77-880; Cerea, G., Vaghi, M., Ardizzoia, A., Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations (2003) Anticancer Res, 23, pp. 1951-1954; Lissoni, P., Is there a role for melatonin in supportive care? (2002) Support Care Cancer, 10, pp. 110-116; Lissoni, P., Barni, S., Ardizzoia, A., Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin (1992) Oncology, 49, pp. 336-339; Lissoni, P., Barni, S., Fossati, V., A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour (1995) Support Care Cancer, 3, pp. 194-197; Lissoni, P., Barni, S., Mandala, M., Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status (1999) Eur J Cancer, 35, pp. 1688-1692; Lissoni, P., Barni, S., Tancini, G., A randomised study with subcutaneous low-dose interleukin 2 alone vs. interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma (1994) Br J Cancer, 69, pp. 196-199; Lissoni, P., Brivio, F., Barni, S., Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: Its efficacy in preventing hypotension (1990) Anticancer Res, 10, pp. 1759-1761; Lissoni, P., Brivio, O., Brivio, F., Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma (1996) J Pineal Res, 21, pp. 239-242; Lissoni, P., Mandala, M., Brivio, F., Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin (2000) Eur Urol, 38, pp. 115-118; Lissoni, P., Meregalli, S., Fossati, V., A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer (1994) Tumori, 80, pp. 464-467; Lissoni, P., Paolorossi, F., Ardizzoia, A., A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state (1997) J Pineal Res, 23, pp. 15-19; Lissoni, P., Pittalis, S., Ardizzoia, A., Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin (1996) Support Care Cancer, pp. 313-316; Lissoni, P., Tancini, G., Barni, S., Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin (1997) Support Care Cancer, 5, pp. 126-129; Ghielmini, M., Pagani, O., de Jong, J., Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer (1999) Br J Cancer, 80, pp. 1058-1061; Sarma, A., Rodriguez, M.A., Cabanillas, F., A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma (2004) J Clin Oncol, 22, p. 8066; Di, W.-L., Kadva, A., Johnston, A., Silman, R., Variable bioavailability of oral melatonin (1997) N Engl J Med, 336, pp. 1028-1029; Meyers, C.A., Wefel, J.S., The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity (2003) J Clin Oncol, 21, pp. 3557-3558; Murray, K.J., Scott, C., Zachariah, B., Importance of the Mini-Mental Status Examination in the treatment of patients with brain metastases: A report from the Radiation Therapy Oncology Group protocol 91-04 (2000) Int J Radiat Oncol Biol Phys, 48, pp. 59-64","Berk, L.; Department of Radiation Oncology; H. Lee Moffitt Cancer Center; University of South Florida Tampa, FL, United States; email: Berklb@moffitt.usf.edu",,,,,,,,03603016,,IOBPD,10.1016/j.ijrobp.2007.01.012,"English","International Journal of Radiation Oncology Biology Physics",Article,Scopus
"Zheng Q.-H., Gao M., Mock B.H., Wang S., Hara T., Nazih R., Miller M.A., Receveur T.J., Lopshire J.C., Groh W.J., Zipes D.P., Hutchins G.D., DeGrado T.R.","Synthesis and biodistribution of new radiolabeled high-affinity choline transporter inhibitors [11C]hemicholinium-3 and [18F]hemicholinium-3",2007,"Bioorganic and Medicinal Chemistry Letters",17,8,,2220,2224,,4,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33947702669&partnerID=40&rel=R8.0.0","Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, United States; Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN 46202, United States","The high-affinity choline transporter (CHT1) system is an attractive target for the development of positron emission tomography (PET) biomarkers to probe brain, cardiac, and cancer diseases. An efficient and convenient synthesis of new radiolabeled CHT1 inhibitors [11C]hemicholinium-3 and [18F]hemicholinium-3 by solid-phase extraction (SPE) technique using a cation-exchange CM Sep-Pak cartridge has been well developed. The preliminary evaluation of both tracers through biodistribution studies in 9L-glioma rats has been performed, and the uptakes in the heart and tumor were observed, while very low brain uptake was seen. Â© 2007 Elsevier Ltd. All rights reserved.","[11C]hemicholinium-3 ([11C]HC-3); [18F]hemicholinium-3 ([18F]HC-3); Biodistribution; High-affinity choline transporter (CHT1); Positron emission tomography (PET)","choline derivative; hemicholinium 3 carbon 11; hemicholinium 3 fluorine 18; radiopharmaceutical agent; animal model; animal tissue; article; brain; cation exchange; choline uptake; drug distribution; drug synthesis; evaluation; glioma; heart; isotope labeling; nonhuman; rat; solid phase extraction; Animals; Brain; Carbon Radioisotopes; Cation Transport Proteins; Fluorine Radioisotopes; Glioma; Hemicholinium 3; Myocardium; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Rats; Rattus",,"Carbon Radioisotopes; Cation Transport Proteins; CHT1 protein, rat; Fluorine Radioisotopes; Hemicholinium 3, 312-45-8; Radiopharmaceuticals",,,"Smart, L.A., (1983) J. Med. Chem., 26, p. 104; Gilissen, C., de Groot, T., Bronfman, F., van Leuven, F., Verbruggen, A.M., Bormans, G.M., (2003) J. Nucl. Med., 44, p. 269; Hoover, D.B., Ganote, C.E., Ferguson, S.M., Blakely, R.D., Parsons, R.L., (2004) Cardiovasc. Res., 62, p. 112; Woolf, N.J., (1991) Prog. Neurobiol., 37, p. 475; Crick, S.J., Sheppard, M.N., Anderson, R.H., Polak, J.M., Wharton, J., (1996) J. Anat., 188, p. 403; Arvidsson, U., Riedl, M., Elde, R., Meister, B., (1997) J. Comp. Neurol., 378, p. 454; Schafer, M.K., Weihe, E., Erickson, J.D., Eiden, L.E., (1995) J. Mol. Neurosci., 6, p. 225; Schafer, M.K., Weihe, E., Eiden, L.E., Erickson, J.D., (1994) J. Mol. Neurosci., 5, p. 1; Schafer, M.K., Eiden, L.E., Weihe, E., (1998) Neuroscience, 84, p. 361; Suszkiw, J.B., Pilar, G., (1976) J. Neurochem., 26, p. 1133; Kuhar, M.J., Sethy, V.H., Roth, R.H., Aghajanian, G.K., (1973) J. Neurochem., 20, p. 581; Apparsundaram, S., Ferguson, S.M., Geroge Jr., A.L., Blakely, R.D., (2000) Biochem. Biophys. Res. Commun., 276, p. 862; Apparsundaram, S., Ferguson, S.M., Blakely, R.D., (2001) Biochem. Soc. Trans., 29, p. 711; Okuda, T., Haga, T., (2000) FEBS Lett., 484, p. 92; Misawa, H., Nakata, K., Matsuura, J., Nagao, M., Okuda, T., Haga, T., (2001) Neuroscience, 105, p. 87; Kus, L., Borys, E., Ping, C.Y., Ferguson, S.M., Blakely, R.D., Emborg, M.E., Kordower, J.H., Mufson, E.J., (2003) J. Comp. Neurol., 463, p. 341; Ferguson, S.M., Savchenko, V., Apparsundaram, S., Zwick, M., Wright, J., Heilman, C.J., Levey, A.I., Blakely, R.D., (2003) J. Neurosci., 23, p. 9697; Hara, T., Kosaka, N., Shinoura, N., Kondo, T., (1997) J. Nucl. Med., 38, p. 842; DeGrado, T.R., Coleman, R.E., Wang, S., Baldwin, S.W., Orr, M.D., Robertson, C.N., Polascik, T.J., Price, D.T., (2000) Cancer Res., 61, p. 110; DeGrado, T.R., Baldwin, S.W., Wang, S., Orr, M.D., Liao, R.P., Friedman, H.S., Reiman, R., Coleman, R.E., (2001) J. Nucl. Med., 42, p. 1805; Hara, T., Bansal, A., DeGrado, T.R., (2006) Mol. Imaging, 5, p. 498; Mulholland, K.K., Wieland, D.M., Kilbourn, M.R., Frey, K.A., Sherman, P.S., Carey, J.E., Kuhl, D.E., (1998) Synapse, 30, p. 263; Gao, M., Miller, M.A., DeGrado, T.R., Mock, B.H., Lopshire, J.C., Rosenberger, J.G., Dusa, C., Zheng, Q.-H., (2007) Bioorg. Med. Chem., 15, p. 1289; Haarstad, V.B., Domer, F.R., Chihal, D.M., Rege, A.B., Charles, H.C., (1976) J. Med. Chem., 19, p. 760; Mock, B.H., Mulholland, G.K., Vavrek, M.T., (1999) Nucl. Med. Biol., 26, p. 467; Mock, B.H., Zheng, Q.-H., DeGrado, T.R., (2005) J. Labelled Compd. Radiopharm., 48, pp. S225; Iwata, R., Pascali, C., Bogni, A., Furumoto, S., Terasaki, K., Yanai, K., (2002) Appl. Radiat. Isot., 57, p. 347; Gillis, R.J., Barry, J.A., Ross, B.D., (1994) Magn. Reson. Med., 32, p. 310; Walum, E., (1981) Cell Mol. Neurobiol., 1, p. 389; Liu, X., Wang, J.-Q., Zheng, Q.-H., (2005) Biomed. Chromatogr., 19, p. 379; Barinaga, M., (1999) Science, 278, p. 1226; note","Zheng, Q.-H.; Department of Radiology; Indiana University School of Medicine Indianapolis, IN 46202, United States; email: qzheng@iupui.edu",,,,,,,,0960894X,,BMCLE,10.1016/j.bmcl.2007.01.105,"English","Bioorganic and Medicinal Chemistry Letters",Article,Scopus
"Loder R.T., Huffman G., Toney E., Wurtz L.D., Fallon R.","Abnormal rib number in childhood malignancy: Implications for the scoliosis surgeon",2007,"Spine",32,8,,904,910,,1,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-34247189659&partnerID=40&rel=R8.0.0","James Whitcomb Riley Children's Hospital, Indianapolis, IN, United States; Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Pediatrics, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Orthopaedic Surgery, Pennsylvania State University, Hershey, PA, United States; James Whitcomb Riley Hospital for Children, 702 Barnhill Drive, Indianapolis, IN 46202, United States","STUDY DESIGN. Retrospective review. OBJECTIVE. To determine if rib anomalies are present in pediatric malignancies in the United States. SUMMARY OF BACKGROUND DATA. Scoliosis surgeons view radiographs of the entire spine, counting the number of ribs. A European study noted that rib anomalies were more common in certain malignancies. We wished to determine if this is also true in the United States. If so, the potential for screening, early detection of malignancy, and a better understanding of tumor biology is possible. METHODS. A retrospective review of 218 children with malignancy and a control group of 200 children with polytrauma or suspected child abuse was performed. Chest radiographs were reviewed to determine the number of ribs, and the presence of rib anomalies. 24 ribs was considered normal, <24 or >24 was considered abnormal. P < 0.05 was considered significant. RESULTS. The average age was 6.8 Â± 5.5 years and number of ribs was 23.8 Â± 0.6. Rib number was normal in 86.8%. There were significant differences between the malignancy and control groups in age (control, 5.7 Â± 5.1 years; malignancy, 7.8 Â± 5.7 years, P = 0.00007), rib number (control, 23.9 Â± 0.5; malignancy, 23.7 Â± 0.7, P = 0.001), and normal/abnormal rib counts (control, 92% normal; malignancy, 82% normal, P = 0.003). In the malignant group, 50% had a lymphoproliferative malignancy, 33% a solid tumor, and 17.0% a neural tumor. Neural malignancies had a higher incidence of rib abnormalities compared with lymphoproliferative or solid malignancies (P = 0.01). Relative to the control group, those with a neural and lymphoproliferative malignancy were 6.23 (95% CI, 2.7-14.5) and 2.0 (95% CI, 1.0-4.1) times more likely to have an abnormal rib count. CONCLUSIONS. Homeobox genes, important in vertebral and rib sequencing, are abnormally expressed in many different malignancies. This association is a question of great interest. What is the potential for rib number being used as a predictor of childhood malignancy? Can these findings be expanded to adults? These questions require further research. The association noted in this study is interesting but should not yet be used to alarm parents regarding an increased risk of malignancy in their children. Â© 2007 Lippincott Williams & Wilkins, Inc.","Child; Malignancy; Rib number","article; cancer risk; childhood cancer; controlled study; female; human; lymphoproliferative disease; major clinical study; male; nerve tumor; priority journal; retrospective study; rib malformation; school child; solid tumor; spine radiography; thorax radiography; United States; Adolescent; Brain Neoplasms; Child; Child, Preschool; Female; Genes, Homeobox; Humans; Incidence; Infant; Leukemia, Lymphocytic, Acute; Male; Neoplasms; Neuroblastoma; Prevalence; Retrospective Studies; Ribs; Sarcoma; Sarcoma, Ewing's; Scoliosis; Soft Tissue Neoplasms; Wilms Tumor",,,,,"Anbazhagan, A., Raman, V., Homeobox genes: Molecular link between congenital anomalies and cancer (1997) Eur J Cancer, 33, pp. 635-637; MeÌ�hes, K., Signer, E., PluÌˆss, H.J., Increased prevalence of minor anomalies in childhood malignancy (1985) Eur J Pediatr, 144, pp. 243-249; Schumacher, R., Mai, A., Gutjahr, P., Association of rib anomalies and malignancy in childhood (1992) Eur J Pediatr, 151, pp. 432-434; Danseco, E.R., Miller, T.R., Spicer, R.S., Incidence and cost of 1987-1994 childhood injuries: Demographic breakdowns (2000) Pediatrics, 105, pp. e27; Kilborn, T.N., Teh, J., Goodman, T.R., Paediatric manifestations of Langerhans cell histiocytosis: A review of the clinical and radiological findings (2003) Clin Radiol, 58, pp. 269-278; Egeler, R.M., D'Angio, G.J., Langerhans cell histiocytosis (1995) J Pediatr, 127, pp. 1-11; Herzog, K.M., Tubbs, R.R., Langerhans cell histiocytosis (1998) Adv Anat Pathol, 5, pp. 347-358; Arceci, R.J., The histiocytoses: The fall of the Tower of Babel (1999) Eur J Cancer, 35, pp. 747-769; Narod, S.A., Hawkins, M.M., Robertson, C.M., Congenital anomalies and childhood cancer in Great Britain (1997) Am J Hum Genet, 60, pp. 474-485; Burke, A.C., Nelson, C.E., Morgan, B.A., Hox genes and the evolution of vertebrate axial morphology (1995) Development, 121, pp. 333-346; Carapuco, M., NoÌ�voa, A., Bobola, N., Hox genes specify vertebral types in the presomitic mesoderm (2005) Genes Dev, 19, pp. 2116-2121; Wallin, J., Wilting, J., Koseki, H., The role of Pax-1 in axial skeleton development (1994) Development, 120, pp. 1109-1121; Johnson, D.R., O'Higgins, P.O., Is there a link between changes in the vertebral 'hox code' and the shape of vertebrae? A quantitative study of shape change in the cervical vertebral column of mice (1996) J Theor Biol, 183, pp. 89-93; Rodrigo, I., Hill, R.E., Balling, R., Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome (2003) Development, 130, pp. 473-482; Galis, F., Why do almost all mammals have seven cervical vertebrae? Developmental constraints, Hox genes, and cancer (1999) J Exp Zool (Mol Dev Evol), 285, pp. 19-26; Wellik, D.M., Capecchi, M.R., Hox10 and Hox 11 genes are required to globally pattern the mammalian skeleton (2003) Science, 301, pp. 363-367; Peters, H., Wilm, B., Sakai, N., Pax1 and Pax9 synergistically regulate vertebral column development (1999) Development, 126, pp. 5399-5408; Horan, G.S.B., Wu, K., Wolgemuth, D.J., Homeotic transformation of cervical vertebrae in Hoxa-4 mutant mice (1994) Proc Natl Acad Sci USA, 91, pp. 12644-12648; Condie, B.G., Capecchi, M.R., Mice homozygous for a targeted disruption of Hoxd-3 (Hox-4.1) exhibit anterior transformations of the first and second cervical vertebrae, the atlas and the axis (1993) Development, 119, pp. 579-595; ZaÌ�kaÌ�ny, J., GeÌ�rard, M., Faviere, B., Deletion of a HoxD enhancer induces transcriptional heterochrony leading to transposition of the sacrum (1997) EMBO J, 16, pp. 4393-4402; Christ, B., Schmidt, C., Huang, R., Segmentation of the vertebral body (1998) Anat Embryol, 197, pp. 1-8; Lettice, L., Hecksher-SÃ¸rensen, J., Hill, R., The role of Bapx1 (Nkx3.2) in the development and evolution of the axial skeleton (2001) J Anat, 199, pp. 181-187; van den Akker, E., Forlani, S., Chawengsaksophak, K., Cdx1 and Cdx2 have overlapping functions in anteroposterior patterning and posterior axis elongation (2002) Development, 129, pp. 2181-2193; Wewer, U.M., Mercurio, A.M., Chung, S.Y., Deoxyribonucleic-binding homeobox proteins are augmented in human cancer (1990) Lab Invest, 63, pp. 447-454; Mark, M., Rijli, F.M., Chambon, P., Homeobox genes in embryogenesis and pathogenesis (1997) Pediatr Res, 42, pp. 421-429; Cillo, C., Faiella, A., Cantile, M., Homeobox genes and cancer (1999) Exp Cell Res, 248, pp. 1-9; Barr, F.G., Chromosomal translocations involving paired box transcription factors in human cancer (1997) Int J Biochem Cell Biol, 29, pp. 1449-1461; Giampolo, A., Acampora, D., Zappavigna, V., Differential expression of human HOX-2 genes along the anterior-posterior axis in embryonic central nervous system (1989) Differentiation, 40, pp. 191-197; Shen, W.-F., Detmer, K., Mathews, C.H.E., Modulation of homeobox gene expression alters the phenotype of human hematopoietic cell lines (1992) EMBO J, 11, pp. 983-989; Kobayashi, N., Furukawa, T., Takatsu, T., Congenital anomalies in children with malignancy (1968) Paediatria Universitatis Tokyo, p. 16; Oorthuys, A.M., de Vaan, G.A.M., Behrendt, H., Palmar flexion creases in childhood neoplasia (1979) Cancer, 43, pp. 749-759; Robison, L.L., Swanson, T., Day, D.L., Renal anomalies in childhood acute lymphoblastic leukemia (1982) N Engl J Med, 307, pp. 1086-1087; Bellah, R., D'Andrea, A., Darillis, E., The association of congenital neuroblastoma and congenital heart disease (1989) Pediatr Radiol, 19, pp. 119-121; Reisman, M., Goldenberg, E.D., Gordon, J., Congenital heart disease and neuroblastoma (1966) Am J Dis Child, 111, pp. 308-310; KajtaÌ�r, P., Weisenbach, J., MeÌ�hes, K., Association of Wilms tumour with spina bifida occulta (1990) Eur J Pediatr, 149, pp. 594-596; Goodman FR, Scambler PJ. Human HOX gene mutations. Clin Genet 2001;59:1-11Smith, C.A., Tuan, R.S., Human PAX gene expression and development of the vertebral column (1994) Clin Orthop, 302, pp. 241-250; Ross, A.J., Ruiz-Perez, V., Wang, Y., A homeobox gene, HLXB9, is the major locus for dominantly inherited sacral agenesis (1998) Nat Genet, 20, pp. 358-361; LoÌ�pez, B.C., DaÌ�viÌ�d, K.M., Crockard, H.A., Inadequate PAX-1 gene expression as a cause of agenesis of the thoracolumbar spine with failure of segmentation (1997) J Neurosurg, 86, pp. 1018-1021; Boulet, A.M., Capecchi, M.R., Targeted disruption of hoxc-4 causes esophageal defects and vertebral transformations Dev Biol, 177 (177), pp. 232-249; Tribioli, C., Lufkin, T., The murine Bapx1 homebox gene plays a critical role in embryonic development of the axial skeleton and spleen (1999) Development, 126, pp. 5699-5711; Grier, D.G., Thompson, A., Kwasniewska, A., The pathophysiology of HOX genes and their role in cancer (2005) J Pathol, 205, pp. 154-171; Pineault, N., Abramovich, C., Ohta, H., Differential and common leukomogenic potentials of multiple NPU98-Hox fusion proteins alone or with Meis1 (2004) Mol Cell Biol, 24, pp. 1907-1917; Perkins, A., Kongsuwan, K., Visvader, J., Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia (1990) Proc Natl Acad Sci USA, 87, pp. 8398-8402; Blatt, C., Sachs, L., Deletion of homeobox gene in myeloid leukemias with a deletion in chromosome 2 (1988) Biochem Biophys Res Commun, 156, pp. 1265-1270; Moskow, J.J., Bullrich, F., Huebner, K., Meis 1, a PBX-1 related homeobox gene involved in myeloid leukemia in BXH-2 mice (1995) Mol Cell Biol, 15, pp. 5434-5443; Nakamura, T., Largaespada, D.A., Shaughnessy Jr, J.D., Cooperative activation of Hoxa and Pbx1-rleated genes in murine myeloid leukemia (1996) Nat Genet, 12, pp. 149-153; Chi, N., Epstein, J.A., Getting your Pax straight: Pax proteins in development and disease (2002) Trends Genet, 18, pp. 41-47; Davis, R.J., C'Cruz, D.M., Lovell, M.A., Fusion of PXA7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma (1994) Cancer Res, 54, pp. 2869-2872; Shimamoto, T., Ohyashiki, K., Toyama, K., Homeobox genes in hematopoiesis and leukemogenesis (1998) Int J Hematol, 67, pp. 339-350; Hatano, M., Roberts, C.W.M., Minden, M., Deregulation of a homeobox gene, HOX 11, by the t(10;14) in T cell leukemia (1991) Science, 253, pp. 79-82; DubeÌ�, I.D., Kamel-Reid, S., Yuan, C.C., A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14) (1991) Blood, 78, pp. 2996-3003; Lu, M., Gong, Z., Shen, W., The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein (1991) EMBO J, 10, pp. 2905-2910; Nakamura, T., Largaespada, D.A., Shaughnessy Jr, J.D., Fusion of the nucleoprotein gene NUP98 to HOXA9 by the chromosome translocation of t(7;11)(p15;p15) in human myeloid leukemia (1996) Nat Genet, 12, pp. 154-158; Kawagoe, H., Humphries, R.K., Blair, A., Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells (1999) Leukemia, 13, pp. 687-698; Lawrence, H.J., Rozenfeld, S., Cruz, C., Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias (1999) Leukemia, 13, pp. 1993-1999; Stuart, E.T., Kioussi, C., Aguzzi, A., Pax5 expression correlates with the increasing malignancy in human astrocytomas (1994) Clin Cancer Res, 1, pp. 207-214; Kozmik, K., Sure, U., RuÌˆedi, D., Deregulated expression of PAX5 in medulloblastoma (1995) Proc Natl Acad Sci USA, 92, pp. 5709-5713; Geerts, D., Schilderink, N., Jorritsma, G., The role of the MEIS homeobox genes in neuroblastoma (2003) Cancer Lett, 197, pp. 87-92; Pelletier, J., Bruening, W., Li, F.P., WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumor (1991) Nature, 353, pp. 431-434; Dressler, G.R., Douglas, E.C., Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilm's tumor (1992) Proc Natl Acad Sci USA, 89, pp. 1179-1183; Poleev, A., Fickenscher, H., Mundlos, S., PAX8, a human paired box gene: Isolation and expression in developing thyroid, kidney, and Wilm's tumor (1992) Development, 116, pp. 611-623; Cillo, C., Barba, P., Freschi, G., HOX gene expression in normal and neoplastic human kidney (1992) Int J Cancer, 51, pp. 892-897; Tiberio, C., Barba, P., Magli, M.C., HOX gene expression in human smallcell lung cancers xenografted into nude mice (1994) Int J Cancer, 58, pp. 608-615; De Vita, G., Barba, P., Odartchenko, N., Expression of homeoboxcontaining genes in primary and metastatic colorectal cancer (1993) Eur J Cancer, 29, pp. 887-893; Vider, B.Z., Zimber, A., Hirsch, D., Human colorectal carcinogenesis is associated with deregulation of homebox gene expression (1997) Biochem Biophys Res Commun, 22, pp. 742-748","Loder, R.T.; James Whitcomb Riley Hospital for Children; 702 Barnhill Drive Indianapolis, IN 46202, United States; email: rloder@iupui.edu",,,,,,,,03622436,,SPIND,10.1097/01.brs.0000259834.28893.97,"English","Spine",Article,Scopus
"Patel A.A., Gupta D., Seligson D., Hattab E.M., Balis U.J., Ulbright T.M., Kohane I.S., Berman J.J., Gilbertson J.R., Dry S., Schirripa O., Yu H., Becich M.J., Parwani A.V.","Availability and quality of paraffin blocks identified in pathology archives: A multi-institutional study by the Shared Pathology Informatics Network (SPIN)",2007,"BMC Cancer",7,, 37,,,,4,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33847776571&partnerID=40&rel=R8.0.0","Department of Pathology, Center for Pathology Informatics, University of Pittsburgh, Pittsburgh, PA, United States; Department of Pathology, University of California, Los Angeles, CA, United States; Department of Pathology, Indiana University, Indianapolis, IN, United States; Department of Pathology, Harvard University, Boston, MA, United States; Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States","Background: Shared Pathology Informatics Network (SPIN) is a tissue resource initiative that utilizes clinical reports of the vast amount of paraffin-embedded tissues routinely stored by medical centers. SPIN has an informatics component (sending tissue-related queries to multiple institutions via the internet) and a service component (providing histopathologically annotated tissue specimens for medical research). This paper examines if tissue blocks, identified by localized computer searches at participating institutions, can be retrieved in adequate quantity and quality to support medical researchers. Methods: Four centers evaluated pathology reports (1990-2005) for common and rare tumors to determine the percentage of cases where suitable tissue blocks with tumor were available. Each site generated a list of 100 common tumor cases (25 cases each of breast adenocarcinoma, colonic adenocarcinoma, lung squamous carcinoma, and prostate adenocarcinoma) and 100 rare tumor cases (25 cases each of adrenal cortical carcinoma, gastro-intestinal stromal tumor [GIST], adenoid cystic carcinoma, and mycosis fungoides) using a combination of Tumor Registry, laboratory information system (LIS) and/or SPIN-related tools. Pathologists identified the slides/blocks with tumor and noted first 3 slides with largest tumor and availability of the corresponding block. Results: Common tumors cases (n = 400), the institutional retrieval rates (all blocks) were 83% (A), 95% (B), 80% (C), and 98% (D). Retrieval rate (tumor blocks) from all centers for common tumors was 73% with mean largest tumor size of 1.49 cm; retrieval (tumor blocks) was highest-lung (84%) and lowest-prostate (54%). Rare tumors cases (n = 400), each institution's retrieval rates (all blocks) were 78% (A), 73% (B), 67% (C), and 84% (D). Retrieval rate (tumor blocks) from all centers for rare tumors was 66% with mean largest tumor size of 1.56 cm; retrieval (tumor blocks) was highest for GIST (72%) and lowest for adenoid cystic carcinoma (58%). Conclusion: A ssessment shows availability and quality of archival tissue blocks that are retrievable and associated electronic data that can be of value for researchers. This study serves to compliment the data from which uniform use of the SPIN query tools by all four centers will be measured to assure and highlight the usefulness of archival material for obtaining tumor tissues for research. Â© 2007 Patel et al; licensee BioMed Central Ltd.",,"access to information; adenoid cystic carcinoma; article; brain tumor; breast adenocarcinoma; cancer registry; cancer research; colon adenocarcinoma; computer program; controlled study; gastrointestinal stromal tumor; histopathology; hospital information system; human; human tissue; information dissemination; information retrieval; information system; Internet; lung squamous cell carcinoma; mycosis fungoides; prostate adenocarcinoma; qualitative analysis; quantitative analysis; tumor volume; health care facility; medical informatics; neoplasm; organization and management; pathology; statistics; United States; utilization review; paraffin; Humans; Medical Informatics; Neoplasms; Paraffin Embedding; Pathology, Clinical; Tissue Banks; United States",,,,,"Abati, A., Liotta, L.A., Looking forward in diagnostic pathology: The molecular superhighway (1996) Cancer, 78 (1), pp. 1-3. , 10.1002/(SICI)1097-0142(19960701)78:1<1::AID-CNCR1>3.0.CO;2-S 8646703; Fetsch, P.A., Simone, N.L., Bryant-Greenwood, P.K., Marincola, F.M., Filie, A.C., Petricoin, E.F., Liotta, L.A., Abati, A., Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: Potential for diagnostic applications (2002) Am J Clin Pathol, 118 (6), pp. 870-876. , 10.1309/EJKL-7328-KFPR-56WA 12472280; http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-01-006.html, Shared Pathology Informatics Network: Release Date: March 27, 2000, RFA: CA-01-006, National Cancer InstituteBecich, M.J., The role of the pathologist as tissue refiner and data miner: The impact of functional genomics on the modern pathology laboratory and the critical roles of pathology informatics and bioinformatics (2000) Mol Diagn, 5 (4), pp. 287-299. , 10.1054/modi.2000.20431 11172493; http://www.cancerdiagnosis.nci.nih.gov/spin/, Shared Pathology Informatics Network websiteMarshall, E., Panel proposes tighter rules for tissue studies (1998) Science, 282 (5397), pp. 2165-2166. , 10.1126/science.282.5397.2165a 9890818; Mizuno, T., Nagamura, H., Iwamoto, K.S., Ito, T., Fukuhara, T., Tokunaga, M., Tokuoka, S., Seyama, T., RNA from decades-old archival tissue blocks for retrospective studies (1998) Diagn Mol Pathol, 7 (4), pp. 202-208. , 10.1097/00019606-199808000-00004 9917130; Qualman, S.J., France, M., Grizzle, W.E., LiVolsi, V.A., Moskaluk, C.A., Ramirez, N.C., Washington, M.K., Establishing a tumour bank: Banking, informatics and ethics (2004) Br J Cancer, 90 (6), pp. 1115-1119. , 10.1038/sj.bjc.6601678 15026787; Cooperberg, M.R., Broering, J.M., Litwin, M.S., Lubeck, D.P., Mehta, S.S., Henning, J.M., Carroll, P.R., The contemporary management of prostate cancer in the United States: Lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry (2004) J Urol, 171 (4), pp. 1393-1401. , 10.1097/01.ju.0000107247.81471.06 15017184; Lubeck, D.P., Litwin, M.S., Henning, J.M., Stier, D.M., Mazonson, P., Fisk, R., Carroll, P.R., The CaPSURE database: A methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor (1996) Urology, 48 (5), pp. 773-777. , 10.1016/S0090-4295(96)00226-9 8911524; Grizzle, W., Grody, W.W., Noll, W.W., Sobel, M.E., Stass, S.A., Trainer, T., Travers, H., Woodruff, K., Recommended policies for uses of human tissue in research, education, and quality control. Ad Hoc Committee on Stored Tissue, College of American Pathologists (1999) Arch Pathol Lab Med, 123 (4), pp. 296-300. , 10320140; Grizzle, W.E., Aamodt, R., Clausen, K., LiVolsi, V., Pretlow, T.G., Qualman, S., Providing human tissues for research: How to establish a program (1998) Arch Pathol Lab Med, 122 (12), pp. 1065-1076. , 9870854; Grizzle, W.E., Woodruff, K.H., Trainer, T.D., The pathologist's role in the use of human tissues in research--legal, ethical, and other issues (1996) Arch Pathol Lab Med, 120 (10), pp. 909-912. , 12046602; Wertz, D.C., Archived specimens: A platform for discussion (1999) Community Genet, 2 (2-3), pp. 51-60. , 10.1159/000016187 11787507; Becich, M.J., Gilbertson, J.R., Gupta, D., Patel, A., Grzybicki, D.M., Raab, S.S., Pathology and patient safety: The critical role of pathology informatics in error reduction and quality initiatives (2004) Clin Lab Med, 24 (4), pp. 913-943. , vi 10.1016/j.cll.2004.05.019 15555749; Melamed, J., Datta, M.W., Becich, M.J., Orenstein, J.M., Dhir, R., Silver, S., Fidelia-Lambert, M., Berman, J.J., The cooperative prostate cancer tissue resource: A specimen and data resource for cancer researchers (2004) Clin Cancer Res, 10 (14), pp. 4614-4621. , 10.1158/1078-0432.CCR-04-0240 15269132; Patel, A.A., Kajdacsy-Balla, A., Berman, J.J., Bosland, M., Datta, M.W., Dhir, R., Gilbertson, J., Becich, M.J., The development of common data elements for a multi-institute prostate cancer tissue bank: The Cooperative Prostate Cancer Tissue Resource (CPCTR) experience (2005) BMC Cancer, 5, p. 108. , 1236914 16111498 10.1186/1471-2407-5-108; Glass, A.G., Donis-Keller, H., Mies, C., Russo, J., Zehnbauer, B., Taube, S., Aamodt, R., The Cooperative Breast Cancer Tissue Resource: Archival tissue for the investigation of tumor markers (2001) Clin Cancer Res, 7 (7), pp. 1843-1849. , 11448894; http://acsb.ucsf.edu/, AIDS and Cancer Specimen ResourcePatel, A.A., Gilbertson, J.R., Parwani, A.V., Dhir, R., Datta, M.W., Gupta, R., Berman, J.J., Becich, M.J., An informatics model for tissue banks - Lessons learned from the Cooperative Prostate Cancer Tissue Resource (2006) BMC Cancer, 6 (1), p. 120. , 1484486 16677389 10.1186/1471-2407-6-120; Beckwith, B.A., Mahaadevan, R., Balis, U.J., Kuo, F., Development and evaluation of an open source software tool for deidentification of pathology reports (2006) BMC Med Inform Decis Mak, 6, p. 12. , 1421388 16515714 10.1186/1472-6947-6-12; Gupta, D., Saul, M., Gilbertson, J., Evaluation of a deidentification (De-Id) software engine to share pathology reports and clinical documents for research (2004) Am J Clin Pathol, 121 (2), pp. 176-186. , 10.1309/E6K3-3GBP-E5C2-7FYU 14983930 14983930; McDonald, C.J., Dexter, P., Schadow, G., Chueh, H.C., Abernathy, G., Hook, J., Blevins, L., Berman, J.J., SPIN query tools for de-identified research on a humongous database (2005) AMIA Annu Symp Proc, pp. 515-519. , 16779093; Mitchell, K.J., Becich, M.J., Berman, J.J., Chapman, W.W., Gilbertson, J., Gupta, D., Harrison, J., Crowley, R.S., Implementation and evaluation of a negation tagger in a pipeline-based system for information extract from pathology reports (2004) Medinfo, 11 (PART 1), pp. 663-667; Mitchell, K.J., Crowley, R.S., Gupta, D., Gilbertson, J., A knowledge-based approach to information extraction from surgical pathology reports (2003) AMIA Annu Symp Proc, p. 937. , 1479971 14728442; Namini, A.H., Berkowicz, D.A., Kohane, I.S., Chueh, H., A submission model for use in the indexing, searching, and retrieval of distributed pathology case and tissue specimens (2004) Medinfo, 11 (PART 2), pp. 1264-1267. , 15361017; Schadow, G., McDonald, C.J., Extracting structured information from free text pathology reports (2003) AMIA Annu Symp Proc, pp. 584-588. , 1480213 14728240; Gilbertson, J.R., Gupta, R., Nie, Y., Patel, A.A., Becich, M.J., Automated clinical annotation of tissue bank specimens (2004) Medinfo, 11 (PART 1), pp. 607-610. , 15360884; Holzbach, A.M., Chueh, H., Porter, A.J., Kohane, I.S., Berkowicz, D., A query engine for distributed medical databases (2004) Medinfo, 11, p. 1519","Parwani, A.V.; Department of Pathology; Center for Pathology Informatics; University of Pittsburgh Pittsburgh, PA, United States; email: parwaniav@upmc.edu",,,,,,,,14712407,,BCMAC,10.1186/1471-2407-7-37,"English","BMC Cancer",Article,Scopus
"Xu J., Peng H., Zhang J.-T.","Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy",2007,"Current Medicinal Chemistry",14,6,,689,701,,3,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33947580644&partnerID=40&rel=R8.0.0","Department of Pharmacology and Toxicology, Indiana University Cancer Center, Indiana University School of Medicine, 1044 W. Walnut St., Indianapolis, IN 46202, United States","Human ABCG2, a member of the ATP-binding cassette transporter superfamily which transports a wide variety of substrates, is highly expressed in placental syncytiotrophoblasts, in the canalicular membranes of liver, in the apical membrane of the small intestine epithelium, and at the luminal surface of the endothelial cells of human brain micro vessels. This strategic tissue localization indicates that ABCG2 plays an important role in absorption, distribution, and elimination of xenobiotics and drugs. High ABCG2 expression has also been detected in many hematological malignancies and solid tumors, indicating that ABCG2 is likely responsible also for the multidrug resistance in cancer chemotherapy. Indeed, ABCG2 can actively transport structurally diverse conjugated- or unconjugated-organic molecules and various anticancer drugs. Many chemo-sensitizing agents have been discovered, which can be developed for increasing drug adsorption and reversing drug resistance in cancer chemotherapy by inhibiting ABCG2 function or expression. This review summarizes current knowledge on ABCG2, its relevance to multidrug resistance and drug disposition, and its evergrowing numbers of substrates and inhibitors. Â© 2007 Bentham Science Publishers Ltd.","ABC transporter; ABCG2; Chemo-sensitization; Drug resistance; Inhibitors; MDR; Oligomerization; Substrates","9 aminocamptothecin; antineoplastic agent; biochanin A; biricodar; breast cancer resistance protein; camptothecin; cimetidine; cyclosporin; daunorubicin; diethylstilbestrol; doxorubicin; elacridar; fibrinogen receptor antagonist; flavopiridol; fumitremorgin C; gefitinib; idarubicin; imatinib; irinotecan; isoquercitrin; me 3229; me 3277; methotrexate; mitoxantrone; multidrug resistance protein 1; rubitecan; tamoxifen; topotecan; unindexed drug; verapamil; acute granulocytic leukemia; antineoplastic activity; biliary excretion; bioavailability; blood placenta barrier; brain blood vessel; cancer; cancer chemotherapy; clinical trial; drug absorption; drug bioavailability; drug clearance; drug disposition; drug distribution; drug elimination; drug inhibition; drug metabolism; drug penetration; drug potentiation; drug resistance; drug sensitization; drug structure; drug targeting; drug transport; drug uptake; human; liver membrane; multidrug resistance; nonhuman; placental transfer; protein expression; protein function; protein structure; review; small intestine mucosa; structure activity relation; syncytiotrophoblast; tissue distribution; Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms",,"biochanin A, 491-80-5; biricodar, 174254-13-8; camptothecin, 7689-03-4; cimetidine, 51481-61-9, 70059-30-2; cyclosporin, 79217-60-0; daunorubicin, 12707-28-7, 20830-81-3, 23541-50-6; diethylstilbestrol, 30498-85-2, 56-53-1; doxorubicin, 23214-92-8, 25316-40-9; elacridar, 143664-11-3; flavopiridol, 131740-09-5, 146426-40-6; fumitremorgin C, 118974-02-0; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7; idarubicin, 57852-57-0, 58957-92-9; imatinib, 152459-95-5, 220127-57-1; irinotecan, 100286-90-6; isoquercitrin, 21637-25-2, 482-35-9; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; mitoxantrone, 65271-80-9, 70476-82-3; rubitecan, 91421-42-0; tamoxifen, 10540-29-1; topotecan, 119413-54-6, 123948-87-8; verapamil, 152-11-4, 52-53-9; ABCG2 protein, human; Antineoplastic Agents; ATP-Binding Cassette Transporters; Neoplasm Proteins","gf 120918; gleevec; me 3229; me 3277; zd 1839",,"Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., Ross, D.D., (1998) Proc. Natl. Acad. Sci. USA, 95, p. 15665; Allikmets, R., Schriml, L.M., Hutchinson, A., Romano-Spica, V., Dean, M., (1998) Cancer Res., 58, p. 5337; Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Bates, S.E., (1999) Cancer Res., 59, p. 8; Han, B., Zhang, J.T., (2004) Curr. Med. Chem. Anti-Cancer Agents, 4, p. 31; Allen, J.D., Brinkhuis, R.F., Wijnholds, J., Schinkel, A.H., (1999) Cancer Res., 59, p. 4237; Dean, M., Allikmets, R., (2001) J. Bioenerg. Biomembr., 33, p. 475; Borst, P., Elferink, R.O., (2002) Annu. Rev. Biochem., 71, p. 537; Dean, M., Rzhetsky, A., Allikmets, R., (2003) ABC Proteins, from Bacteria to Man, p. 47. , In I.B. Holland; S. P. Cole; K. Kuchler; C.F. Higgins, eds.; Academic Press: Amsterdam; Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., (2006) Nat. Rev. Drug Discov., 5, p. 219; Diop, N.K., Hrycyna, C.A., (2005) Biochemistry, 44, p. 5420; Mohrmann, K., van Eijndhoven, M.A., Schinkel, A.H., Schellens, J.H., (2005) Cancer Chemother. Pharmacol, 56, p. 344; Ozvegy, C., Litman, T., Szakacs, G., Nagy, Z., Bates, S., Varadi, A., Sarkadi, B., (2001) Biochem. Biophys. Res. Commun., 285, p. 111; Litman, T., Druley, T.E., Stein, W.D., Bates, S.E., (2001) Cell Mol. Life Sci., 58, pp. 931-959; Kage, K., Tsukahara, S., Sugiyama, T., Asada, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y., (2002) Int. J. Cancer, 97, p. 626; Sullivan, D.T., Sullivan, M.C., (1975) Biochem. Genet., 13, p. 603; Ewart, G.D., Howells, A., (1998) J. Methods Enzymol., 292, p. 213; Graf, G.A., Yu, L., Li, W.P., Gerard, R., Tuma, P.L., Cohen, J.C., Hobbs, H.H., (2003) J. Biol. Chem., 278, p. 48275; Henriksen, U., Gether, U., Litman, T., (2005) J. Cell Sci., 118, p. 1417; Litman, T., Jensen, U., Hansen, A., Covitz, K.M., Zhan, Z., Fetsch, P., Abati, A., Bates, S.E., (2002) Biochim. Biophys. Acta, 1565, p. 6; Xu, J., Liu, Y., Yang, Y., Bates, S., Zhang, J.T., (2004) J. Biol. Chem., 279, pp. 19781-19789; Bhatia, A., Schafer, H.J., Hrycyna, C.A., (2005) Biochemistry, 44, p. 10893; McDevitt, C.A., Collins, R.F., Conway, M., Modok, S., Storm, J., Kerr, I.D., Ford, R.C., Callaghan, R., (2006) Structure, 14, p. 1623; Henriksen, U., Fog, J.U., Litman, T., Gether, U., (2005) J. Biol. Chem., 280, p. 36926; Mitomo, H., Kato, R., Ito, A., Kasamatsu, S., Ikegami, Y., Kii, I., Kudo, A., Ishikawa, T., (2003) Biochem. J., 373, p. 767; Bustos, D.M., Velours, J., (2005) J. Biol. Chem., 280, p. 29004; Polgar, O., Robey, R.W., Morisaki, K., Dean, M., Michejda, C., Sauna, Z.E., Ambudkar, S.V., Bates, S.E., (2004) Biochemistry, 43, p. 9448; Ewart, G.D., Cannell, D., Cox, G.B., Howells, A.J., (1994) J. Biol. Chem., 269, p. 10370; Polgar, O., Ozvegy-Laczka, C., Robey, R.W., Morisaki, K., Okada, M., Tamaki, A., Koblos, G., Bates, S.E., (2006) Biochemistry, 45, p. 5251; Ozvegy, C., Varadi, A., Sarkadi, B., (2002) J. Biol. Chem., 277, p. 47980; Janvilisri, T., Venter, H., Shahi, S., Reuter, G., Balakrishnan, L., van Veen, H.W., (2003) J. Biol. Chem., 278, p. 20645; Mao, Q., Conseil, G., Gupta, A., Cole, S.P., Unadkat, J.D., (2004) Biochem. Biophys. Res. Commun., 320, p. 730; Chloupkova, M., Reaves, S.K., LeBard, L.M., Koeller, D.M., (2004) FEBS Lett., 569, p. 65; Maliepaard, M., Scheffer, G.L., Faneyte, I.F., van Gastelen, M.A., Pijnenborg, A.C., Schinkel, A.H., van De Vijver, M.J., Schellens, J.H., (2001) Cancer Res., 61, p. 3458; Jonker, J.W., Smit, J.W., Brinkhuis, R.F., Maliepaard, M., Beijnen, J.H., Schellens, J.H., Schinkel, A.H., (2000) J. Natl. Cancer Inst., 92, p. 1651; Staud, F., Vackova, Z., Pospechova, K., Pavek, P., Ceckova, M., Libra, A., Cygalova, L., Fendrich, Z., (2006) J. Pharmacol. Exp. Ther., 319, p. 53; Yasuda, S., Itagaki, S., Hirano, T., Iseki, K., (2005) Biosci. Biotechnol. Biochem., 69, p. 1871; Mathias, A.A., Hitti, J., Unadkat, J.D., (2005) Am. J. Physiol. Regul. Integr. Comp. Physiol., 289, pp. R963; Cooray, H.C., Blackmore, C.G., Maskell, L., Barrand, M.A., (2002) Neuroreport, 13, p. 2059; Eisenblatter, T., Galla, H., (2002) J. Biochem. Biophys. Res. Commun., 293, p. 1273; Zhang, W., Mojsilovic-Petrovic, J., Andrade, M.F., Zhang, H., Ball, M., Stanimirovic, D.B., (2003) FASEB J., 17, p. 2085; Cisternino, S., Mercier, C., Bourasset, F., Roux, F., Scherrmann, J.M., (2004) Cancer Res., 64, p. 3296; Kruijtzer, C.M., Beijnen, J.H., Rosing, H., ten Bokkel Huinink, W.W., Schot, M., Jewell, R.C., Paul, E.M., Schellens, J.H., (2002) J. Clin. Oncol., 20, p. 2943; Gutmann, H., Hruz, P., Zimmermann, C., Beglinger, C., Drewe, J., (2005) Biochem. Pharmacol., 70, p. 695; Adachi, Y., Suzuki, H., Schinkel, A.H., Sugiyama, Y., (2005) Mol. Pharmacol., 67, pp. 923-928; Sesink, A.L., Arts, I.C., de Boer, V.C., Breedveld, P., Schellens, J.H., Hollman, P.C., Russel, F.G., (2005) Mol. Pharmacol., 67, p. 1999; Okudaira, N., Komiya, I., Sugiyama, Y., (2000) J. Pharmacol. Exp. Ther., 295, p. 717; Kondo, C., Onuki, R., Kusuhara, H., Suzuki, H., Suzuki, M., Okudaira, N., Kojima, M., Sugiyama, Y., (2005) Pharm. Res., 22, p. 613; Zhou, S., Schuetz, J.D., Bunting, K.D., Colapietro, A.M., Sampath, J., Morris, J.J., Lagutina, I., Sorrentino, B.P., (2001) Nat. Med., 7, p. 1028; Scharenberg, C.W., Harkey, M.A., Torok-Storb, B., (2002) Blood, 99, pp. 507-512; Zhou, S., Morris, J.J., Barnes, Y., Lan, L., Schuetz, J.D., Sorrentino, B.P., (2002) Proc. Natl. Acad. Sci. USA, 99, p. 12339; Dean, M., Fojo, T., Bates, S., (2005) Nat. Rev. Cancer, 5, p. 275; Ross, D.D., Karp, J.E., Chen, T.T., Doyle, L.A., (2000) Blood, 96, p. 365; Sargent, J.M., Williamson, C.J., Maliepaard, M., Elgie, A.W., Scheper, R.J., Taylor, C.G., (2001) Br. J. Haematol., 115, p. 257; Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F., Sauerbrey, A., (2002) Leukemia, 16, p. 1443; Abbott, B.L., Colapietro, A.M., Barnes, Y., Marini, F., Andreeff, M., Sorrentino, B.P., (2002) Blood, 100, p. 4594; Sauerbrey, A., Sell, W., Steinbach, D., Woigt, A., Zintl, F., (2002) Br. J. Haematol., 118, p. 147; Plasschaert, S.L., van der Kolk, D.M., de Bont, E.S., Kamps, W.A., Morisaki, K., Bates, S.E., Scheffer, G.L., de Vries, E.G., (2003) Clin. Cancer Res., 9, p. 5171; Ren, J.H., Du, X.Y., Guo, X.N., Wang, Y., Zhang, J.N., Lin, F.R., Dong, Z.R., (2004) Zhongguo Shi Yan Xue Ye Xue Za Zhi, 12, p. 55; van der Kolk, D.M., Vellenga, E., Scheffer, G.L., Muller, M., Bates, S.E., Scheper, R.J., de Vries, E.G., (2002) Blood, 99, p. 3763; van den Heuvel-Eibrink, M.M., Wiemer, E.A., Prins, A., Meijerink, J.P., Vossebeld, P.J., van der Holt, B., Pieters, R., Sonneveld, P., (2002) Leukemia, 16, p. 833; Uggla, B., Stahl, E., Wagsater, D., Paul, C., Karlsson, M.G., Sirsjo, A., Tidefelt, U., (2005) Leuk. Res., 29, p. 141; Benderra, Z., Faussat, A.M., Sayada, L., Perrot, J.Y., Tang, R., Chaoui, D., Morjani, H., Legrand, O., (2005) Clin. Cancer Res., 11, p. 7764; Wilson, C.S., Davidson, G.S., Martin, S.B., Andries, E., Potter, J., Harvey, R., Ar, K., Willman, C.L., (2006) Blood, 108, p. 685; Honjo, Y., Hrycyna, C.A., Yan, Q.W., Medina-Perez, W.Y., Robey, R.W., van de Laar, A., Litman, T., Bates, S.E., (2001) Cancer Res., 61, p. 6635; Robey, R.W., Honjo, Y., Morisaki, K., Nadjem, T.A., Runge, S., Risbood, M., Poruchynsky, M.S., Bates, S.E., (2003) Br. J. Cancer, 89, p. 1971; Miwa, M., Tsukahara, S., Ishikawa, E., Asada, S., Imai, Y., Sugimoto, Y., (2003) Int. J. Cancer, 107, p. 757; Volk, E.L., Farley, K.M., Wu, Y., Li, F., Robey, R.W., Schneider, E., (2002) Cancer Res., 62, p. 5035; Volk, E.L., Schneider, E., (2003) Cancer Res., 63, p. 5538; Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D.D., Miyake, K., Bates, S.E., (2000) J. Cell Sci., 113 (PART 11), p. 2011; Chen, Y.N., Mickley, L.A., Schwartz, A.M., Acton, E.M., Hwang, J.L., Fojo, A.T., (1990) J. Biol. Chem., 265, p. 10073; Hazlehurst, L.A., Foley, N.E., Gleason-Guzman, M.C., Hacker, M.P., Cress, A.E., Greenberger, L.W., De Jong, M.C., Dalton, W.S., (1999) Cancer Res., 59, p. 1021; Rabindran, S.K., Ross, D.D., Doyle, L.A., Yang, W., Greenberger, L.M., (2000) Cancer Res., 60, p. 47; Maliepaard, M., van Gastelen, M.A., de Jong, L.A., Pluim, D., van Waardenburg, R.C., Ruevekamp-Helmers, M.C., Floot, B.G., Schellens, J.H., (1999) Cancer Res., 59, p. 4559; Maliepaard, M., van Gastelen, M.A., Tohgo, A., Hausheer, F.H., van Waardenburg, R.C., de Jong, L.A., Pluim, D., Schellens, J.H., (2001) Clin. Cancer Res., 7, p. 935; Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kohno, S., (2001) Biochem. Biophys. Res. Commun., 288, p. 827; Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Kohno, S., (2001) Biochem. Biophys. Res. Commun., 280, p. 1216; Ishii, M., Iwahana, M., Mitsui, I., Minami, M., Imagawa, S., Tohgo, A., Ejima, A., (2000) Anticancer Drugs, 11, p. 353; Rajendra, R., Gounder, M.K., Saleem, A., Schellens, J.H., Ross, D.D., Bates, S.E., Sinko, P., Rubin, E.H., (2003) Cancer Res., 63, p. 3228; Yoshikawa, M., Ikegami, Y., Hayasaka, S., Ishii, K., Ito, A., Sano, K., Suzuki, T., Ishikawa T. Tanabe, S., (2004) Int. J. Cancer, 110, p. 921; Ishikawa, T., Ikegami, Y., Sano, K., Nakagawa, H., Sawada, S., (2006) Curr. Pharm. Des., 12, p. 313; Allen, J.D., Van Dort, S.C., Buitelaar, M., van Tellingen, O., Schinkel, A.H., (2003) Cancer Res., 63, p. 1339; Robey, R.W., Medina-Perez, W.Y., Nishiyama, K., Lahusen, T., Miyake, K., Litman, T., Senderowicz, A.M., Bates, S.E., (2001) Clin. Cancer Res., 7, p. 145; Burger, H., van Tol, H., Boersma, A.W., Brok, M., Wiemer, E.A., Stoter, G., Nooter, K., (2004) Blood, 104, p. 2940; Erlichman, C., Boerner, S.A., Hallgren, C.G., Spieker, R., Wang, X.Y., James, C.D., Scheffer, G.L., Kaufmann, S.H., (2001) Cancer Res., 61, p. 739; Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler, P., (2004) Cancer Res., 64, p. 2333; Robey, R.W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J.T., Litman, T., Bates, S.E., (2001) Biochim. Biophys. Acta, 1512, p. 171; Suzuki, M., Suzuki, H., Sugimoto, Y., Sugiyama, Y., (2003) J. Biol. Chem., 278, p. 22644; Kondo, C., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J., Kobayashi, D., Ieiri, I., Sugiyama, Y., (2004) Pharm. Res., 21, p. 1895; Chen, Z.S., Robey, R.W., Belinsky, M.G., Shchaveleva, I., Ren, X.Q., Sugimoto, Y., Ross, D.D., Kruh, G.D., (2003) Cancer Res., 63, p. 4048; Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y., (2003) Mol. Pharmacol., 64, p. 610; Jonker, J.W., Buitelaar, M., Wagenaar, E., Van Der Valk, M.A., Scheffer, G.L., Scheper, R.J., Plosch, T., Schinkel, A.H., (2002) Proc. Natl. Acad. Sci. USA, 99, p. 15649; Woehlecke, H., Pohl, A., Alder-Baerens, N., Lage, H., Herrmann, A., (2003) Biochem. J., 376, p. 489; Wang, X., Furukawa, T., Nitanda, T., Okamoto, M., Sugimoto, Y., Akiyama, S., Baba, M., (2003) Mol. Pharmacol., 63, p. 65; Wang, X., Nitanda, T., Shi, M., Okamoto, M., Furukawa, T., Sugimoto, Y., Akiyama, S., Baba, M., (2004) Biochem. Pharmacol., 68, p. 1363; Imai, Y., Tsukahara, S., Asada, S., Sugimoto, Y., (2004) Cancer Res., 64, p. 4346; Polli, J.W., Baughman, T.M., Humphreys, J.E., Jordan, K.H., Mote, A.L., Webster, L.O., Barnaby, R., Serabjit-Singh, C., (2004) J. Drug Metab. Dispos., 32, p. 722; Breedveld, P., Zelcer, N., Pluim, D., Sonmezer, O., Tibben, M.M., Beijnen, J.H., Schinkel, A.H., Schellens, J.H., (2004) Cancer Res., 64, p. 5804; Pavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J.W., Schinkel, A.H., (2005) J. Pharmacol. Exp. Ther., 312, p. 144; Gedeon, C., Behravan, J., Koren, G., Piquette-Miller, M., (2006) Placenta, 27, p. 1096; Robey, R.W., Fetsch, P.A., Polgar, O., Dean, M., Bates, S.E., (2006) Res. Vet. Sci., 81, p. 345; Shukla, S., Robey, R.W., Bates, S.E., Ambudkar, S.V., (2006) Biochemistry, 45, p. 8940; Juliano, R.L., Ling, V., (1976) Biochim. Biophys. Acta, 455, p. 152; Minderman, H., O'Loughlin, K.L., Pendyala, L., Baer, M.R., (2004) Clin. Cancer Res., 10, p. 1826; Minderman, H., Brooks, T.A., O'Loughlin, K.L., Ojima, I., Bernacki, R.J., Baer, M.R., (2004) Cancer Chemother. Pharmacol., 53, p. 363; Robey, R.W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., Bates, S.E., (2004) Cancer Res., 64, p. 1242; de Bruin, M., Miyake, K., Litman, T., Robey, R., Bates, S.E., (1999) Cancer Lett., 146, p. 117; Seiden, M.V., Swenerton, K.D., Matulonis, U., Campos, S., Rose, P., Batist, G., Ette, E., Charpentier, D., (2002) Gynecol. Oncol., 86, p. 302; Rago, R.P., Einstein Jr., A., Lush, R., Beer, T.M., Ko, Y.J., Henner, W.D., Bubley, G., Dalton, W.S., (2003) Cancer Chemother. Pharmacol., 51, p. 297; Rabindran, S.K., He, H., Singh, M., Brown, E., Collins, K.I., Annable, T., Greenberger, L.M., (1998) Cancer Res., 58, p. 5850; van Loevezijn, A., Allen, J.D., Schinkel, A.H., Koomen, G., (2001) J. Bioorg. Med. Chem. Lett., 11, p. 29; Allen, J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J.H., Schinkel, A.H., (2002) Mol. Cancer Ther., 1, p. 417; Woehlecke, H., Osada, H., Herrmann, A., Lage, H., (2003) Int. J. Cancer, 107, p. 721; Sugimoto, Y., Tsukahara, S., Imai, Y., Sugimoto, Y., Ueda, K., Tsuruo, T., (2003) Mol. Cancer Ther., 2, p. 105; Zhang, S., Yang, X., Morris, M.E., (2004) Mol. Pharmacol., 65, p. 1208; Cooray, H.C., Janvilisri, T., van Veen, H.W., Hladky, S.B., Barrand, M.A., (2004) Biochem. Biophys. Res. Commun., 317, p. 269; Kuhnau, J., (1976) World Rev. Nutr. Diet., 24, p. 117; Zhang, S., Yang, X., Coburn, R.A., Morris, M.E., (2005) Biochem. Pharmacol., 70, p. 627; Boumendjel, A., Di Pietro, A., Dumontet, C., Barron, D., (2002) Med. Res. Rev., 22, p. 512; Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J.M., Barron, D., Di Pietro, A., (1998) Proc. Natl. Acad. Sci. USA, 95, p. 9831; Boumendjel, A., Bois, F., Beney, C., Mariotte, A.M., Conseil, G., Di Pietro, A., (2001) Bioorg. Med. Chem. Lett., 11, p. 75; Bobrowska-Hagerstrand, M., Wrobel, A., Mrowczynska, L., Soderstrom, T., Shirataki, Y., Motohashi, N., Molnar, J., Hagerstrand, H., (2003) Oncol. Res., 13, p. 463; Ahmed-Belkacem, A., Pozza, A., Munoz-Martinez, F., Bates, S.E., Castanys, S., Gamarro, F., Di Pietro, A., Perez-Victoria, J.M., (2005) Cancer Res., 65, p. 4852; Ozvegy-Laczka, C., Hegedus, T., Varady, G., Ujhelly, O., Schuetz, J.D., Varadi, A., Keri, G., Sarkadi, B., (2064) Mol. Pharmacol., 65, p. 1485; Yang, C.H., Chen, Y.C., Kuo, M.L., (2003) Anticancer Res., 23, p. 2519; Shiozawa, K., Oka, M., Soda, H., Yoshikawa, M., Ikegami, Y., Tsurutani, J., Nakatomi, K., Kohno, S., (2004) Int. J. Cancer, 108, p. 146; Gupta, A., Zhang, Y., Unadkat, J.D., Mao, Q., (2004) J. Pharmacol. Exp. Ther., 310, p. 334; Cooray, H.C., Shahi, S., Cahn, A.P., van Veen, H.W., Hladky, S.B., Barrand, M.A., (2006) Eur. J. Pharmacol., 531, p. 25; Jin, J., Shabi, S., Kang, H.K., van Veen, H.W., Fan, T.P., (2006) Biochem. Biophys. Res. Commun., 345, p. 1308; Chearwae, W., Shukla, S., Limtrakul, P., Ambudkar, S.V., (2006) Mol. Cancer Ther., 5, p. 199; Holm, P.S., Scanlon, K.J., Dietel, M., (1994) Br. J. Cancer, 70, p. 239; Kobayashi, H., Dorai, T., Holland, J.F., Ohnuma, T., (1994) Cancer Res., 54, p. 1271; Kowalski, P., Wichert, A., Holm, P.S., Dietel, M., Lage, H., (2001) Cancer Gene Ther., 8, p. 185; Kowalski, P., Stein, U., Scheffer, G.L., Lage, H., (2002) Cancer Gene Ther., 9, p. 579; Ee, P.L., He, X., Ross, D.D., Beck, W.T., (2004) Mol. Cancer Ther., 3, p. 1577; Li, W.T., Zhou, G.Y., Song, X.R., Chi, W.L., Ren, R.M., Wang, X.W., (2005) Neoplasma, 52, p. 219","Zhang, J.-T.; Department of Pharmacology and Toxicology; IUCC; Indiana University School of Medicine; 1044 W. Walnut St. Indianapolis, IN 46202, United States; email: jianzhan@iupui.edu",,,,,,,,09298673,,CMCHE,10.2174/092986707780059580,"English","Current Medicinal Chemistry",Review,Scopus
"Mathew R.M., Vandenberghe R., Garcia-Merino A., Yamamoto T., Landolfi J.C., Rosenfeld M.R., Rossi J.E., Thiessen B., Dropcho E.J., Dalmau J.","Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis",2007,"Neurology",68,12,,900,905,,7,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-34147134976&partnerID=40&rel=R8.0.0","Department of Neurology, Division Neuro-oncology, University of Pennsylvania, Philadelphia; Department of Neurology, University Hospital Gasthuisberg, Leuven, Belgium; Department of Neurology, CliÌ�nica Puerta de Hierro, Madrid, Spain; Department of Neurology, University of Tokyo Hospital, Japan; New Jersey Neuroscience Institute, JFK Medical Center, Edison; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada; Department of Neurology, Indiana University Medical Center, Indianapolis, United States; Division Neuro-oncology, Department of Neurology, University of Pennsylvania, 3 W. Gates, 3400 Spruce Street, Philadelphia, PA 19104, United States","OBJECTIVE: To report the presence of microscopic neoplasms of the testis in men with anti-Ma2-associated encephalitis (Ma2-encephalitis) and to discuss the clinical implications. METHODS: Orchiectomy specimens were examined using immunohistochemistry with Ma2 and Oct4 antibodies. RESULTS: Among 25 patients with Ma2-encephalitis younger than 50 years, 19 had germ-cell tumors, and 6 had no evidence of cancer. These 6 patients underwent orchiectomy because they fulfilled five criteria: 1) demonstration of anti-Ma2 antibodies in association with MRI or clinical features compatible with Ma2-encephalitis, 2) life-threatening or progressive neurologic deficits, 3) age < 50 years, 4) absence of other tumors, and 5) new testicular enlargement or risk factors for germ-cell tumors, mainly cryptorchidism or ultrasound evidence of testicular microcalcifications. All orchiectomy specimens showed intratubular-germ cell neoplasms unclassified type (IGCNU) and other abnormalities including microcalcifications, atrophy, fibrosis, inflammatory infiltrates, or hypospermatogenesis. Ma2 was expressed by neoplastic cells in three of three patients examined. Even though most patients had severe neurologic deficits at the time of orchiectomy (median progression of symptoms, 10 months), 4 had partial improvement and prolonged stabilization (8 to 84 months, median 22.5 months) and two did not improve after the procedure. CONCLUSIONS: In young men with Ma2-encephalitis, 1) the disorder should be attributed to a germ-cell neoplasm of the testis unless another Ma2-expressing tumor is found, 2) negative tumor markers, ultrasound, body CT, or PET do not exclude an intratubular germ-cell neoplasm of the testis, and 3) if no tumor is found, the presence of the five indicated criteria should prompt consideration of orchiectomy. Â©2007AAN Enterprises, Inc.",,"antibody; ma2 antibody; oct4 antibody; article; calcification; clinical article; clinical feature; cryptorchism; echography; encephalitis; fibrosis; genital system disease; germ cell tumor; human; human tissue; hypospermatogenesis; immunohistochemistry; inflammatory infiltrate; male; neurologic disease; nuclear magnetic resonance imaging; orchiectomy; priority journal; risk factor; testicular enlargement; testis atrophy; testis cancer; testis tumor; tumor cell; Adult; Antigens, Neoplasm; Autoantibodies; Brain; Diagnosis, Differential; Early Diagnosis; Humans; Limbic Encephalitis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Nerve Tissue Proteins; Neural Pathways; Orchiectomy; Predictive Value of Tests; Testicular Neoplasms; Tumor Markers, Biological",,"Antigens, Neoplasm; Autoantibodies; Ma2 antigen; Nerve Tissue Proteins; Tumor Markers, Biological",,,"Graus, F., Dalmau, J., Rene, R., Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival (1997) J Clin Oncol, 15, pp. 2866-2872; Darnell, R.B., Posner, J.B., Paraneoplastic syndromes involving the nervous system (2003) N Engl J Med, 349, pp. 1543-1554; Younes-Mhenni, S., Janier, M.F., Cinotti, L., FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes (2004) Brain, 127, pp. 2331-2338; Dalmau, J., Graus, F., Villarejo, A., Clinical analysis of anti-Ma2-associated encephalitis (2004) Brain, 127, pp. 1831-1844; Montironi, R., Intratubular germ cell neoplasia of the testis: Testicular intraepithelial neoplasia (2002) Eur Urol, 41, pp. 651-654; Mathew RM, Yamamoto T, Nakamura K, Dropcho E, Tsuji S, Dalmau J. Orchiectomy for suspected microscopic tumor in patients with paraneoplastic anti-Ma2 encephalitis. 58th annual meeting of the AAN; San Diego, CA; April 5, 2006. Abstract and video clips available at: http://www.abstracts2view.com/aan/ view.php?nu=AAN06L_PL01.001; http://www.marathonmultimedia.com/aan_library/ master2.php?ud=56136Landolfi, J.C., Nadkarni, M., Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: Case study (2003) Neurooncol, 5, pp. 214-216; Rosenfeld, M.R., Eichen, J.G., Wade, D.F., Posner, J.B., Dalmau, J., Molecular and clinical diversity in paraneoplastic immunity to Ma proteins (2001) Ann Neurol, 50, pp. 339-348; Furneaux, H.M., Rosenblum, M.K., Dalmau, J., Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration (1990) N Engl J Med, 322, pp. 1844-1851; Cattoretti, G., Pileri, S., Parravicini, C., Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections (1993) J Pathol, 171, pp. 83-98; Voltz, R., Gultekin, S.H., Rosenfeld, M.R., A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer (1999) N Engl J Med, 340, pp. 1788-1795; Waragai, M., Chiba, A., Uchibori, A., Fukushima, T., Anno, M., Tanaka, K., Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy (2006) J Neurol Neurosurg Psychiatry, 77, pp. 111-113; Blumenthal, D.T., Salzman, K.L., Digre, K.B., Jensen, R.L., Dunson, W.A., Dalmau, J., Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis (2006) Neurology, 67, pp. 146-149; Bosl, G.J., Motzer, R.J., Testicular germ-cell cancer (1997) N Engl J Med, 337, pp. 242-253; Hattab, E.M., Tu, P.H., Wilson, J.D., Cheng, L., OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma (2005) Am J Surg Pathol, 29, pp. 368-371; Jones, T.D., Ulbright, T.M., Eble, J.N., Cheng, L., OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis (2004) Clin Cancer Res, 10, pp. 8544-8547; Jones, T.D., Ulbright, T.M., Eble, J.N., Baldridge, L.A., Cheng, L., OCT4 staining in testicular tumors: A sensitive and specific marker for seminoma and embryonal carcinoma (2004) Am J Surg Pathol, 28, pp. 935-940; Linke, J., Loy, V., Dieckmann, K.P., Prevalence of testicular intraepithelial neoplasia in healthy males (2005) J Urol, 173, pp. 1577-1579; Harland, S.J., Cook, P.A., Fossa, S.D., Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group (1998) J Urol, 160, pp. 1353-1357; Derogee, M., Bevers, R.F., Prins, H.J., Jonges, T.G., Elbers, F.H., Boon, T.A., Testicular microlithiasis, a premalignant condition: Prevalence, histopathologic findings, and relation to testicular tumor (2001) Urology, 57, pp. 1133-1137; Vegni-Talluri, M., Bigliardi, E., Vanni, M.G., Tota, G., Testicular microliths: Their origin and structure (1980) J Urol, 124, pp. 105-107; Kim, B., Winter III, T.C., Ryu, J.A., Testicular microlithiasis: Clinical significance and review of the literature (2003) Eur Radiol, 13, pp. 2567-2576; Miller, R.L., Wissman, R., White, S., Ragosin, R., Testicular microlithiasis: A benign condition with a malignant association (1996) J Clin Ultrasound, 24, pp. 197-202; Bryniarski, K., Szczepanik, M., Maresz, K., Ptak, M., Ptak, W., Subpopulations of mouse testicular macrophages and their immunoregulatory function (2004) Am J Reprod Immunol, 52, pp. 27-35; Sundstrom, J., Verajnkorva, E., Salminen, E., Pelliniemi, L.J., Pollanen, P., Experimental testicular teratoma promotes formation of humoral immune responses in the host testis (1999) J Reprod Immunol, 42, pp. 107-126; Castle, J., Sakonju, A., Dalmau, J., Newman-Toker, D.E., Anti-Ma2-associated encephalitis with normal FDG-PET: A case of pseudo-Whipple's Disease (2006) Nat Clin Pract Neurol, 10, pp. 566-572; Dieckmann, K.P., Loy, V., False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN)-an update (2003) Eur Urol, 43, pp. 516-521; Dieckmann, K.P., Pottek, T., Heinemann, V., Hopker, W.W., Loy, V., Four testicular biopsies failing to detect a case of testicular intraepithelial neoplasia (2004) Acta Oncol, 43, pp. 212-214; Bonita, R., Beaglehole, R., Modification of Rankin Scale: Recovery of motor function after stroke (1988) Stroke, 19, pp. 1497-1500","Dalmau, J.; Division Neuro-oncology; Department of Neurology; University of Pennsylvania; 3 W. Gates, 3400 Spruce Street Philadelphia, PA 19104, United States; email: josep.dalmau@uphs.upenn.edu",,,,,,,,00283878,,NEURA,10.1212/01.wnl.0000252379.81933.80,"English","Neurology",Article,Scopus
"Ahles T.A., Saykin A.J.","Candidate mechanisms for chemotherapy-induced cognitive changes",2007,"Nature Reviews Cancer",7,3,,192,201,,14,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33847195328&partnerID=40&rel=R8.0.0","Department of Psychiatry and Behavioural Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Department of Psychiatry (Neuropsychology Program), Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States; New Hampshire Hospital, Concord, NH, United States; Department of Radiology, Indiana University, School of Medicine, Indianapolis, IN, United States","The mechanism(s) for chemotherapy-induced cognitive changes are largely unknown; however, several candidate mechanisms have been identified. We suggest that shared genetic risk factors for the development of cancer and cognitive problems, including low-efficiency efflux pumps, deficits in DNA-repair mechanisms and/or a deregulated immune response, coupled with the effect of chemotherapy on these systems, might contribute to cognitive decline in patients after chemotherapy. Furthermore, the genetically modulated reduction of capacity for neural repair and neurotransmitter activity, as well as reduced antioxidant capacity associated with treatment-induced reduction in oestrogen and testosterone levels, might interact with these mechanisms and/or have independent effects on cognitive function. Â© 2007 Nature Publishing Group.",,"estrogen; progesterone; antioxidant activity; cancer chemotherapy; cognition; DNA repair; gene control; genetic risk; human; nerve regeneration; neurotransmission; priority journal; review; risk factor; Animals; Antineoplastic Agents; Brain; Cognition Disorders; Genetic Predisposition to Disease; Humans; Neoplasms; Risk Factors",,"progesterone, 57-83-0; Antineoplastic Agents",,,"Silberfarb, P.M., Chemotherapy and cognitive defects in cancer patients (1983) Annu. Rev. Med, 34, pp. 35-46; Wieneke, M.H., Dienst, E.R., Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer (1995) Psychooncology, 4, pp. 61-66; van Dam, F.S., Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. [comment] (1998) J. Natl Cancer Inst, 90, pp. 210-218; Schagen, S.B., Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma (1999) Cancer, 85, pp. 640-650; Brezden, C.B., Cognitive function in breast cancer patients receiving adjuvant chemotherapy (2000) J. Clin. Oncol, 18, pp. 2695-2701; Ahles, T.A., Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma (2002) J. Clin. Oncol, 20, pp. 485-493; Tchen, M., Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer (2003) J. Clin. Oncol, 21, pp. 4175-4183; Castellon, S.A., Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen (2004) J. Clin. Exp. Neuropsychol, 26, pp. 955-969; Wefel, J.S., The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial (2004) Cancer, 100, pp. 2292-2299; Schilling, V., The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational study (2005) The Breast, 14, pp. 142-150; Jenkins, V., A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer (2006) Br. J. Cancer, 94, pp. 828-834; Donovan, K.A., Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma (2005) Cancer, 104, pp. 2499-2507; Tannock, I. F., Ahles, T. A., Ganz, P. A. & van Dam, F. S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J. Clin. Oncol. 22, 2233-2239 (2004). This paper provides an overview of a consensus conference that included most of the researchers from around the world who were conducting research on chemotherapy-induced cognitive changesAhles, T.A., Saykin, A.J., Breast cancer chemotherapy-related cognitive dysfunction (2002) Clin. Breast Cancer, (SUPPL. 3), pp. S84-S90; Ferguson, R.J., Ahles, T.A., Low neuropsychologic performance among adult cancer survivors treated with chemotherapy (2003) Curr. Neurol. Neurosci. Rep, 3, pp. 215-222; Anderson-Hanley, C., Sherman, M.L., Riggs, R., Agocha, V.V., Compas, B.E., Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature (2003) J. Int. Neuropsychol. Soc, 9, pp. 967-982; Saykin, A.J., Ahles, T.A., McDonald, B.C., Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological and neuroimaging perspectives (2003) Sem. Clin. Neuropsych, 8, pp. 201-216; Stemmer, S., White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support (1994) Am. J. Neuroradiol, 15, pp. 1267-1273; Saykin, A.J., Altered brain activation following systemic chemotherapy for breast cancer: Interim analysis from a prospective study (2006) J. Int. Neuropsychol. Soc, 12, p. 131; Kreukels, B.P., Electrophysiological correlates of information processing in breast-cancer patients treated with chemotherapy (2005) Breast Cancer Res. Treat, 94, pp. 53-61; Kreukels, B.P., Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study (2006) Clin. Breast Cancer, 7, pp. 67-78; Wefel, J.S., Chemobrain in breast carcinoma? A prologue (2004) Cancer, 101, pp. 466-475; Meyers, C.A., Albitar, M., Estey, E., Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome (2005) Cancer, 104, pp. 788-793; Ahles, T.A., Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, a study for Cancer and Leukemia Group B (1998) J. Clin. Oncol, 16, pp. 1954-1960; Wagner, L.I., Trajectory of cognitive impairment during breast cancer treatment: A prospective analysis (2006) J. Clin. Oncol. Suppl, 24, p. 8500; Heflin, L.H., Cancer as a risk factor for long-term cognitive deficits and dementia (2005) J. Natl Cancer Inst, 97, pp. 854-856; Verstappen, C.C.P., Heimans, J.J., Hoekman, K., Postma, T.J., Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management (2003) Drugs, 63, pp. 1549-1563; Troy, L., Cisplatin-based therapy: A neurological and neuropsychological review (2000) Psychooncology, 9, pp. 29-39; Ginos, J.Z., 13N]cisplatin PET to assess pharmacokinetics of intro-arterial versus intravenous chemotherapy for malignant brain tumors (1987) J. Nucl. Med, 28, pp. 1844-1852; Mitsuki, S., Pharmacokinetics of 11C-labelled BCNU and SARCNU in gliomas studied by PET (1991) J.Neurooncol, 10, pp. 47-55; Gangloff, A., Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18F-Fluoropaclitaxel (2005) J. Nucl. Med, 46, pp. 1866-1871; Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M. & Noble, M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5, 22 [Epub ahead of print] (2006). This is an excellent paper describing in vitro and in vivo (mice) studies showing that common chemotherapy agents caused increased cell death and decreased cell division in the subventricular zone and in the dentate gyrus of the hippocampus, and in the corpus callosum. These effects were seen with doses that were not effective in causing cell death in tumor cell linesJamroziak, K., Robak, T., Pharmacogenomics of MDR1/ABCB1 gene: The influence on risk and clinical outcome of haematological malignancies (2004) Hematology, 9, pp. 91-105; Hoffmeyer, S., Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo (2000) Proc. Natl Acad. Sci. USA, 97, pp. 3473-3478; Kreb, R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234, 4-33 (2006). This manuscript describes evidence for genetic variability in drug transporters and their influence on drug disposition and clinical responseMuramatsu, T., Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice (2004) Oncol. Res, 14, pp. 331-343; Uhr, M., Holsboer, F., Muller, M.B., Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b p-glycoproteins (2002) J. Neuroendocrinol, 14, pp. 753-759; Rolig, R. L. & McKinnon, P. J. Linking DNA damage and neurodegeneration. Trends Neurosci. 23, 417-424 (2000). This paper provides an overview of the evidence linking DNA damage to neurodegeneration and cognitive functionGoode, E.L., Ulrich, C.M., Potter, J.D., Polymorphisms in DNA repair genes and associations with cancer risk (2002) Cancer Epidemiol. Biomarkers Prev, 11, pp. 1513-1530; Caldecott, K.W., DNA single-strand breaks and neurodegeneration (2004) DNA Repair, 3, pp. 875-882; Abner, C.W., McKinnon, P.J., The DNA double-strand break response in the nervous system (2004) DNA Repair, 3, pp. 1141-1147; Fishel, M. L., Vasko, M. R. & Kelley, M. R. DNA repair in neurons: so if they don't divide what's to repair? Mutat. Res. 614, 24-36 (2007). This paper reviews the relevance of DNA-repair pathways to DNA damage in post-mitotic neurons, and the impact of DNA damage on neuronal survival and brain ageing. Additionally, these authors relate DNA repair to neurotoxicity associated with chemotherapy, including cognitive side effects and peripheral neuropathySedletska, Y., Giraud-Panis, M.-J., Malinge, J.-M., Cisplatin is a DNA-damaging antitumour coumpound triggering multifactorial biochemical responses in cancer cells: Importance of apoptotic pathways (2005) Curr. Med. Chem. Anticancer Agents, 5, pp. 251-265; Blasiak J. et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat. Res. 554, 139-148 (2004). Using the comet assay, these investigators showed greater DNA damage and lower DNA repair efficacy in patients with breast cancer, both before and after chemotherapyNadin, S.B., Vargas-Roig, L.M., Drago, G., Ibarra, J., Ciocca, D.R., DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: A pilot study on the implications in response to chemotherapy (2006) Cancer Lett, 239, pp. 84-87; Wardell, T.M., Changes in human mitochondrial genome after treatment of malignant disease (2003) Mutat. Res, 525, pp. 19-27; Weijl, N.I., Non-protein bound iron release during chemotherapy in cancer patients (2004) Clin. Sci, 106, pp. 475-484; Kaya, E., Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma (2005) J. Int. Med. Res, 33, pp. 687-692; Papageorgiou, M., Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies (2005) Leukemia Res, 29, pp. 11-16; Kennedy, D.D., Ladas, E.J., Rheingold, S.R., Blumberg, J., Kelly, K.M., Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment (2005) Ped. Blood Cancer, 44, pp. 378-385; Mariani, E., Polidori, M.C., Cherubini, A., Mecocci, P., Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview (2005) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci, 827, pp. 65-75; Migliore, L. et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol. Aging 26, 567-573 (2005). The results of this study showed that patients with mild cognitive impairment, a condition characterized by a relatively isolated impairment in memory in the context of normal functioning in other areas, had higher levels of DNA damage compared with older adults without mild cognitive impairmentKeller, J. N. et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156 (2005). This study showed that patients who had been diagnosed with mild cognitive impairment had elevated levels of DNA damage in the brain at autopsy, suggesting a relationship between DNA damage seen peripherally in this population and DNA damage in the CNSHarrison, J.F., Oxidative stress-induced apoptosis in neurons correlates with mitcochondrial DNA base exicision repair pathway imbalance (2005) Nucleic Acids Res, 33, pp. 4660-4671; Vajdovich, P., Redox status in dogs with non-hodgkin lymphomas. An ESR study (2005) Cancer Lett, 224, pp. 339-346; Hung, R., Hall, J., Brennan, P., Boffetta, P., Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review (2005) Am. J. Epidemiol, 162, pp. 925-942; von Zglinicki, T., Martin-Ruiz, C.M., Telomeres as biomarkers for ageing and age-related diseases (2005) Curr. Mol. Med, 5, pp. 197-203; Vasa-Nicotera, M., Mapping of a major locus that determines telomere length in humans (2005) Am. J. Hum. Genet, 76, pp. 147-151; Schroder, C.P., Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplation (2001) Br. J. Cancer, 84, pp. 1348-1353; Lahav, M., Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation (2005) Transplantation, 80, pp. 969-976; Maccormick, R. E. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med. Hypotheses 67, 212-215 (2006). This manuscript reviews the evidence that morbidity associated with chemotherapy might be related to acceleration of the ageing processFlanary, B.E., Streit, W.J., Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes (2004) Glia, 45, pp. 75-88; Wilson, C.J., Finch, C.E., Cohen, H.J., Cytokines and cognition - the case for head-to-toe inflammatory paradigm (2002) J. Am. Geriatr. Soc, 50, pp. 2041-2056; Tonelli, L.H., Postolache, T.T., Sternberg, E.M., Inflammatory genes and neural activity: Involvement of immune genes in synaptic function and behavior (2005) Front. Biosci, 10, pp. 675-680; Cleeland, C.S., Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms (2003) Cancer, 97, pp. 2919-2925; Kelley, K.W., Cytokine-induced sickness behavior (2003) Brain Behav. Immun, 17, pp. S112-S118; Maier, S.F., Watkins, L.R., Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatments (2003) Brain Behav. Immun, 17, pp. S125-S131; Reichenberg, A., Cytokine-associated emotional and cognitive disturbances in humans (2001) Arch. Gen. Psych, 58, pp. 445-452; Krabbe, K.S., Low-dose endotoxemia and human neuropsychological functions (2005) Brain Behav. Immun, 19, pp. 453-460; Trask, P.C., Esper, P., Riba, M., Redman, B., Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions (2000) J. Clin. Oncol, 18, pp. 2316-2326; Scheibel, R.S., Valentine, A.D., O'Brien, S., Meyers, C.A., Cognitive dysfunction and depression during treatment with interferon-Î± and chemotherapy (2004) J.Neuropsych. Clin. Neurosci, 16, pp. 185-191; Capuron, L., Ravaud, A., Dantzer, R., Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-Î± treatments in cancer patients (2001) Psychosom. Med, 63, pp. 376-386; Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., Boulamatsis, D., Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes (2002) Br. J. Cancer, 87, pp. 21-27; Pusztai, L., Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy (2004) Cytokine, 25, pp. 94-102; Penson, R.T., Chtokines IL-1Î², IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFÎ± in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel (2000) Int. J. Gynecol. Cancer, 10, pp. 33-41; Callado-Hidalgo, A., Bower, J.E., Ganz, P.A., Cole, S.W., Irwin, M.R., Inflammatory biomarkers for persistent fatigue in breast cancer survivors Clin. Cancer Res, 12, pp. 2759-2766; Bower, J.E., Ganz, P.A., Aziz, N., Fahey, J.L., Fatigue and proinflammatory cytokine activity in breast cancer survivors (2002) Psychosom. Med, 64, pp. 604-611; Balkwill, F., Mantovani, A., Inflammation and cancer: Back to Virchow? (2001) Lancet, 357, pp. 539-545; de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24-37 (2006). This paper presents evidence in support of a role for chronic inflammation in enhancing the predisposition to develop cancer. Furthermore, the authors present evidence that genetic polymorphisms that regulate immune function can affect cancer riskMcGeer, P.L., McGeer, E.G., Polymorphisms in inflammatory genes and risk of Alzheimer Disease (2001) Arch. Neurol, 58, pp. 1790-1792; Morley, K.I., Montgomery, G.W., The genetics of cognitive processes: Candidate genes in humans and animals (2001) Behav. Genet, 31, pp. 511-531; Chen, Y., Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury (1997) Neuroscience, 80, pp. 1255-1262; Hartman, R.E., Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease (2002) J. Neurosci, 22, pp. 10083-10087; Sabo, T., Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities (2000) Neuroscience, 101, pp. 879-884; Laws, S.M., APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss (2002) Mol. Psych, 7, pp. 768-775; Nathoo, N., Genetic vulnerability following traumatic brain injury: The role of apolipoprotein E (2003) Mol. Pathol, 56, pp. 132-136; Ahles, T. A., Saykin, A. J. & Noll, W. W. et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12, 612-619 (2003) This is the first study to show an association between APOE genotype and cognitive functioning in long-term cancer survivorsLind, J., Reduced hippocampal volume in non-demented carriers of the apolipoprotein E Îµ4: Relation to chronological age and recognition memory (2006) Neurosci. Lett, 396, pp. 23-27; Pang, P.T., Lu, B., Regulation of late-phase LTP and long-term memory in normal and ageing hippocampus: Role of secreted proteins tPA and BDNF (2004) Age. Res. Rev, 3, pp. 407-430; Savitz, J., Solms, M. & Ramesar, R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain Behav. 5, 311-328 (2006). This paper provides an excellent review of the research examining the relationship between genetic variability and cognitive functioning with an emphasis on dopamine receptor genes, catechol-O-methyltransferase (COMT) and brain-derived neurotrophic factor (BDNF)Egan, M.F., The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function (2003) Cell, 112, pp. 257-269; Hariri, A.R., Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance (2003) J. Neurosci, 23, pp. 6690-6694; Pezawas, L., The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology (2004) J. Neurosci, 24, pp. 10099-10102; McAllister, T.W., Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments (2004) Curr. Psych. Rep, 6, pp. 364-371; Weinberger, D.R., Prefrontal neurons and the genetics of schizophrenia (2001) Biol. Psychiatry, 50, pp. 825-844; Malhotra, A.K., A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition (2001) Am. J. Psych, 159, pp. 652-654; Zec, R.F., Trivedi, M.A., The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: A critical and theoretical review (2002) Neuropsychol. Rev, 12, pp. 65-109; Bender, D.M., Paraska, K.K., Sereika, S.M., Ryan, C.M., Berga, S.L., Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review (2001) J. Pain Sympt. Manage, 21, pp. 407-424; Jenkins, V.A., Bloomfield, D.J., Shilling, V.M., Edginton, T.L., Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study (2005) Br. J. Urol, 96, pp. 48-53; Unfer, T.C., Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women (2006) Clin. Chim. Acta, 369, pp. 73-77; Chisu, V., Lepore, M.G., Zedda, M., Farina, V., Testosterone induces neuroprotection from oxidative stress. Effects on catalase activity and 3-Nitro-L-styrosine incorporation into Î±-tubulin in a mouse neuroblastoma cell line (2006) Arch. Ital. Biol, 144, pp. 63-73; Lee, D.-C., Im, J.-A., Kim, J.-H., Lee, H.-R., Shim, J.-Y., Effect of long-term hormone therapy on telomere length in postmenopausal women (2005) Yonsei Med. J, 46, pp. 471-479; Theodoulou, M., Seidman, A.D., Cardiac effects of adjuvant therapy for early breast cancer (2003) Semin. Oncol, 30, pp. 730-739; Miller, D.B., O' Callaghan, J.P., Aging, stress and the hippocampus (2005) Age. Res. Rev, 4, pp. 123-140; Hukovic, N., Brown, E.S., Effects of prescription corticosteroids on mood and cognition (2003) Adv. Psychosom. Med, 24, pp. 161-167; Lee, G.D., Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy (2006) Clin. Cancer Res, 12, pp. 198-205; Winocur, G., Vardy, J, Bims, M. A., Kerr, L. & Tannock, I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol. Biochem. Behav. 85, 66-75 (2006). These investigators developed an animal model of chemotherapy-induced cognitive deficits and showed deficits in memory and learning tasks in mice treated with chemotherapy that were similar to deficits seen in breast cancer survivors","Ahles, T.A.; Department of Psychiatry and Behavioural Sciences; Memorial Sloan-Kettering Cancer Center New York, NY, United States; email: ahlest@mskcc.org",,,,,,,,1474175X,,NRCAC,10.1038/nrc2073,"English","Nature Reviews Cancer",Review,Scopus
"Fishel M.L., Vasko M.R., Kelley M.R.","DNA repair in neurons: So if they don't divide what's to repair?",2007,"Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis",614,1-2,,24,36,,13,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33845518305&partnerID=40&rel=R8.0.0","Department of Pediatrics, (Section of Hematology/Oncology), Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, United States; Department of Pharmacology and Toxicology, Indiana University School of Medicine, 1044 W. Walnut St, Indianapolis, IN 46202, United States; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 1044 W. Walnut, Indianapolis, IN 46202, United States","Neuronal DNA repair remains one of the most exciting areas for investigation, particularly as a means to compare the DNA repair response in mitotic (cancer) vs. post-mitotic (neuronal) cells. In addition, the role of DNA repair in neuronal cell survival and response to aging and environmental insults is of particular interest. DNA damage caused by reactive oxygen species (ROS) such as generated by mitochondrial respiration includes altered bases, abasic sites, and single- and double-strand breaks which can be prevented by the DNA base excision repair (BER) pathway. Oxidative stress accumulates in the DNA of the human brain over time especially in the mitochondrial DNA (mtDNA) and is proposed to play a critical role in aging and in the pathogenesis of several neurological disorders including Parkinson's disease, ALS, and Alzheimer's diseases. Because DNA damage accumulates in the mtDNA more than nuclear DNA, there is increased interest in DNA repair pathways and the consequence of DNA damage in the mitochondria of neurons. The type of damage that is most likely to occur in neuronal cells is oxidative DNA damage which is primarily removed by the BER pathway. Following the notion that the bulk of neuronal DNA damage is acquired by oxidative DNA damage and ROS, the BER pathway is a likely area of focus for neuronal studies of DNA repair. BER variations in brain aging and pathology in various brain regions and tissues are presented. Therefore, the BER pathway is discussed in greater detail in this review than other repair pathways. Other repair pathways including direct reversal, nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination and non-homologous end joining are also discussed. Finally, there is a growing interest in the role that DNA repair pathways play in the clinical arena as they relate to the neurotoxicity and neuropathy associated with cancer treatments. Among the numerous side effects of cancer treatments, major clinical effects include neurocognitive dysfunction and peripheral neuropathy. These symptoms occur frequently and have not been effectively studied at the cellular or molecular level. Studies of DNA repair may help our understanding of how those cells that are not dividing could succumb to neurotoxicity with the clinical manifestations discussed in the following article. Â© 2006 Elsevier B.V. All rights reserved.","Base excision repair; Direct reversal repair; Mitochondrial base excision repair; Neurons","DNA base; amnesia; article; cancer chemotherapy; cancer radiotherapy; cancer therapy; cell death; clinical feature; cognitive defect; comprehension; DNA repair; excision repair; homologous recombination; human; ionizing radiation; memory disorder; mismatch repair; nerve cell; neurologic disease; neurotoxicity; nonhuman; peripheral neuropathy; priority journal; Aging; Animals; Antineoplastic Agents; Brain; Cell Nucleus; Cell Proliferation; DNA Damage; DNA Repair; Humans; Mitochondria; Models, Neurological; Neurons; Oxidative Stress",,"Antineoplastic Agents",,,"Brooks, P.J., DNA repair in neural cells: basic science and clinical implications (2002) Mutat. Res., 509, pp. 93-108; Kruman, I.I., Why do neurons enter the cell cycle? (2004) Cell Cycle, 3, pp. 769-773; McMurray, C.T., To die or not to die: DNA repair in neurons (2005) Mutat. Res., 577, pp. 260-274; Hamilton, S.R., Liu, B., Parsons, R.E., Papadopoulos, N., Jen, J., Powell, S.M., Krush, A.J., Tetu, B., The molecular basis of Turcot's syndrome (1995) N. Engl. J. Med., 332, pp. 839-847; Taddei, F., Vulic, M., Radman, M., Matic, I., Genetic variability and adaptation to stress (1997) EXS, 83, pp. 271-290; Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., Yankner, B.A., Gene regulation and DNA damage in the ageing human brain (2004) Nature, 429, pp. 883-891; Nouspikel, T., Hanawalt, P.C., When parsimony backfires: neglecting DNA repair may doom neurons in Alzheimer's disease (2003) Bioessays, 25, pp. 168-173; Nagy, Z., Esiri, M.M., Smith, A.D., Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions (1997) Acta Neuropathol. (Berl), 93, pp. 294-300; Fonnum, F., Lock, E.A., The contributions of excitotoxicity, glutathione depletion and DNA repair in chemically induced injury to neurones: exemplified with toxic effects on cerebellar granule cells (2004) J. Neurochem., 88, pp. 513-531; Bergamini, C.M., Gambetti, S., Dondi, A., Cervellati, C., Oxygen, reactive oxygen species and tissue damage (2004) Curr. Pharm. Des., 10, pp. 1611-1626; Poli, G., Leonarduzzi, G., Biasi, F., Chiarpotto, E., Oxidative stress and cell signalling (2004) Curr. Med. Chem., 11, pp. 1163-1182; Rao, A.V., Balachandran, B., Role of oxidative stress and antioxidants in neurodegenerative diseases (2002) Nutr. Neurosci., 5, pp. 291-309; Dropcho, E.J., Neurotoxicity of cancer chemotherapy (2004) Semin. Neurol., 24, pp. 419-426; Fuemmeler, B.F., Elkin, T.D., Mullins, L.L., Survivors of childhood brain tumors: behavioral, emotional, and social adjustment (2002) Clin. Psychol. Rev., 22, pp. 547-585; Visovsky, C., Chemotherapy-induced peripheral neuropathy (2003) Cancer Invest., 21, pp. 439-451; Wampler, M.A., Hamolsky, D., Hamel, K., Melisko, M., Topp, K.S., Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer (2005) Clin. J. Oncol. Nurs., 9, pp. 189-193; Armstrong, T., Almadrones, L., Gilbert, M.R., Chemotherapy-induced peripheral neuropathy (2005) Oncol. Nurs. Forum, 32, pp. 305-311; Singleton, J.R., Evaluation and treatment of painful peripheral polyneuropathy (2005) Semin. Neurol., 25, pp. 185-195; Wong, C.S., Van der Kogel, A.J., Mechanisms of radiation injury to the central nervous system: implications for neuroprotection (2004) Mol. Interv., 4, pp. 273-284; Kuenzle, C.C., Enzymology of DNA replication and repair in the brain (1985) Brain Res., 357, pp. 231-245; LeDoux, S.P., Williams, B.A., Hollensworth, B.S., Shen, C., Thomale, J., Rajewsky, M.F., Brent, T.P., Wilson, G.L., Glial cell-specific differences in repair of O6-methylguanine (1996) Cancer Res., 56, pp. 5615-5619; Pegg, A.E., Dolan, M.E., Moschel, R.C., Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase (1995) Prog. Nucleic Acid Res. Mol. Biol., 51, pp. 167-223; Gerson, S.L., MGMT: its role in cancer aetiology and cancer therapeutics (2004) Nat. Rev. Cancer, 4, pp. 296-307; Tano, K., Shiota, S., Collier, J., Foote, R.S., Mitra, S., Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine (1990) Proc. Natl. Acad. Sci. U.S.A., 87, pp. 686-690; Mecocci, P., MacGarvey, U., Kaufman, A.E., Koontz, D., Shoffner, J.M., Wallace, D.C., Beal, M.F., Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain (1993) Ann. Neurol., 34, pp. 609-616; Jenner, P., Oxidative stress in Parkinson's disease (2003) Ann. Neurol., 53 (SUPPL. 3), pp. S26-S36. , (discussion S36-28); Bogdanov, M., Brown, R.H., Matson, W., Smart, R., Hayden, D., O'Donnell, H., Flint Beal, M., Cudkowicz, M., Increased oxidative damage to DNA in ALS patients (2000) Free Radic. Biol. Med., 29, pp. 652-658; Shaikh, A.Y., Martin, L.J., DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis (2002) Neuromol. Med., 2, pp. 47-60; Sayre, L.M., Smith, M.A., Perry, G., Chemistry and biochemistry of oxidative stress in neurodegenerative disease (2001) Curr. Med. Chem., 8, pp. 721-738; Lyras, L., Cairns, N.J., Jenner, A., Jenner, P., Halliwell, B., An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease (1997) J. Neurochem., 68, pp. 2061-2069; Wang, H., Cheng, E., Brooke, S., Chang, P., Sapolsky, R., Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults (2003) J. Neurochem., 87, pp. 1527-1534; Velazquez, J.L., Han, D., Carlen, P.L., Neurotransmitter modulation of gap junctional communication in the rat hippocampus (1997) Eur. J. Neurosci., 9, pp. 2522-2531; Wang, D., Luo, M., Kelley, M.R., Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition (2004) Mol. Cancer Ther., 3, pp. 679-686; Fung, H., Demple, B., A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells (2005) Mol. Cell., 17, pp. 463-470; Iida, T., Furuta, A., Nakabeppu, Y., Iwaki, T., Defense mechanism to oxidative DNA damage in glial cells (2004) Neuropathology, 24, pp. 125-130; Ide, H., Kotera, M., Human DNA glycosylases involved in the repair of oxidatively damaged DNA (2004) Biol. Pharm. Bull., 27, pp. 480-485; Lu, A.L., Li, X., Gu, Y., Wright, P.M., Chang, D.Y., Repair of oxidative DNA damage: mechanisms and functions (2001) Cell. Biochem. Biophys., 35, pp. 141-170; Hazra, T.K., Hill, J.W., Izumi, T., Mitra, S., Multiple DNA glycosylases for repair of 8-oxoguanine and their potential in vivo functions (2001) Prog. Nucleic Acid Res. Mol. Biol., 68, pp. 193-205; Araneda, S., Mermet, N., Verjat, T., Angulo, J.F., Radicella, J.P., Expression of Kin17 and 8-OxoG DNA glycosylase in cells of rodent and quail central nervous system (2001) Brain Res. Bull., 56, pp. 139-146; Verjat, T., Dhenaut, A., Radicella, J.P., Araneda, S., Detection of 8-oxoG DNA glycosylase activity and OGG1 transcripts in the rat CNS (2000) Mutat. Res., 460, pp. 127-138; Lin, L.H., Cao, S., Yu, L., Cui, J., Hamilton, W.J., Liu, P.K., Up-regulation of base excision repair activity for 8-hydroxy-2â€²-deoxyguanosine in the mouse brain after forebrain ischemia-reperfusion (2000) J. Neurochem., 74, pp. 1098-1105; Fukae, J., Takanashi, M., Kubo, S., Nishioka, K., Nakabeppu, Y., Mori, H., Mizuno, Y., Hattori, N., Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders (2005) Acta Neuropathol. (Berl), 109, pp. 256-262; Cardozo-Pelaez, F., Stedeford, T.J., Brooks, P.J., Song, S., Sanchez-Ramos, J.R., Effects of diethylmaleate on DNA damage and repair in the mouse brain (2002) Free Radic. Biol. Med., 33, pp. 292-298; Imam, S.Z., Karahalil, B., Hogue, B.A., Souza-Pinto, N.C., Bohr, V.A., Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age-dependent manner (2005) Neurobiol. Aging; Aspinwall, R., Rothwell, D.G., Roldan-Arjona, T., Anselmino, C., Ward, C.J., Cheadle, J.P., Sampson, J.R., Hickson, I.D., Cloning and characterization of a functional human homolog of Escherichia coli endonuclease III (1997) Proc. Natl. Acad. Sci. U.S.A., 94, pp. 109-114; Karahalil, B., Hogue, B.A., de Souza-Pinto, N.C., Bohr, V.A., Base excision repair capacity in mitochondria and nuclei: tissue-specific variations (2002) Faseb J., 16, pp. 1895-1902; Kisby, G.E., Lesselroth, H., Olivas, A., Samson, L., Gold, B., Tanaka, K., Turker, M.S., Role of nucleotide- and base-excision repair in genotoxin-induced neuronal cell death (2004) DNA Rep. (Amst), 3, pp. 617-627; Endres, M., Biniszkiewicz, D., Sobol, R.W., Harms, C., Ahmadi, M., Lipski, A., Katchanov, J., Jaenisch, R., Increased postischemic brain injury in mice deficient in uracil-DNA glycosylase (2004) J. Clin. Invest., 113, pp. 1711-1721; Wilson, T.M., Rivkees, S.A., Deutsch, W.A., Kelley, M.R., Differential expression of the apurinic/apyrimidinic endonuclease (APE/ref-1) multifunctional DNA base excision repair gene during fetal development and in adult rat brain and testis (1996) Mutat. Res., 362, pp. 237-248; Ono, Y., Matsumoto, K., Furuta, T., Ohmoto, T., Akiyama, K., Seki, S., Relationship between expression of a major apurinic/apyrimidinic endonuclease (APEX nuclease) and susceptibility to genotoxic agents in human glioma cell lines (1995) J. Neurooncol., 25, pp. 183-192; Walton, M., Lawlor, P., Sirimanne, E., Williams, C., Gluckman, P., Dragunow, M., Loss of Ref-1 protein expression precedes DNA fragmentation in apoptotic neurons (1997) Brain Res. Mol. Brain Res., 44, pp. 167-170; Gillardon, F., Bottiger, B., Hossmann, K.A., Expression of nuclear redox factor ref-1 in the rat hippocampus following global ischemia induced by cardiac arrest (1997) Brain Res. Mol. Brain Res., 52, pp. 194-200; Edwards, M., Kent, T.A., Rea, H.C., Wei, J., Quast, M., Izumi, T., Mitra, S., Perez-Polo, J.R., APE/Ref-1 responses to ischemia in rat brain (1998) Neuroreport, 9, pp. 4015-4018; Morita-Fujimura, Y., Fujimura, M., Kawase, M., Chan, P.H., Early decrease in apurinic/apyrimidinic endonuclease is followed by DNA fragmentation after cold injury-induced brain trauma in mice (1999) Neuroscience, 93, pp. 1465-1473; Fujimura, M., Morita-Fujimura, Y., Kawase, M., Chan, P.H., Early decrease of apurinic/apyrimidinic endonuclease expression after transient focal cerebral ischemia in mice (1999) J. Cereb. Blood Flow Metab., 19, pp. 495-501; Kawase, M., Fujimura, M., Morita-Fujimura, Y., Chan, P.H., Reduction of apurinic/apyrimidinic endonuclease expression after transient global cerebral ischemia in rats: implication of the failure of DNA repair in neuronal apoptosis (1999) Stroke, 30, pp. 441-448. , (discussion 449); Lewen, A., Sugawara, T., Gasche, Y., Fujimura, M., Chan, P.H., Oxidative cellular damage and the reduction of APE/Ref-1 expression after experimental traumatic brain injury (2001) Neurobiol. Dis., 8, pp. 380-390; Sakurai, M., Nagata, T., Abe, K., Horinouchi, T., Itoyama, Y., Tabayashi, K., Oxidative damage and reduction of redox factor-1 expression after transient spinal cord ischemia in rabbits (2003) J. Vasc. Surg., 37, pp. 446-452; Quach, N., Chan, T., Lu, T.A., Schreiber, S.S., Tan, Z., Induction of DNA repair proteins, Ref-1 and XRCC1, in adult rat brain following kainic acid-induced seizures (2005) Brain Res., 1042, pp. 236-240; Edwards, M., Rassin, D.K., Izumi, T., Mitra, S., Perez-Polo, J.R., APE/Ref-1 responses to oxidative stress in aged rats (1998) J. Neurosci. Res., 54, pp. 635-638; Kisby, G.E., Milne, J., Sweatt, C., Evidence of reduced DNA repair in amyotrophic lateral sclerosis brain tissue (1997) Neuroreport, 8, pp. 1337-1340; Olkowski, Z.L., Mutant AP endonuclease in patients with amyotrophic lateral sclerosis (1998) Neuroreport, 9, pp. 239-242; Vasko, M.R., Guo, C., Kelley, M.R., The multifunctional DNA repair/redox enzyme Ape1/Ref-1 promotes survival of neurons after oxidative stress (2005) DNA Rep. (Amst), 4, pp. 367-379; Evans, A.R., Limp-Foster, M., Kelley, M.R., Going APE over ref-1 (2000) Mutat. Res., 461, pp. 83-108; Chiarugi, A., Characterization of the molecular events following impairment of NF-kappaB-driven transcription in neurons (2002) Brain Res. Mol. Brain Res., 109, pp. 179-188; Culmsee, C., Siewe, J., Junker, V., Retiounskaia, M., Schwarz, S., Camandola, S., El-Metainy, S., Krieglstein, J., Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons (2003) J. Neurosci., 23, pp. 8586-8595; Sugo, N., Aratani, Y., Nagashima, Y., Kubota, Y., Koyama, H., Neonatal lethality with abnormal neurogenesis in mice deficient in DNA polymerase beta (2000) Embo J., 19, pp. 1397-1404; Mishra, O.P., Akhter, W., Ashraf, Q.M., Delivoria-Papadopoulos, M., Hypoxia-induced modification of poly (ADP-ribose) polymerase and dna polymerase beta activity in cerebral cortical nuclei of newborn piglets: role of nitric oxide (2003) Neuroscience, 119, pp. 1023-1032; Rao, K.S., Annapurna, V.V., Raji, N.S., Harikrishna, T., Loss of base excision repair in aging rat neurons and its restoration by DNA polymerase beta (2000) Brain Res. Mol. Brain Res., 85, pp. 251-259; Rao, K.S., Annapurna, V.V., Raji, N.S., DNA polymerase-beta may be the main player for defective DNA repair in aging rat neurons (2001) Ann. N.Y. Acad. Sci., 928, pp. 113-120; Krishna, T.H., Mahipal, S., Sudhakar, A., Sugimoto, H., Kalluri, R., Rao, K.S., Reduced DNA gap repair in aging rat neuronal extracts and its restoration by DNA polymerase beta and DNA-ligase (2005) J. Neurochem., 92, pp. 818-823; Montecucco, A., Biamonti, G., Savini, E., Focher, F., Spadari, S., Ciarrocchi, G., DNA ligase I gene expression during differentiation and cell proliferation (1992) Nucleic Acids Res., 20, pp. 6209-6214; Druzhyna, N.M., Hollensworth, S.B., Kelley, M.R., Wilson, G.L., Ledoux, S.P., Targeting human 8-oxoguanine glycosylase to mitochondria of oligodendrocytes protects against menadione-induced oxidative stress (2003) Glia, 42, pp. 370-378; Rachek, L.I., Grishko, V.I., Musiyenko, S.I., Kelley, M.R., LeDoux, S.P., Wilson, G.L., Conditional targeting of the DNA repair enzyme hOGG1 into mitochondria (2002) J. Biol. Chem., 277, pp. 44932-44937; LeDoux, S.P., Driggers, W.J., Hollensworth, B.S., Wilson, G.L., Repair of alkylation and oxidative damage in mitochondrial DNA (1999) Mutat. Res., 434, pp. 149-159; Kaina, B., Christmann, M., DNA repair in resistance to alkylating anticancer drugs (2002) Int. J. Clin. Pharmacol. Ther., 40, pp. 354-367; LeDoux, S.P., Wilson, G.L., Base excision repair of mitochondrial DNA damage in mammalian cells (2001) Prog. Nucleic Acid Res. Mol. Biol., 68, pp. 273-284; Linnane, A.W., Marzuki, S., Ozawa, T., Tanaka, M., Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases (1989) Lancet, 1, pp. 642-645; Ledoux, S.P., Shen, C.C., Grishko, V.I., Fields, P.A., Gard, A.L., Wilson, G.L., Glial cell-specific differences in response to alkylation damage (1998) Glia, 24, pp. 304-312; de Souza-Pinto, N.C., Bohr, V.A., The mitochondrial theory of aging: involvement of mitochondrial DNA damage and repair (2002) Int. Rev. Neurobiol., 53, pp. 519-534; Bohr, V.A., Mitochondrial DNA repair (2001) Prog. Nucleic Acid Res. Mol. Biol., 68, pp. 255-256; Bohr, V.A., Dianov, G.L., Oxidative DNA damage processing in nuclear and mitochondrial DNA (1999) Biochimie, 81, pp. 155-160; Croteau, D.L., Stierum, R.H., Bohr, V.A., Mitochondrial DNA repair pathways (1999) Mutat. Res., 434, pp. 137-148; Nakano, T., Katafuchi, A., Shimizu, R., Terato, H., Suzuki, T., Tauchi, H., Makino, K., Ide, H., Repair activity of base and nucleotide excision repair enzymes for guanine lesions induced by nitrosative stress (2005) Nucleic Acids Res., 33, pp. 2181-2191; Bohr, V.A., Stevnsner, T., de Souza-Pinto, N.C., Mitochondrial DNA repair of oxidative damage in mammalian cells (2002) Gene, 286, pp. 127-134; Bohr, V.A., Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells (2002) Free Radic. Biol. Med., 32, pp. 804-812; Chen, D., Lan, J., Pei, W., Chen, J., Detection of DNA base-excision repair activity for oxidative lesions in adult rat brain mitochondria (2000) J. Neurosci. Res., 61, pp. 225-236; Hollensworth, S.B., Shen, C., Sim, J.E., Spitz, D.R., Wilson, G.L., LeDoux, S.P., Glial cell type-specific responses to menadione-induced oxidative stress (2000) Free Radic. Biol. Med., 28, pp. 1161-1174; Harrison, J.F., Hollensworth, S.B., Spitz, D.R., Copeland, W.C., Wilson, G.L., LeDoux, S.P., Oxidative stress-induced apoptosis in neurons correlates with mitochondrial DNA base excision repair pathway imbalance (2005) Nucleic Acids Res., 33, pp. 4660-4671; Nouspikel, T., Hanawalt, P.C., DNA repair in terminally differentiated cells (2002) DNA Rep. (Amst), 1, pp. 59-75; Christmann, M., Tomicic, M.T., Roos, W.P., Kaina, B., Mechanisms of human DNA repair: an update (2003) Toxicology, 193, pp. 3-34; Fleck, O., Nielsen, O., DNA repair (2004) J. Cell Sci., 117, pp. 515-517; Wood, R.D., DNA repair in eukaryotes (1996) Ann. Rev. Biochem., 65, pp. 135-167; Magnaldo, T., Sarasin, A., Xeroderma pigmentosum: from symptoms and genetics to gene-based skin therapy (2004) Cells Tissues Organs, 177, pp. 189-198; Lindahl, T., Karran, P., Wood, R.D., DNA excision repair pathways (1997) Curr. Opin. Genet. Dev., 7, pp. 158-169; Marti, T.M., Kunz, C., Fleck, O., DNA mismatch repair and mutation avoidance pathways (2002) J. Cell Physiol., 191, pp. 28-41; Brooks, P.J., Marietta, C., Goldman, D., DNA mismatch repair and DNA methylation in adult brain neurons (1996) J. Neurosci., 16, pp. 939-945; Marietta, C., Palombo, F., Gallinari, P., Jiricny, J., Brooks, P.J., Expression of long-patch and short-patch DNA mismatch repair proteins in the embryonic and adult mammalian brain (1998) Brain Res. Mol. Brain Res., 53, pp. 317-320; Belloni, M., Uberti, D., Rizzini, C., Ferrari-Toninelli, G., Rizzonelli, P., Jiricny, J., Spano, P., Memo, M., Distribution and kainate-mediated induction of the DNA mismatch repair protein MSH2 in rat brain (1999) Neuroscience, 94, pp. 1323-1331; Francisconi, S., Codenotti, M., Ferrari-Toninelli, G., Uberti, D., Memo, M., Preservation of DNA integrity and neuronal degeneration (2005) Brain Res. Brain Res. Rev., 48, pp. 347-351; Wells, R.D., Dere, R., Hebert, M.L., Napierala, M., Son, L.S., Advances in mechanisms of genetic instability related to hereditary neurological diseases (2005) Nucleic Acids Res., 33, pp. 3785-3798; Belloni, M., Uberti, D., Rizzini, C., Jiricny, J., Memo, M., Induction of two DNA mismatch repair proteins, MSH2 and MSH6, in differentiated human neuroblastoma SH-SY5Y cells exposed to doxorubicin (1999) J. Neurochem., 72, pp. 974-979; David, P., Efrati, E., Tocco, G., Krauss, S.W., Goodman, M.F., DNA replication and postreplication mismatch repair in cell-free extracts from cultured human neuroblastoma and fibroblast cells (1997) J. Neurosci., 17, pp. 8711-8720; Panigrahi, G.B., Lau, R., Montgomery, S.E., Leonard, M.R., Pearson, C.E., Slipped (CTG)*(CAG) repeats can be correctly repaired, escape repair or undergo error-prone repair (2005) Nat. Struct. Mol. Biol., 12, pp. 654-662; Merlo, D., Di Stasi, A.M., Bonini, P., Mollinari, C., Cardinale, A., Cozzolino, F., Wisden, W., Garaci, E., DNA repair in post-mitotic neurons: a gene-trapping strategy (2005) Cell Death Differ., 12, pp. 307-309; Ren, K., de Ortiz, S.P., Non-homologous DNA end joining in the mature rat brain (2002) J. Neurochem., 80, pp. 949-959; Hefferin, M.L., Tomkinson, A.E., Mechanism of DNA double-strand break repair by non-homologous end joining (2005) DNA Rep. (Amst), 4, pp. 639-648; Tuteja, R., Tuteja, N., Ku autoantigen: a multifunctional DNA-binding protein (2000) Crit. Rev. Biochem. Mol. Biol., 35, pp. 1-33; Sekiguchi, J.M., Gao, Y., Gu, Y., Frank, K., Sun, Y., Chaudhuri, J., Zhu, C., Alt, F.W., Nonhomologous end-joining proteins are required for V(D)J recombination, normal growth, and neurogenesis (1999) Cold Spring Harb. Symp. Quant. Biol., 64, pp. 169-181; Sugawara, T., Noshita, N., Lewen, A., Kim, G.W., Chan, P.H., Neuronal expression of the DNA repair protein Ku 70 after ischemic preconditioning corresponds to tolerance to global cerebral ischemia (2001) Stroke, 32, pp. 2388-2393; Kim, G.W., Noshita, N., Sugawara, T., Chan, P.H., Early decrease in DNA repair proteins, Ku70 and Ku86, and subsequent DNA fragmentation after transient focal cerebral ischemia in mice (2001) Stroke, 32, pp. 1401-1407; Barton, D., Loprinzi, C., Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible (2002) Clin. Breast Cancer, 3 (SUPPL. 3), pp. S121-S127; Nagel, B.J., Palmer, S.L., Reddick, W.E., Glass, J.O., Helton, K.J., Wu, S., Xiong, X., Mulhern, R.K., Abnormal hippocampal development in children with medulloblastoma treated with risk-adapted irradiation (2004) AJNR Am. J. Neuroradiol., 25, pp. 1575-1582; Schagen, S.B., Hamburger, H.L., Muller, M.J., Boogerd, W., van Dam, F.S., Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function (2001) J. Neurooncol., 51, pp. 159-165; Schagen, S.B., Muller, M.J., Boogerd, W., Van Dam, F.S., Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective (2002) Clin. Breast Cancer, 3 (SUPPL. 3), pp. S100-S108; Schagen, S.B., Muller, M.J., Boogerd, W., Rosenbrand, R.M., van Rhijn, D., Rodenhuis, S., van Dam, F.S., Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients (2002) Ann. Oncol., 13, pp. 1387-1397; Ness, K.K., Bhatia, S., Baker, K.S., Francisco, L., Carter, A., Forman, S.J., Robison, L.L., Gurney, J.G., Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study (2005) Arch. Pediatr. Adolesc. Med., 159, pp. 706-713; Scharer, O.D., Chemistry and biology of DNA repair (2003) Angew Chem. Int. Ed. Engl., 42, pp. 2946-2974; Izumi, T., Wiederhold, L.R., Roy, G., Roy, R., Jaiswal, A., Bhakat, K.K., Mitra, S., Hazra, T.K., Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage (2003) Toxicology, 193, pp. 43-65","Kelley, M.R.; Department of Pediatrics; (Section of Hematology/Oncology); Herman B Wells Center for Pediatric Research, Indiana University School of Medicine; 1044 W. Walnut Indianapolis, IN 46202, United States; email: mkelley@iupui.edu",,,,,,,,00275107,,MRFME,10.1016/j.mrfmmm.2006.06.007,"English","Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis",Article,Scopus
"Cheng L., Sung M.-T., Cossu-Rocca P., Jones T.D., MacLennan G.T., De Jong J., Lopez-Beltran A., Montironi R., Looijenga L.H.J.","OCT4: Biological functions and clinical applications marker of germ cell neoplasia",2007,"Journal of Pathology",211,1,,1,9,,9,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33846228391&partnerID=40&rel=R8.0.0","Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, United States; Department of Urology, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, United States; Department of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Centre, Chang Gung University College of Medicine, Kaohsiung, Taiwan; Dipartimento di Patologia, UniversitaÌ� di Sassari, Sassari, Italy; Department of Pathology, Case Western Reserve University, Cleveland, OH, United States; Department of Pathology, Josephine Nefkens Institute Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, Netherlands; Department of Pathology, Cordoba University, Cordoba, Spain; Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), Ancona, Italy","Germ cell tumours (GCTs) are a heterogeneous group of neoplasms, which develop in the gonads as well as in extragonadal sites, that share morphological patterns and an over-all good prognosis, owing to their responsiveness to current surgical, chemotherapeutic, and radiotherapeutic measures. GCTs demonstrate extremely interesting biological features because of their close relationships with normal embryonal development as demonstrated by the pluripotentiality of some undifferentiated GCT variants. The similarities between GCTs and normal germ cell development have made it possible to identify possible pathogenetic pathways in neoplastic transformation and progression of GCTs. Genotypic and immunophenotypic profiles of these tumours are also useful in establishing and narrowing the differential diagnosis in cases of suspected GCTs. Recently, OCT4 (also known as OCT3 or POU5F1), a transcription factor that has been recognized as fundamental in the maintenance of pluripotency in embryonic stem cells and primordial germ cells, has been proposed as a useful marker for GCTs that exhibit features of pluripotentiality, specifically seminoma/dysgerminoma/ germinoma and embryonal carcinoma. The development of commercially available OCT4-specific antibodies suitable for immunohistochemistry on paraffin-embedded specimens has generated increasing numbers of reports of OCT4 expression in a wide variety of gonadal and extragonadal GCTs. OCT4 immunostaining has been shown to be a sensitive and specific marker for seminomatous/(dys)germinomatous tumours and in embryonal carcinoma variants of non-seminomatous GCTs, whether in primary gonadal or extragonadal sites or in metastatic lesions. Therefore, OCT4 immunohistochemistry is an additional helpful marker both in the differential diagnosis of specific histological subtypes of GCTs and in establishing a germ cell origin for some metastatic tumours of uncertain primary. OCT4 expression has also been reported in pre-invasive conditions such as intratubular germ cell neoplasia, unclassified (IGCNU) and the germ cell component of gonadoblastoma. Additionally, OCT4 immunostaining shows promise as a useful tool in managing patients known to be at high risk for the development of invasive GCTs. Copyright Â© 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.","Embryonal carcinoma; Germ cell tumuor; Oct3/4; POU5F1; Seminoma; Stem cell biomarkers; Testis","octamer transcription factor 4; tumor marker; cancer risk; carcinogenesis; cryptorchism; diagnostic accuracy; diagnostic value; dysgerminoma; embryonal carcinoma; embryonic stem cell; gene expression; germ cell tumor; gonadoblastoma; histopathology; human; immunohistochemistry; immunoreactivity; infertility; malignant transformation; nonhuman; ovary tumor; pluripotent stem cell; primordial germ cell; priority journal; protein analysis; protein expression; protein function; review; risk assessment; risk factor; seminoma; testis tumor; tumor biopsy; Brain Neoplasms; Diagnosis, Differential; Female; Humans; Lymphatic Metastasis; Male; Neoplasms, Germ Cell and Embryonal; Octamer Transcription Factor-3; Ovarian Neoplasms; Testicular Neoplasms; Tumor Markers, Biological",,"Octamer Transcription Factor-3; Tumor Markers, Biological",,,"Nichols, J., Zernike, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4 (1998) Cell, 95, pp. 379-391; Donovan, P.J., High Oct-ane fuel powers the stem cell (2001) Nat Genet, 29, pp. 246-247; Ovitt, C.E., Scholer, H.R., The molecular biology of Oct-4 in the early mouse embryo (1998) Mol Hum Reprod, 4, pp. 1021-1031; Pesce, M., Scholer, H.R., Oct-4: Gatekeeper in the beginnings of mammalian development (2001) Stem Cells, 19, pp. 271-278; Ben-Shushan, E., Sharir, H., Pikarsky, E., Bergman, Y., A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor: Retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells (1995) Mol Cell Biol, 15, pp. 1034-1048; Gidekel, S., Bergman, Y., A unique developmental pattern of Oct-3/4 DNA methylation is controlled by a cis-demodification element (2002) J Biol Chem, 277, pp. 34521-34530; Hattori, N., Nishino, K., Ko, Y.G., Hattori, N., Ohgane, J., Tanaka, S., Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells (2004) J Biol Chem, 279, pp. 17063-17069; Deb-Rinker, P., Ly, D., Jezierski, A., Sikorska, M., Walker, P.R., Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation (2005) J Biol Chem, 280, pp. 6257-6260; Gidekel, S., Pizov, G., Bergman, Y., Pikarsky, E., Oct-3/4 is a dose-dependent oncogenic fate determinant (2003) Cancer Cell, 4, pp. 361-370; Kehler, J., Tolkunova, E., Koschorz, B., Pesce, M., Gentile, L., Boiani, M., Oct4 is required for primordial germ cell survival (2004) EMBO Rep, 5, pp. 1078-1083; Boiani, M., Eckardt, S., Scholer, H.R., McLaughlin, K.J., Oct4 distribution and level in mouse clones: Consequences for pluripotency (2002) Genes Dev, 16, pp. 1209-1219; Niwa, H., Miyazaki, J., Smith, A.G., Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells (2000) Nat Genet, 24, pp. 372-376; Hay, D.C., Sutherland, L., Clark, J., Burdon, T., Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells (2004) Stem Cells, 22, pp. 225-235; Velkey, J.M., O'Shea, K.S., Oct4 RNA interference induces trophectoderm differentiation in mouse embryonic stem cells (2003) Genesis, 37, pp. 18-24; van Berlo, R.J., Oosterhuis, J.W., Schrijnemakers, E., Schoots, C.J., de Jong, B., Darnjanov, I., Yolk-sac carcinoma develops spontaneously as a late occurrence in slow-growing teratoid tumors produced from transplanted 7-day mouse embryos (1990) Int J Cancer, 45, pp. 153-155; Kraft, H.J., Mosselman, S., Smits, H.A., Hohenstein, P., Pick, E., Chen, Q., Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells (1996) J Biol Chem, 271, pp. 12873-12878; Palumbo, C., van Roozendaal, K., Gillis, A.J., van Gurp, R.H., de Munnik, H., Oosterhuis, J.W., Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms (2002) J Pathol, 196, pp. 467-477; Looijenga, L.H., Stoop, H., de Leeuw, H.P., de Gouveia Brazao, C.A., Gillis, A.J., van Roozendaal, K.E., POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors (2003) Cancer Res, 63, pp. 2244-2250; Jones, T.D., Ulbright, T.M., Eble, J.N., Baldridge, L.A., Cheng, L., OCT4 staining in testicular tumors: A sensitive and specific marker for seminoma and embryonal carcinoma (2004) Am J Surg Pathol, 28, pp. 935-940; De Jong, J., Stoop, H., Dohle, G.R., Bangma, C.H., Kliffen, M., van Esser, J.W., Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours (2005) J Pathol, 206, pp. 242-249; Reuter, V.E., Origins and molecular biology of testicular germ cell tumors (2005) Mod Pathol, 18 (SUPPL. 2), pp. S51-S60; Rajpert-De Meyts, E., Hanstein, R., Jorgensen, N., Graem, N., Vogt, P.H., Skakkebaek, N.E., Developmental expression of POU5F1 (OCT-3/4) in normal and dysgenetic human gonads (2004) Hum Reprod, 19, pp. 1338-1344; Jones, T.D., Ulbright, T.M., Eble, J.N., Cheng, L., OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis (2004) Clin Cancer Res, 10, pp. 8544-8547; Gaskell, T.L., Esnal, A., Robinson, L.L., Anderson, R.A., Saunders, P.T., Immunohistochemical profiling of germ cells within the human fetal testis: Identification of three subpopulations (2004) Biol Reprod, 71, pp. 2012-2021; Honecker, F., Stoop, H., de Krijger, R.R., Chris Lau, Y.F., Bokemeyer, C., Looijenga, L.H., Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells (2004) J Pathol, 203, pp. 849-857; Hughes, I.A., Houk, C., Ahmed, S.F., Lee, P.A., Consensus statement on management of intersex disorders (2006) Arch Dis Child, 91, pp. 554-563; Cools, M., van Aerde, K., Kersemaekers, A.M., Boter, M., Drop, S.L., Wolffenbuttel, K.P., Morphological and immunohistochemical differences between gonadal maturation delay and early germ cell neoplasia in patients with undervirilisation syndromes (2005) J Clin Endocrinol Metab, 90, pp. 5295-5303; Cools, M., Drop, S.L., Wolffenbuttel, K.P., Oosterhuis, J.W., Looijenga, L.H., Germ cell tumors in the intersex gonad: Old paths, new directions, moving frontiers (2006) Endocr Rev, 27, pp. 468-484; Cools, M., Stoop, H., Kersemaekers, A.M., Drop, S.L., Wolffenbuttel, K.P., Bourguinon, J.P., Gonadoblastoma arising in undifferentiated gonadal tissue within dysgenetic gonads (2006) J Clin Endocrinol Metab, 91, pp. 2404-2413; Jones, T.D., MacLennan, G.T., Bonnin, J.M., Varsegi, M.F., Blair, J.E., Cheng, L., Screening for intratubular germ cell neoplasia of the testis using OCT4 immunohistochemistry (2006) Am J Surg Pathol, 30, pp. 1427-1431; Montironi, R., Intratubular germ cell neoplasia of the testis: Testicular intraepithelial neoplasia (2002) Eur Urol, 41, pp. 651-654; Cheng, L., Thomas, A., Roth, L.M., Zheng, W., Michael, H., Karim, F.W., OCT4: A novel biomarker for dysgerminoma of the ovary (2004) Am J Surg Pathol, 28, pp. 1341-1346; Kersemaekers, A.M., Honecker, F., Stoop, H., Cools, M., Molier, M., Wolffenbuttel, K., Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: An immunohistochemical study for OCT3/4 and TSPY (2005) Hum Pathol, 36, pp. 512-521; Stoop, H., Honecker, F., Cools, M., de Krijger, R., Bokemeyer, C., Looijenga, L.H., Differentiation and development of human female germ cells during prenatal gonadogenesis: An immunohistochemical study (2005) Hum Reprod, 20, pp. 1466-1476; Hattab, E.M., Tu, P.H., Wilson, J.D., Cheng, L., OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma (2005) Am J Surg Pathol, 29, pp. 368-371; Sung, M.T., MacLennan, G.T., Cheng, L., Retroperitoneal seminoma in limited biopsies: Morphologic criteria and immunohistochemical findings in 30 cases (2006) Am J Surg Pathol, 30, pp. 766-773; Cheng, L., Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry (2004) Cancer, 101, pp. 2006-2010; Barnea, E., Bergman, Y., Synergy of SF1 and RAR in activation of Oct-3/4 promoter (2000) J Biol Chem, 275, pp. 6608-6619; Berney, D.M., Shamash, J., Pieroni, K., Oliver, R.T., Loss of CD30 expression in metastatic embryonal carcinoma: The effects of chemotherapy? (2001) Histopathology, 39, pp. 382-385; Sung, M.T., Jones, T.D., Beck, S.D., Foster, R.S., Cheng, L., OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy (2006) Hum Pathol, 37, pp. 662-667; Hoei-Hansen, C.E., Rajpert-De Meyts, E., Daugaard, G., Skakkebaek, N.E., Carcinoma in situ testis, the progenitor of testicular germ cell tumours: A clinical review (2005) Ann Oncol, 16, pp. 863-868; De Gouveia Brazao, C.A., Pierik, F.H., Oosterhuis, J.W., Dohle, G.R., Looijenga, L.H., Weber, R.F., Bilateral testicular microlithiasis predicts the presence of the precursor of testicular germ cell tumors in subfertile men (2004) J Urol, 171, pp. 158-160; Dieckmann, K.P., Skakkebaek, N.E., Carcinoma in situ of the testis: Review of biological and clinical features (1999) Int J Cancer, 83, pp. 815-822; Pauls, K., Franke, F.E., Buttner, R., Zhou, H., Gonadoblastoma: Evidence for a stepwise progression to dysgerminoma in a dysgenetic ovary (2005) Virchows Arch, 447, pp. 603-609","Cheng, L.; Department of Pathology and Laboratory Medicine; Indiana University School of Medicine; 350 West 11th Street Indianapolis, IN 46202, United States; email: lcheng@upui.edu",,,,,,,,00223417,,JPTLA,10.1002/path.2105,"English","Journal of Pathology",Review,Scopus
"Pan C.-X., Zhang H., Lara Jr. P.N., Cheng L.","Small-cell carcinoma of the urinary bladder: Diagnosis and management",2006,"Expert Review of Anticancer Therapy",6,12,,1707,1713,,1,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33846068222&partnerID=40&rel=R8.0.0","University of California at Davis, Department of Internal Medicine, Division of Hematology/Oncology, 4501 X Street, Sacramento, CA 95817, United States; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, United States","Small-cell carcinoma of the urinary bladder (SCCUB) accounts for less than 1% of all cancers arising in the urinary bladder. Current diagnosis and management of SCCUB are often patterned after small-cell lung cancer (SCLC). However, SCCUB therapy is different from that for SCLC. For example, many patients with SCCUB undergo local resection, which is rarely performed in SCLC. As in SCLC, platinum-etoposide combination chemotherapy is employed as the main systemic treatment option for SCCUB. Chemotherapy is usually combined with other therapeutic modalities, especially in patients whose disease is limited to the locoregional area. Owing to the rarity of this malignancy, no prospective study has been performed that establishes the efficacy and duration of chemotherapy or the relative efficacy of platinum-etoposide versus other chemotherapeutic regimens. This article provides a comprehensive review of the current status of SCCUB diagnosis and management, as well as some unique insights into this rare tumor. Â© 2006 Future Drugs Ltd.","Chemotherapy; Radiation therapy; Small cell carcinoma of the urinary bladder; Small cell lung cancer; Targeted therapy","antineoplastic agent; carboplatin; CD56 antigen; chromogranin; cisplatin; cyclophosphamide; cytokeratin 20; cytokeratin 7; doxorubicin; etoposide; fluorodeoxyglucose f 18; fluorouracil; gastrin releasing peptide; gemcitabine; ifosfamide; irinotecan; methotrexate; neuron specific enolase; paclitaxel; platinum complex; serotonin; somatomedin C; synaptophysin; taxane derivative; topotecan; vasoactive intestinal polypeptide; vinblastine; bladder biopsy; bladder carcinogenesis; bladder carcinoma; brain metastasis; cancer adjuvant therapy; cancer combination chemotherapy; cancer palliative therapy; cancer radiotherapy; cancer regression; cancer staging; cancer survival; clinical feature; cystectomy; cystoscopy; diagnostic value; disease marker; drug efficacy; drug response; drug substitution; drug withdrawal; human; immunohistochemistry; positron emission tomography; prognosis; repeated drug dose; review; skull irradiation; small cell carcinoma; systemic therapy; treatment duration; tumor differentiation; unspecified side effect; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Lineage; Chemotherapy, Adjuvant; Chromosome Aberrations; Combined Modality Therapy; Cystectomy; Female; Hematuria; Humans; Keratin-20; Keratin-7; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Palliative Care; Radiotherapy, Adjuvant; Risk Factors; Smoking; Survival Rate; Tumor Markers, Biological; Urinary Bladder Neoplasms",,"carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; etoposide, 33419-42-0; fluorodeoxyglucose f 18, 63503-12-8; fluorouracil, 51-21-8; gastrin releasing peptide, 74815-57-9, 80043-53-4; gemcitabine, 103882-84-4; ifosfamide, 3778-73-2; irinotecan, 100286-90-6; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; paclitaxel, 33069-62-4; serotonin, 50-67-9; somatomedin C, 67763-96-6; topotecan, 119413-54-6, 123948-87-8; vasoactive intestinal polypeptide, 37221-79-7; vinblastine, 865-21-4; Keratin-20; Keratin-7; Neoplasm Proteins; Tumor Markers, Biological",,,"Cramer, S.F., Aikawa, M., Cebelin, M., Neurosecretory granules in small cell invasive carcinoma of the urinary bladder (1981) Cancer, 47, pp. 724-730; Blomjous, C.E., Vos, W., De Voogt, H.J., Van der Valk, P., Meijer, C.J., Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases (1989) Cancer, 64, pp. 1347-1357; Cheng, L., Pan, C.X., Yang, X.J., Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients (2004) Cancer, 101, pp. 957-962; Choong, N.W., Quevedo, J.F., Kaur, J.S., Small cell carcinoma of the urinary bladder. The Mayo Clinic experience (2005) Cancer, 103, pp. 1172-1178; Abrahams, N.A., Moran, C., Reyes, A.O., Siefker-Radtke, A., Ayala, A.G., Small cell carcinoma of the bladder: A contemporary clinicopathological study of 51 cases (2005) Histopathology, 46, pp. 57-63; Wang, H.L., Lu, D.W., Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix (2004) Am. J. Surg. Pathol., 28, pp. 901-908; Terracciano, L., Richter, J., Tornillo, L., Chromosomal imbalances in small cell carcinomas of the urinary bladder (1999) J. Pathol., 189, pp. 230-235; Cheng, L., Jones, T.D., McCarthy, R.P., Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma (2005) Am. J. Pathol., 166, pp. 1533-1539; Kratzke, R.A., Greatens, T.M., Rubins, J.B., Rb and p161NK4a expression in resected non-small cell lung tumors (1996) Cancer Res., 56, pp. 3415-3420; Taga, S., Osaki, T., Ohgami, A., Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma (1997) Cancer, 80, pp. 389-395; Leonard, C., Huret, J.L., From cytogenetics to cytogenomics of bladder cancers (2002) Bull. Cancer, 89, pp. 166-173. , Groupe francais de cytogenetique oncologique; Atkin, N.B., Baker, M.C., Wilson, G.D., Chromosome abnormalities and p53 expression in a small cell carcinoma of the bladder (1995) Cancer Genet. Cytogenet., 79, pp. 111-114; Rohr, U.P., Rehfeld, N., Pflugfelder, L., Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer (2004) Int. J. Cancer, 111, pp. 259-263; Tamborini, F., Bonadiman, L., Negri, T., Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer (2004) Clin. Cancer Res., 10, pp. 8214-8219; Pan, C.X., Yang, X.J., Lopez-Beltran, A., c-kit expression in small cell carcinoma of the urinary bladder: Prognostic and therapeutic implications (2005) Mod. Pathol., 18, pp. 320-323; Reck, M., von Pawel, J., Macha, H.N., Randomized Phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer (2003) J. Natl Cancer Inst., 95, pp. 1118-1127; Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells (2003) Proc. Natl Acad. Sci. USA, 100, pp. 3983-3988; Singh, S.K., Clarke, I.D., Terasaki, M., Identification of a cancer stem cell in human brain tumors (2003) Cancer Res., 63, pp. 5821-5828; Kim, C.F., Jackson, E.L., Woolfenden, A.E., Identification of bronchioalveolar stem cells in normal lung and lung cancer (2005) Cell, 121, pp. 823-835; Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., Maitland, N.J., Prospective identification of tumorigenic prostate cancer stem cells (2005) Cancer Res., 65, pp. 10946-10951; Fukuoka, M., Furuse, K., Saijo, N., Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer (1991) J. Natl Cancer Inst., 83, pp. 855-861; Christopher, M.E., Seftel, A.D., Sorenson, K., Resnick, M.I., Small cell carcinoma of the genitourinary tract: An immunohistochemical, electron microscopic and clinicopathological study (1991) J. Urol., 146, pp. 382-388; Grignon, D.J., Ro, J.Y., Ayala, A.G., Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases (1992) Cancer, 69, pp. 527-536; Cheng, L., Leibovich, B.C., Cheville, J.C., Paraganglioma of the urinary bladder: Can biologic potential be predicted? (2000) Cancer, 88, pp. 844-852; Cheng, L., Scheithauer, B.W., Leibovich, B.C., Ramnani, D.M., Cheville, J.C., Bostwick, D.G., Neurofibroma of the urinary bladder (1999) Cancer, 86, pp. 505-513; Partanen, S., Asikainen, U., Oat cell carcinoma of the urinary bladder with ectopic adrenocorticotropic hormone production (1985) Hum. Pathol., 16, pp. 313-315; Reyes, C.V., Soneru, I., Small cell carcinoma of the urinary bladder with hypercalcemia (1985) Cancer, 56, pp. 2530-2533; Ali, S.Z., Reuter, V.E., Zakowski, M.F., Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features (1997) Cancer, 79, pp. 356-361; (2004) WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, , Eble JN, Sauter G, Epstein J (Eds). IARC Press, Lyon, France; Mills, S.E., Wolfe III, J.T., Weiss, M.A., Small cell undifferentiated carcinoma of the urinary bladder. A light-microscopic, immunocytochemical, and ultrastructural study of 12 cases (1987) Am. J. Surg. Pathol., 11, pp. 606-617; Soriano, P., Navarro, S., Gil, M., Llombart-Bosch, A., Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases (2004) Virchows Arch., 445, pp. 292-297; Jiang, J., Ulbright, T.M., Younger, C., Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis (2001) Arch. Pathol. Lab. Med., 125, pp. 921-923; Miettinen, M., Keratin 20: Immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas (1995) Mod. Pathol., 8, pp. 384-388; Jones, T.D., Kernek, K.M., Yang, X.J., Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: An immunohistochemical profile of 44 cases (2005) Hum. Pathol., 36, pp. 718-723; Bradley, J.D., Dehdashti, F., Mintun, M.A., Govindan, R., Trinkaus, K., Siegel, B.A., Positron emission tomography in limited-stage small-cell lung cancer: A prospective study (2004) J. Clin. Oncol., 22, pp. 3248-3254; Skarlos, D.V., Samantas, E., Kosmidis, P., Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer (1994) Ann. Oncol., 5, pp. 601-607. , A Hellenic Co-operative Oncology Group study; Ciombor, K.K., Rocha Lima, C.M., Management of small cell lung cancer (2006) Curr. Treat. Options Oncol., 7, pp. 59-68; Dreicer, R., Manola, J., Roth, B.J., Cohen, M.B., Hatfield, A.K., Wilding, G., Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study (2000) J. Clin. Oncol., 18, pp. 1058-1061; Bajorin, D.F., McCaffrey, J.A., Dodd, P.M., Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a Phase II trial evaluating two dosing schedules (2000) Cancer, 88, pp. 1671-1678; Reck, M., von Pawel, J., Macha, H.N., Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years'-follow-up results from a randomised Phase III trial (2006) Lung Cancer, 53, pp. 67-75; Loehrer Sr., P.J., Ansari, R., Gonin, R., Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study (1995) J. Clin. Oncol., 13, pp. 2594-2599; Lohrisch, C., Murray, N., Pickles, T., Sullivan, L., Small cell carcinoma of the bladder: Long term outcome with integrated chemoradiation (1999) Cancer, 86, pp. 2346-2352; Bex, A., Nieuwenhuijzen, J.A., Kerst, M., Small cell carcinoma of bladder: A single-center prospective study of 25 cases treated in analogy to small cell lung cancer (2005) Urology, 65, pp. 295-299; Pedersen, A.G., Kristjansen, P.E., Hansen, H.H., Prophylactic cranial irradiation and small cell lung cancer (1988) Cancer Treat. Rev., 15, pp. 85-103; Auperin, A., Arriagada, R., Pignon, J.P., Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission (1999) N. Engl. J. Med., 341, pp. 476-484. , Prophylactic Cranial Irradiation Overview Collaborative Group; Isaka, T., Maruno, M., Sato, M., Brain metastasis from small-cell neuroendocrine carcinoma of the urinary bladder: A case report (2002) Brain Tumor Pathol., 19, pp. 117-122; Warde, P., Payne, D., Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis (1992) J. Clin. Oncol., 10, pp. 890-895; Choi, N.C., Carey, R.W., Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: An update (1989) Int. J. Radial. Oncol. Biol. Phys., 17, pp. 307-310; Papac, R.J., Son, Y., Bien, R., Tiedemann, D., Keohane, M., Yesner, R., Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy (1987) Int. J. Radiat. Oncol. Biol. Phys., 13, pp. 993-998; Lester, J.F., Hudson, E., Barber, J.B., Bladder preservation in small cell carcinoma of the urinary bladder: An institutional experience and review of the literature (2006) Clin. Oncol., 18, pp. 608-611; Gaspar, L.E., Gay, E.G., Crawford, J., Putnam, J.B., Herbst, R.S., Bonner, J.A., Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base (2005) Clin. Lung Cancer, 6, pp. 355-360","Pan, C.-X.; University of California at Davis; Department of Internal Medicine; Division of Hematology/Oncology; 4501 X Street Sacramento, CA 95817, United States; email: cxpan@ucdavis.edu",,,,,,,,14737140,,ERATB,10.1586/14737140.6.12.1707,"English","Expert Review of Anticancer Therapy",Review,Scopus
"Hara T., Bansal A., DeGrado T.R.","Choline transporter as a novel target for molecular imaging of cancer",2006,"Molecular Imaging",5,4,,498,509,,5,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33846430535&partnerID=40&rel=R8.0.0","Department of Radiology, Indiana University School of Medicine, Indianapolis, IN; 1345 West 16th Street, Indianapolis, IN 46202-9028","Abnormalities of choline processing in cancer cells have been used as a basis for imaging of cancer with positron emission tomography and magnetic resonance spectroscopy. In this study, the transport mechanism for choline was investigated in cultured PC-3 prostate cancer cells. Furthermore, tritiated hemicholinium 3 (HC-3), a well-known inhibitor of choline transport, was studied as a prototypic molecular imaging probe in PC-3 cells and 9L glioma-bearing rats. [3H]Choline uptake by PC-3 cells was found to have both facultative and nonfacilitative components. Facultative transport was characterized by partial sodium dependence and intermediate affinity (K M = 9.7 Â± 0.8 Î¼M). HC-3 inhibited choline with a K I of 10.5Â± 2.2 Î¼M. Ouabain (1 mM) caused a 94% reduction in choline uptake. At physiologic choline concentration, phosphocholine was the rapid and predominant metabolic fate. The binding of [3H]HC-3 to PC-3 cells was rapid and specific (competitively blocked with unlabeled HC-3). Biodistribution of [3H]HC-3 in 9L glioma-bearing rats showed the ranking of uptake to be kidney > lung > tumor > liver > skeletal muscle â‰ˆ blood > brain. In comparison with [14C]choline, [ 3H]HC-3 showed over twofold higher tumor uptake and favorable uptake ratios of tumor to blood, tumor to muscle, tumor to lung, and tumor to liver. The data demonstrate the quantitative importance of an intermediate-affinity, partially sodium-dependent choline transport system on choline processing in PC-3 cancer cells. The biodistribution properties of [3H]HC-3 in tumor-bearing rats encourage the development of molecular imaging probes based on choline transporter binding ligands. Â© 2006 BC Decker Inc.",,"Disease control; Enzyme inhibition; Magnetic resonance spectroscopy; Positron emission tomography; Transport properties; Tumors; Binding ligands; Choline; Facultative transport; Transport mechanism; Medical imaging; carbon; carrier protein; choline; choline transporter; CHT1 protein, human; hemicholinium 3; nerve protein; plasma membrane neurotransmitter transporter; Slc6a8 protein, rat; tritium; animal; article; Fischer 344 rat; glioma; human; kinetics; male; metabolism; neoplasm; prostate tumor; rat; scintiscanning; tumor cell line; Animals; Carbon Radioisotopes; Cell Line, Tumor; Choline; Glioma; Hemicholinium 3; Humans; Kinetics; Male; Membrane Transport Proteins; Neoplasms; Nerve Tissue Proteins; Plasma Membrane Neurotransmitter Transport Proteins; Prostatic Neoplasms; Rats; Rats, Inbred F344; Tritium",,"carbon, 7440-44-0; carrier protein, 80700-39-6; choline, 123-41-1, 13232-47-8, 1927-06-6, 4858-96-2, 62-49-7, 67-48-1; hemicholinium 3, 16478-59-4; tritium, 10028-17-8; Carbon Radioisotopes; choline transporter; Choline, 62-49-7; CHT1 protein, human; Hemicholinium 3, 312-45-8; Membrane Transport Proteins; Nerve Tissue Proteins; Plasma Membrane Neurotransmitter Transport Proteins; Slc6a8 protein, rat, 147652-48-0; Tritium, 10028-17-8",,,"Gillies, R.J., Morse, D.L., In vivo magnetic resonance spectroscopy in cancer (2005) Annu Rev Biomed Eng, 7, pp. 287-326; Hara, T., Kosaka, N., Shinoura, N., Kondo, T., PET imaging of brain tumor with [methyl-11C]choline (1997) J Nucl Med, 38, pp. 842-847; Molier-Hartmann, W., Herminghaus, S., Krings, T., Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions (2002) Neuroradiology, 44, pp. 371-381; Kumar, R., Kumar, M., Jagannathan, N.R., Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate (2004) Urol Res, 32, pp. 36-40; Kwee, S.A., Wei, H., Sesterhenn, I., Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET (2006) J Nucl Med, 47, pp. 262-269; Hara, T., Kosaka, N., Suzuki, T., Uptake rates of 18F- fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: A positron emission tomography study (2003) Chest, 124, pp. 893-901; DeGrado, T.R., Coleman, R.E., Wang, S., Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer (2001) Cancer Res, 61, pp. 110-117; Yoshida, S., Nakagomi, K., Goto, S., 11C-Choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging (2005) Urol Int, 74, pp. 214-220; de Jong, I.J., Pruim, J., Elsinga, P.H., Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET (2003) J Nucl Med, 44, pp. 331-335; Lichy, M.P., Bachert, P., Henze, M., Monitoring individual response to brain-tumour chemotherapy: Proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy (2004) Neuroradiology, 46, pp. 126-129; de Jong, I.J., Pruim, J., Elsinga, P.H., 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer (2003) Eur Urol, 44, pp. 32-38; Ackerstaff, E., Pflug, B.R., Nelson, J.B., Bhujwalla, Z.M., Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells (2001) Cancer Res, 61, pp. 3599-3603; Mori, N., Delsite, R., Natarajan, K., Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline (2004) Mol Imaging, 3, pp. 319-323; Smith, T.A., Eccles, S., Ormerod, M.G., The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate (1991) Br J Cancer, 64, pp. 821-826; Singer, S., Souza, K., Thilly, W.G., Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: A 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study (1995) Cancer Res, 55, pp. 5140-5145; Evelhoch, J.L., Keller, N.A., Corbett, T.H., Response-specific Adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas (1987) Cancer Res, 47, pp. 3396-3401; Katz-Brull, R., Seger, D., Rivenson-Segal, D., Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether- phospholipid synthesis (2002) Cancer Res, 62, pp. 1966-1970; Katz-Brull, R., Degani, H., Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method (1996) Anticancer Res, 16, pp. 1375-1380; Gillies, R.J., Barry, J.A., Ross, B.D., In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells (1994) Magn Reson Med, 32, pp. 310-318; Daly, P.F., Lyon, R.C., Faustino, P.J., Cohen, J.S., Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy (1987) J Biol Chem, 262, pp. 14875-14878; Katz-Brull, R., Margalit, R., Degani, H., Differential routing of choline in implanted breast cancer and normal organs (2001) Magn Reson Med, 46, pp. 31-38; DeGrado, T.R., Balwin, S.W., Wang, S., Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers (2001) J Nucl Med, 42, pp. 1805-1814; Okuda, T., Haga, T., Kanai, Y., Identification and characterization of the high-affinity choline transporter (2000) Nat Neurosci, 3, pp. 120-125; Zhang, L., Dresser, M.J., Gray, A.T., Cloning and functional expression of a human liver organic cation transporter (1997) Mol Pharmacol, 51, pp. 913-921; Gorboulev, V., Ulzheimer, J.C., Akhoundova, A., Cloning and characterization of two human polyspecific organic cation transporters (1997) DNA Cell Biol, 16, pp. 871-881; Schloss, P., Mayser, W., Niehuis, A., Betz, H., Na+-dependent high-affinity uptake of choline into cultured fibroblasts (1994) Biochem Biophys Res Commun, 199, pp. 1320-1325; Michel, V., Yuan, Z., Ramsubir, S., Bakovic, M., Choline transport for phospholipids synthesis (2006) Exp Biol Med, 231, pp. 490-504; Lanks, K., Somers, L., Papirmeister, B., Yamamura, H., Choline transport by neuroblastoma cells in tissue culture (1974) Nature, 252, pp. 476-478; Yorek, M.A., Dunlap, J.A., Spector, A.A., Ginsberg, B.H., Effect of ethanolamine on choline uptake and incorporation into phosphatidylcholine in human Y79 retinoblastoma cells (1986) J Lipid Res, 27, pp. 1205-1213; Plagemann, P.G.W., Choline metabolism and membrane formation in rat hepatoma cells grown in suspension culture. III. Choline transport and uptake by simple diffusion and lack of direct exchange with phosphatidylcholine (1971) J Lipid Res, 12, pp. 715-724; Ribbes, G., Hamza, M., Chap, H., Douste-Blazy, L., Carrier-mediated choline uptake by Krebs II ascites cells (1985) Biochim Biophys Acta, 818, pp. 183-190; Lloveras, J., Hamza, M., Chap, H., Douste-Blazy, L., Action of hemicholinium-3 on phospholipids metabolism in Krebs II ascites cells (1985) Biochem Pharmacol, 34, pp. 3987-3993; Haeffner, E.W., Studies on choline permeation through the plasma membrane and its incorporation into phosphatidylcholine in Ehrlich-Lettre-asdtes tumor cells in vitro (1975) Eur J Biochem, 51, pp. 219-228; Doppler, W., Hoffmann, J., Maly, K., Grunicke, H., Amiloride and 5-N,N-dimethylamiloride inhibit the carrier-mediated uptake of choline in Ehrlich ascites tumor cells (1987) Biochem Pharmacol, 36, pp. 1645-1649; Walum, E., Uptake and release of choline in cultures of human glioma cells (1981) Cell Mol Neurobiol, 1, pp. 389-399; Hernandez-Alcoceba, R., Saniger, L., Campos, J., Choline kinase inhibitors as a novel approach for antiproliferative drug design (1997) Oncogene, 15, pp. 2289-2301; Marquardt, D.W., An algorithm for least squares estimation of nonlinear parameters (1963) J Soc Industrial Appl Math, 2, pp. 431-441; Folch, J., Lees, M., Sloane Stanley, G.H., A simple method for the isolation and purification of total lipides from animal tissues (1957) J Biol Chem, 226, pp. 497-509; Koc, H., Mar, M.H., Ranasinghe, A., Quantitation of choline and its metabolites in tissues and foods by liquid chromatography/electrospray ionization-isotope dilution mass spectrometry (2002) Anal Chem, 74, pp. 4734-4740; Wright, P.S., Morand, J.N., Kent, C., Regulation of phosphatidylcholine biosynthesis in Chinese hamster ovary cells by reversible membrane association of CTP:phosphocholine cytidylyltransferase (1985) J Biol Chem, 260, pp. 7919-7926; Clement, J.M., Kent, C., CTP:phosphocholine cytidylyltransferase: Insights into regulatory mechanisms and novel functions (1999) Biochem Biophys Res Commun, 257, pp. 643-650; Iorio, E., Mezzanzanica, D., Alberti, P., Alterations of choline phospholipids metabolism in ovarian tumor progression (2005) Cancer Res, 65, pp. 9369-9376; Negendank, W.G., Padavic-Shaller, K.A., Li, C.W., Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorous magnetic resonance spectroscopy (1995) Cancer Res, 55, pp. 3286-3294; Glunde, K., Jie, C., Bhujwalla, Z.M., Molecular causes of the aberrant choline phospholipid metabolism in breast cancer (2004) Cancer Res, 64, pp. 4270-4276; Wigler, P.W., Trans effects in cell membrane transport (1981) J Theor Biol, 93, pp. 997-1008; Domino, E.F., Cassino, G.B., Placidi, G.-F., Autoradiographic distribution of 14C-hemicholinium-3 in mouse whole body and dog brain (1974) J Pharmacol Exp Ther, 188, pp. 77-85; Benz, F.W., Long, J.P., Investigations on a series of heterocyclic hemicholinium-3 analogs (1969) J Pharmacol Exp Ther, 166, pp. 225-236","DeGrado, T.R.; 1345 West 16th Street Indianapolis, IN 46202-9028; email: tdegrado@iupui.edu",,,,,,,,15353508,,,10.2310/7290.2006.00032,"English","Molecular Imaging",Article,Scopus
"Smucker P.S., Smith J.L.","Multifocal desmoplastic medulloblastoma in an African-American child with nevoid basal cell carcinoma (Gorlin) syndrome: Case report",2006,"Journal of Neurosurgery",105 PEDIATRICS,SUPPL. 4,,315,320,,1,"http://www.scopus.com/scopus/inward/record.url?eid=2-s2.0-33845698333&partnerID=40&rel=R8.0.0","Division of Pediatric Neurosurgery, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, United States; Division of Pediatric Neurosurgery, James Whitcomb Riley Hospital for Children, 702 Barnhill Drive, Indianapolis, IN 46202, United States","The authors present the case of a 2.5-year-old African-American boy with desmoplastic medulloblastoma (MB) and nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, an autosomal dominant disorder resulting from mutations in the patched (PTCH) gene that predisposes to neoplasias (including basal cell carcinomas [BCCs] and MB) and to widespread congenital malformations. The diagnosis of NBCCS was suspected based on the clinical examination, patient and family medical histories, and histopathological characteristics of the tumor. Radiotherapy was withheld. The diagnosis of NBCCS was confirmed by DNA testing, which revealed a novel mutation in the PTCH gene. This is the first report of an African-American child with MB diagnosed with NBCCS prior to radiotherapy. Although only a small number of patients with MB have NBCCS, the diagnosis must be considered because radiotherapy in such patients can lead to the formation of BCCs and other intracranial neoplasms within the irradiated field. This case emphasizes the importance of obtaining thorough family and patient medical histories and of carefully examining the patient and close relatives for signs of NBCCS to avoid the potentially devastating consequences of missing this diagnosis.","Desmoplastic medulloblastoma; Gorlin syndrome; Nevoid basal cell carcinoma syndrome; Pediatric neurosurgery; PTCH; Sonic hedgehog protein","protein Patched; African American; anamnesis; article; basal cell nevus syndrome; cancer radiotherapy; cancer susceptibility; case report; clinical feature; craniotomy; disease association; disease course; family history; follow up; gene mutation; histopathology; human; laminectomy; male; medulloblastoma; multiple cancer; nuclear magnetic resonance imaging; physical examination; preschool child; priority journal; treatment outcome; tumor diagnosis; tumor localization; African Americans; Basal Cell Nevus Syndrome; Brain Neoplasms; Cerebellar Neoplasms; Cerebral Ventricle Neoplasms; Child, Preschool; Cranial Fossa, Posterior; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Mutation; Neoplasms, Multiple Primary; Receptors, Cell Surface",,"patched receptors; Receptors, Cell Surface",,,"Amlashi, S.F.A., Riffaud, L., Brassier, G., Morandi, X., Nevoid basal cell carcinoma syndrome: Relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature (2003) Cancer, 98, pp. 618-624; Anderson, D.E., Taylor, W.B., Falls, H.F., Davidson, R.T., The nevoid basal cell carcinoma syndrome (1967) Am J Hum Genet, 19, pp. 12-22; Atahan, I.L., Yildiz, F., Ozyar, E., Uzal, D., Zorlu, F., Basal cell carcinomas developing in a case of medulloblastoma associated with Gorlin's syndrome (1998) Pediatr Hematol Oncol, 15, pp. 187-191; Bale, A.E., Yu, K., The hedgehog pathway and basal cell carcinomas (2001) Hum Mol Genet, 10, pp. 757-762; Berman, D.M., Karhadkar, S.S., Hallahan, A.R., Pritchard, J.I., Eberhart, C.G., Watkins, D.N., Medulloblastoma growth inhibition by hedgehog pathway blockade (2002) Science, 297, pp. 1559-1561; Bialer, M.G., Gailani, M.R., McLaughlin, J.A., Petrikovsky, B., Bale, A.E., Prenatal diagnosis of Gorlin syndrome (1994) Lancet, 344, p. 477; Bonifas, J.M., Bare, J.W., Kerschmann, R.L., Master, S.P., Epstein Jr., E.H., Parental origin of chromosome 9q22.3-q31 lost in basal cell carcinomas from basal cell nevus syndrome patients (1994) Hum Mol Genet, 3, pp. 447-448; Carrie, C., Lasset, C., Blay, J.Y., NeÌ�grier, S., Bouffet, E., Barbet, N., Medulloblastoma in adults: Survival and prognostic factors (1993) Radiother Oncol, 29, pp. 301-307; Chatty, E.M., Earle, K.M., Medulloblastoma: A report of 201 cases with emphasis on the relationship of histologic variants to survival (1971) Cancer, 28, pp. 977-983; Cohen Jr., M.M., Nevoid basal cell carcinoma syndrome: Molecular biology and new hypotheses (1999) Int J Oral Maxillofac Surg, 28, pp. 216-223; Corcoran, R.B., Scott, M.P., A mouse model for medulloblastoma and basal cell nevus syndrome (2001) J Neurooncol, 53, pp. 307-318; Cowan, R., Hoban, P., Kelsey, A., Birch, J.M., Gattamaneni, R., Evans, D.G., The gene for the naevoid basal cell carcinoma syndrome acts as a tumor-suppressor gene in medulloblastoma (1997) Br J Cancer, 76, pp. 141-145; Duffner, P.K., Horowitz, M.E., Krischer, J.P., Friedman, H.S., Burger, P.C., Cohen, M.E., Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors (1993) N Engl J Med, 328, pp. 1725-1731; Esposito, S.J., Kast, G., Bradrick, J.P., Basal cell nevus syndrome: A clinical report (1995) J Prosthet Dent, 73, pp. 405-410; Evans, D.G., Birch, J.M., Orton, C.I., Brain tumors and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin Syndrome (1991) Br J Neurosurg, 5, pp. 643-646; Evans, D.G., Farndon, P.A., Burnell, L.D., Gattamaneni, H., Birch, J.M., The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma (1991) Br J Cancer, 64, pp. 959-961; Evans, D.G., Ladusans, E.J., Rimmer, S., Burnell, L.D., Thakker, N., Farndon, P.A., Complications of the naevoid basal cell carcinoma syndrome: Results of a population based study (1993) J Med Genet, 30, pp. 460-464; Farndon, P.A., Del Mastro, R.G., Kilpatrick, M.W., Evans, D.R.G., Location of gene for Gorlin syndrome (1992) Lancet, 339, pp. 581-582; Gelabert-GonzaÌ�lez, M., FernaÌ�ndez-Villa, J., Mutism after posterior fossa surgery. Review of the literature (2001) Clin Neurol Neurosurg, 103, pp. 111-114; Golitz, L.E., Norris, D.A., Luekens Jr., C.A., Charles, D.M., Nevoid basal cell carcinoma syndrome. Multiple basal cell carcinomas of the palms after radiation therapy (1980) Arch Dermatol, 116, pp. 1159-1163; Gorlin, R.J., Nevoid basal cell carcinoma (Gorlin) syndrome: Unanswered issues (1999) J Lab Clin Med, 134, pp. 551-552; Gorlin, R.J., Nevoid basal cell carcinoma syndrome (1995) Dermatol Clin, 13, pp. 113-125; Gorlin, R.J., Goltz, R.W., Multiple naevoid basal cell epithelioma, jaw cysts, bifid rib: A syndrome (1960) N Engl J Med, 262, pp. 908-912; Hahn, H., Wicking, C., Zaphiropoulous, P.G., Gailani, M.R., Shanley, S., Chidambaram, A., Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome (1996) Cell, 85, pp. 841-851; Hasenpusch-Theil, K., Bataille, V., Laehdetie, J., Obermayr, F., Sampson, J.R., Frischauf, A.M., Gorlin syndrome: Identification of 4 novel germ-line mutations of the human patched (PTCH) gene (1998) Hum Mutat, 11, p. 480; Herpers, M.J., Budka, H., Primitive neuroectodermal tumors including the medulloblastoma: Glial differentiation signaled by immunoreactivity for GFAP is restricted to the pure desmoplastic medulloblastoma (""arachnoidal sarcoma of the cerebellum"") (1985) Clin Neuropathol, 4, pp. 12-18; Iwanaga, S., Shimoura, H., Shimizu, M., Numaguchi, Y., Gorlin syndrome: Unusual manifestations in the sella turcica and the sphenoidal sinus (1998) AJNR Am J Neuroradiol, 19, pp. 956-958; Johnson, R.L., Rothman, A.L., Xie, J., Goodrich, L.V., Bare, J.W., Bonifas, J.M., Human homolog of patched, a candidate gene for the basal cell nevus syndrome (1996) Science, 272, pp. 1668-1671; Kantarci, M., Ertas, U., Alper, F., Sutbeyaz, Y., Karasen, R.M., Onbas, O., Gorlin's syndrome with a thin corpus callosum and a third ventricular cyst (2003) Neuroradiology, 45, pp. 390-392; Katsetos, C.D., Herman, M.M., Frankfurter, A., Gass, P., Collins, V.P., Walker, C.C., Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands (1989) Arch Pathol Lab Med, 113, pp. 1019-1029; Keeler, R.F., Binns, W., Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources (1968) Teratology, 1, pp. 5-10; Kimonis, V.E., Goldstein, A.M., Pastakia, B., Yang, M.L., Kase, R., Di-Giovanna, J.J., Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome (1997) Am J Med Genet, 69, pp. 299-308; Korczak, J.F., Brahim, J.S., DiGiovanna, J.J., Kase, R.G., Wexler, L.H., Goldstein, A.M., Nevoid basal cell carcinoma syndrome with medulloblastoma in an African-American boy: A rare case illustrating gene-environment interaction (1997) Am J Med Genet, 69, pp. 309-314; Lo Muzio, L., Nocini, P.F., Savoia, A., Consolo, U., Procaccini, M., Zelante, L., Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals (1999) Clin Genet, 55, pp. 34-40; Neblett, C.R., Waltz, T.A., Anderson, D.E., Neurological involvement in the nevoid basal cell carcinoma syndrome (1971) J Neurosurg, 35, pp. 577-584; O'Malley, S., Weitman, D., Olding, M., Sekhar, L., Multiple neoplasms following craniospinal irradiation for medulloblastoma in a patient with nevoid basal cell carcinoma syndrome. Case report (1997) J Neurosurg, 86, pp. 286-288; Oro, A.E., Higgins, K.M., Hu, Z., Bonifas, J.M., Epstein Jr., E.H., Scott, M.P., Basal cell carcinomas in mice overexpressing sonic hedgehog (1997) Science, 276, pp. 817-821; Ozturk, A., Oguz, K.K., Tumer, C., Balci, S., Neuroradiological findings in a mother and daughter with Gorlin syndrome (2003) Clin Dysmorphol, 12, pp. 145-146; Pramanik, P., Sharma, M.C., Mukhopadhyay, P., Singh, V.P., Sarkar, C., A comparative study of classical vs. desmoplastic medulloblastomas (2003) Neurol Ind, 51, pp. 27-34; Shanley, S., Ratcliffe, J., Hockey, A., Haan, E., Oley, C., Ravine, D., Nevoid basal cell carcinoma syndrome: Review of 118 affected individuals (1994) Am J Med Genet, 50, pp. 282-290; Stavale, J.N., Souza Cruz, J.R., Desmoplastic medulloblastoma: Histologic factors of prognosis (1993) Arq Neuro-Psiq, 51, pp. 487-490; Stavrou, T., Dubovsky, E.C., Reaman, G.H., Goldstein, A.M., Vezina, G., Intracranial calcifications in childhood medulloblastoma: Relation to nevoid basal cell carcinoma syndrome (2000) AJNR Am J Neuroradiol, 21, pp. 790-794; Takanashi, J., Fujii, K., Takano, H., Sugita, K., Kohno, Y., Empty sella syndrome in nevoid basal cell carcinoma syndrome (2000) Brain Dev, 22, pp. 272-274; Wicking, C., Shanley, S., Smyth, I., Gillies, S., Negus, K., Graham, S., Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident (1997) Am J Hum Genet, 60, pp. 21-26; Young, J.L., Miller, R.W., Incidence of malignant tumors in US children (1975) J Pediatr, 86, pp. 254-258; Zedan, W., Robinson, P.A., High, A.S., A novel pleomorphism in the PTC gene allows easy identification of allelic loss in basal cell nevus syndrome lesions (2001) Diagn Mol Pathol, 10, pp. 41-45","Smith, J.L.; Division of Pediatric Neurosurgery; James Whitcomb Riley Hospital for Children; 702 Barnhill Drive Indianapolis, IN 46202, United States; email: jodlsmit@iupui.edu",,,,,,,,00223085,,JONSA,,"English","Journal of Neurosurgery",Article,Scopus